[10-Q] PTC Therapeutics, Inc. Quarterly Earnings Report
Crocs (CROX) posted Q2-25 revenue of $1.15 bn, up 3.4% YoY, with gross margin improving 10 bp to 61.7% despite a softer consumer backdrop and new U.S. footwear tariffs. The Crocs Brand remained the profit engine, delivering $359 mn operating income on 37.4% margin, while HEYDUDE revenue fell 3.9% and incurred a $737 mn non-cash impairment ($430 mn trademark, $307 mn goodwill). These charges swung consolidated operating income to a $428 mn loss and drove a net loss of $492 mn (-$8.82 diluted EPS) versus $229 mn profit last year.
Cash from operations stayed positive at $219 mn but declined 41% YoY; free cash flow funded $194 mn of H1 share buybacks, reducing diluted shares to 55.8 mn. Cash rose to $201 mn; gross debt inched up to $1.38 bn, implying net leverage ~1.4脳 TTM EBITDA (pre-impairment). Intangibles dropped to $1.34 bn after the write-downs.
Management cites a weaker U.S. consumer, higher tariffs (19-30%) and longer stabilization timeline for HEYDUDE as key headwinds. Ongoing class-action and derivative lawsuits add legal overhang. The company nevertheless retains $1.1 bn remaining repurchase authorization and $784 mn revolver capacity, offering liquidity to navigate macro and brand-specific challenges.
Crocs (CROX) ha riportato un fatturato nel secondo trimestre 2025 di 1,15 miliardi di dollari, in crescita del 3,4% su base annua, con un margine lordo migliorato di 10 punti base al 61,7%, nonostante un contesto di consumo pi霉 debole e nuove tariffe sui calzature negli Stati Uniti. Il marchio Crocs ha continuato a essere il motore di profitto, generando un reddito operativo di 359 milioni di dollari con un margine del 37,4%, mentre i ricavi di HEYDUDE sono diminuiti del 3,9% e hanno subito una svalutazione non monetaria di 737 milioni di dollari (430 milioni per marchi e 307 milioni per avviamento). Queste svalutazioni hanno trasformato il reddito operativo consolidato in una perdita di 428 milioni di dollari e hanno causato una perdita netta di 492 milioni di dollari (-8,82 dollari per azione diluita) rispetto a un utile di 229 milioni dell'anno precedente.
La liquidit脿 generata dalle operazioni 猫 rimasta positiva a 219 milioni di dollari, ma 猫 diminuita del 41% su base annua; il flusso di cassa libero ha finanziato 194 milioni di dollari di riacquisti di azioni nel primo semestre, riducendo le azioni diluite a 55,8 milioni. La liquidit脿 猫 aumentata a 201 milioni di dollari; il debito lordo 猫 salito a 1,38 miliardi di dollari, implicando una leva finanziaria netta di circa 1,4 volte l'EBITDA degli ultimi dodici mesi (prima delle svalutazioni). Gli intangibili sono scesi a 1,34 miliardi di dollari dopo le svalutazioni.
La direzione indica come principali ostacoli un consumatore statunitense pi霉 debole, tariffe pi霉 alte (dal 19 al 30%) e un tempo pi霉 lungo per la stabilizzazione di HEYDUDE. Le cause legali in corso, sia collettive che derivanti, rappresentano un ulteriore rischio legale. Tuttavia, la societ脿 mantiene un'autorizzazione residua per riacquisti di azioni di 1,1 miliardi di dollari e una capacit脿 di revolving di 784 milioni di dollari, offrendo liquidit脿 per affrontare le sfide macroeconomiche e specifiche del marchio.
Crocs (CROX) report贸 ingresos en el segundo trimestre de 2025 de 1,15 mil millones de d贸lares, un aumento del 3,4% interanual, con un margen bruto que mejor贸 10 puntos b谩sicos hasta el 61,7%, a pesar de un entorno de consumo m谩s d茅bil y nuevas tarifas en el calzado de EE. UU. La marca Crocs continu贸 siendo el motor de ganancias, generando un ingreso operativo de 359 millones de d贸lares con un margen del 37,4%, mientras que los ingresos de HEYDUDE cayeron un 3,9% y sufrieron una deterioraci贸n no monetaria de 737 millones de d贸lares (430 millones en marcas registradas y 307 millones en fondo de comercio). Estos cargos convirtieron el ingreso operativo consolidado en una p茅rdida de 428 millones de d贸lares y provocaron una p茅rdida neta de 492 millones de d贸lares (-8,82 d贸lares por acci贸n diluida) frente a una ganancia de 229 millones el a帽o pasado.
El efectivo generado por las operaciones se mantuvo positivo en 219 millones de d贸lares, pero disminuy贸 un 41% interanual; el flujo de caja libre financi贸 recompras de acciones por 194 millones en el primer semestre, reduciendo las acciones diluidas a 55,8 millones. El efectivo aument贸 a 201 millones; la deuda bruta subi贸 a 1,38 mil millones, implicando un apalancamiento neto de aproximadamente 1,4 veces el EBITDA de los 煤ltimos doce meses (antes de deterioros). Los intangibles cayeron a 1,34 mil millones tras las depreciaciones.
La direcci贸n se帽ala como principales obst谩culos un consumidor estadounidense m谩s d茅bil, tarifas m谩s altas (19-30%) y un per铆odo de estabilizaci贸n m谩s largo para HEYDUDE. Las demandas colectivas y derivadas en curso a帽aden presi贸n legal. Sin embargo, la empresa mantiene una autorizaci贸n restante para recompras de 1,1 mil millones y una capacidad revolvente de 784 millones, ofreciendo liquidez para navegar desaf铆os macroecon贸micos y espec铆ficos de la marca.
Crocs(CROX)電� 2025雲� 2攵勱赴 毵れ稖鞚� 11鞏� 5觳滊 雼煬搿� 鞝勲厔 雽�牍� 3.4% 歃濌皜頄堨溂氅�, 靻岆箘鞛� 靾橃殧 鞎巾檾鞕� 氙戈淡 鞁犽皽 甏�靹胳棎霃� 攵堦惮頃橁碃 齑濎澊鞚惦鞚� 10bp 靸侅姽頃� 61.7%毳� 旮半頄堨姷雼堧嫟. Crocs 敫岆灉霌滊姅 37.4%鞚� 毵堨鞙茧 3鞏� 5,900毵� 雼煬鞚� 鞓侅梾鞚挫澋鞚� 雮措┌ 靾橃澋鞗� 鞐暊鞚� 頄堨溂雮�, HEYDUDE 毵れ稖鞚� 3.9% 臧愳唽頄堦碃 7鞏� 3,700毵� 雼煬鞚� 牍勴槃旮� 靻愳儊彀啇(靸來憸甓� 4鞏� 3,000毵� 雼煬, 鞓侅梾甓� 3鞏� 700毵� 雼煬)鞚� 旮半頄堨姷雼堧嫟. 鞚措 鞚疙暣 鞐瓣舶 鞓侅梾鞚挫澋鞚� 4鞏� 2,800毵� 雼煬 靻愳嫟搿� 霃岇晞靹瓣碃, 靾滌啇鞁れ潃 4鞏� 9,200毵� 雼煬(頋劃欤茧嫻靾滌啇鞁� -8.82雼煬)毳� 旮半頃� 鞝勲厔 2鞏� 2,900毵� 雼煬 鞚挫澋瓿� 雽�牍勲惄雼堧嫟.
鞓侅梾頇滊彊 順勱笀頋愲鞚� 2鞏� 1,900毵� 雼煬搿� 鞐爠頌� 鞏戫樃頄堨溂雮� 鞝勲厔 雽�牍� 41% 臧愳唽頄堨溂氅�, 鞛夓棳順勱笀頋愲鞚� 靸侂皹旮� 1鞏� 9,400毵� 雼煬鞚� 鞛愳偓欤� 毵れ瀰鞐� 靷毄霅橃柎 頋劃 欤检嫕 靾橂姅 5,580毵� 欤茧 欷勳棃鞀惦媹雼�. 順勱笀鞚� 2鞏� 100毵� 雼煬搿� 歃濌皜頄堦碃, 齑濍秬毂勲姅 13鞏� 8觳滊 雼煬搿� 靻岉彮 歃濌皜頃� 靾滌皑鞛呹笀鞚� 斓滉芳 12臧滌洈 EBITDA(靻愳儊彀啇 鞝�) 雽�牍� 鞎� 1.4氚� 靾橃鞛呺媹雼�. 氍错槙鞛愳偘鞚� 靻愳儊彀啇 鞚错泟 13鞏� 4觳滊 雼煬搿� 臧愳唽頄堨姷雼堧嫟.
瓴届榿歆勳潃 氙戈淡 靻岆箘鞛� 鞁Μ 鞎巾檾, 甏�靹� 鞚胳儊(19~30%), HEYDUDE鞚� 鞎堨爼頇� 旮瓣皠 歆�鞐办潉 欤检殧 鞐拲鞙茧 昙届晿鞀惦媹雼�. 歆勴枆 欷戩澑 歆戨嫧 靻岇啞 氚� 韺岇儩 靻岇啞霃� 氩曥爜 攵�雼挫溂搿� 鞛戩毄頃橁碃 鞛堨姷雼堧嫟. 攴鸽熂鞐愲弰 攵堦惮頃橁碃 須岇偓電� 11鞏� 雼煬鞚� 鞛旍棳 鞛愳偓欤� 毵れ瀰 鞀轨澑瓿� 7鞏� 8,400毵� 雼煬鞚� 毽臣牍� 鞁犾毄 頃滊弰毳� 氤挫湢頃� 瓯办嫓瓴届牅 氚� 敫岆灉霌滊硠 霃勳爠鞚� 攴闺车頃� 鞙犽彊靹膘潉 頇曤炒頃橁碃 鞛堨姷雼堧嫟.
Crocs (CROX) a publi茅 un chiffre d'affaires au deuxi猫me trimestre 2025 de 1,15 milliard de dollars, en hausse de 3,4 % en glissement annuel, avec une marge brute en am茅lioration de 10 points de base 脿 61,7 %, malgr茅 un contexte de consommation plus faible et de nouvelles taxes sur les chaussures aux 脡tats-Unis. La marque Crocs est rest茅e le moteur de profit, g茅n茅rant un r茅sultat op茅rationnel de 359 millions de dollars avec une marge de 37,4 %, tandis que les revenus de HEYDUDE ont diminu茅 de 3,9 % et ont subi une d茅pr茅ciation non mon茅taire de 737 millions de dollars (430 millions pour les marques, 307 millions pour le goodwill). Ces charges ont fait basculer le r茅sultat op茅rationnel consolid茅 vers une perte de 428 millions de dollars et ont entra卯n茅 une perte nette de 492 millions de dollars (-8,82 dollars par action dilu茅e) contre un b茅n茅fice de 229 millions l'ann茅e pr茅c茅dente.
Les flux de tr茅sorerie issus des op茅rations sont rest茅s positifs 脿 219 millions de dollars, mais ont diminu茅 de 41 % en glissement annuel ; le flux de tr茅sorerie disponible a financ茅 194 millions de dollars de rachats d'actions au premier semestre, r茅duisant le nombre d'actions dilu茅es 脿 55,8 millions. La tr茅sorerie a augment茅 脿 201 millions de dollars ; la dette brute a l茅g猫rement augment茅 脿 1,38 milliard, ce qui implique un levier net d'environ 1,4 fois l'EBITDA sur 12 mois glissants (avant d茅pr茅ciation). Les actifs incorporels ont chut茅 脿 1,34 milliard apr猫s les d茅pr茅ciations.
La direction cite comme principaux vents contraires un consommateur am茅ricain plus faible, des taxes plus 茅lev茅es (19-30 %) et un d茅lai de stabilisation plus long pour HEYDUDE. Les poursuites collectives et d茅riv茅es en cours constituent un surcro卯t de risque juridique. N茅anmoins, l'entreprise conserve une autorisation de rachat restante de 1,1 milliard et une capacit茅 de cr茅dit renouvelable de 784 millions, offrant une liquidit茅 pour naviguer 脿 travers les d茅fis macro茅conomiques et sp茅cifiques 脿 la marque.
Crocs (CROX) erzielte im zweiten Quartal 2025 einen Umsatz von 1,15 Mrd. USD, ein Plus von 3,4 % im Jahresvergleich, bei einer um 10 Basispunkte verbesserten Bruttomarge von 61,7 %, trotz eines schw盲cheren Konsumumfelds und neuer US-Schuhz枚lle. Die Marke Crocs blieb die Gewinnquelle und erwirtschaftete einen operativen Gewinn von 359 Mio. USD bei einer Marge von 37,4 %, w盲hrend die Ums盲tze von HEYDUDE um 3,9 % zur眉ckgingen und eine nicht zahlungswirksame Wertminderung von 737 Mio. USD (430 Mio. USD Markenrechte, 307 Mio. USD Gesch盲fts- oder Firmenwert) verbucht wurde. Diese Abschreibungen f眉hrten zu einem konsolidierten operativen Verlust von 428 Mio. USD und einem Nettoverlust von 492 Mio. USD (-8,82 USD verw盲sserter Gewinn je Aktie) gegen眉ber einem Gewinn von 229 Mio. USD im Vorjahr.
Der operative Cashflow blieb mit 219 Mio. USD positiv, sank jedoch um 41 % im Jahresvergleich; der freie Cashflow finanzierte Aktienr眉ckk盲ufe in H枚he von 194 Mio. USD im ersten Halbjahr, wodurch die verw盲sserten Aktien auf 55,8 Mio. reduziert wurden. Die Barmittel stiegen auf 201 Mio. USD; die Bruttoverschuldung stieg leicht auf 1,38 Mrd. USD, was einer Nettoverschuldung von etwa dem 1,4-fachen des EBITDA der letzten zw枚lf Monate (vor Abschreibungen) entspricht. Die immateriellen Verm枚genswerte sanken nach den Abschreibungen auf 1,34 Mrd. USD.
Das Management nennt einen schw盲cheren US-Konsumenten, h枚here Z枚lle (19-30 %) und einen l盲ngeren Stabilisierungszeitraum f眉r HEYDUDE als wesentliche Herausforderungen. Laufende Sammelklagen und Derivatklagen belasten zus盲tzlich rechtlich. Das Unternehmen verf眉gt jedoch weiterhin 眉ber eine verbleibende R眉ckkaufgenehmigung von 1,1 Mrd. USD und eine revolvierende Kreditlinie von 784 Mio. USD, was Liquidit盲t bietet, um makro枚konomische und markenspezifische Herausforderungen zu bew盲ltigen.
- Revenue up 3.4% YoY; Crocs Brand grew 5.0% and maintained strong pricing.
- Gross margin 61.7%, a 10 bp improvement despite tariff headwinds.
- Crocs Brand operating margin 37.4% generated $359 mn profit.
- Operating cash flow $219 mn kept balance-sheet cash at $201 mn.
- $784 mn unused revolver plus $1.1 bn remaining buyback authorization provides liquidity.
- $738 mn impairment on HEYDUDE trademark and goodwill drove net loss.
- Net loss $492 mn; EPS -$8.82 versus $3.77 profit prior year.
- HEYDUDE revenue -3.9% YoY; brand faces weak U.S. demand and tariff pressure.
- SG&A up 11.8%, diluting operating leverage.
- Multiple shareholder lawsuits create legal and reputational risk.
Insights
TL;DR: Large impairment erases profit; core Crocs brand solid but overall outlook tilts negative.
The $738 mn HEYDUDE write-down signals management鈥檚 reduced growth expectations and materially cuts book value (equity now $1.42 bn). While operating metrics for Crocs footwear remain healthy鈥攕ales +5%, margin expansion鈥攇roup net leverage rises as EBITDA base shrinks, tightening covenant headroom. Cash deployment into buybacks looks aggressive given reduced free cash flow and litigation risk. Shares may re-rate lower until HEYDUDE trends, tariff pass-through and legal matters clarify.
TL;DR: Impairment resets HEYDUDE baseline; execution window still open.
Management took decisive non-cash charges, clearing the deck for a multi-year rebuild. HEYDUDE still generated $190 mn quarterly sales and 50% gross margin pre-impairment, evidencing consumer traction. Diversified sourcing and selective price hikes can mitigate tariff impact. If marketing and distribution realignment succeed, the brand could regain growth without heavy capital needs. Liquidity and Crocs cash engine provide strategic flexibility, though investor patience is required.
Crocs (CROX) ha riportato un fatturato nel secondo trimestre 2025 di 1,15 miliardi di dollari, in crescita del 3,4% su base annua, con un margine lordo migliorato di 10 punti base al 61,7%, nonostante un contesto di consumo pi霉 debole e nuove tariffe sui calzature negli Stati Uniti. Il marchio Crocs ha continuato a essere il motore di profitto, generando un reddito operativo di 359 milioni di dollari con un margine del 37,4%, mentre i ricavi di HEYDUDE sono diminuiti del 3,9% e hanno subito una svalutazione non monetaria di 737 milioni di dollari (430 milioni per marchi e 307 milioni per avviamento). Queste svalutazioni hanno trasformato il reddito operativo consolidato in una perdita di 428 milioni di dollari e hanno causato una perdita netta di 492 milioni di dollari (-8,82 dollari per azione diluita) rispetto a un utile di 229 milioni dell'anno precedente.
La liquidit脿 generata dalle operazioni 猫 rimasta positiva a 219 milioni di dollari, ma 猫 diminuita del 41% su base annua; il flusso di cassa libero ha finanziato 194 milioni di dollari di riacquisti di azioni nel primo semestre, riducendo le azioni diluite a 55,8 milioni. La liquidit脿 猫 aumentata a 201 milioni di dollari; il debito lordo 猫 salito a 1,38 miliardi di dollari, implicando una leva finanziaria netta di circa 1,4 volte l'EBITDA degli ultimi dodici mesi (prima delle svalutazioni). Gli intangibili sono scesi a 1,34 miliardi di dollari dopo le svalutazioni.
La direzione indica come principali ostacoli un consumatore statunitense pi霉 debole, tariffe pi霉 alte (dal 19 al 30%) e un tempo pi霉 lungo per la stabilizzazione di HEYDUDE. Le cause legali in corso, sia collettive che derivanti, rappresentano un ulteriore rischio legale. Tuttavia, la societ脿 mantiene un'autorizzazione residua per riacquisti di azioni di 1,1 miliardi di dollari e una capacit脿 di revolving di 784 milioni di dollari, offrendo liquidit脿 per affrontare le sfide macroeconomiche e specifiche del marchio.
Crocs (CROX) report贸 ingresos en el segundo trimestre de 2025 de 1,15 mil millones de d贸lares, un aumento del 3,4% interanual, con un margen bruto que mejor贸 10 puntos b谩sicos hasta el 61,7%, a pesar de un entorno de consumo m谩s d茅bil y nuevas tarifas en el calzado de EE. UU. La marca Crocs continu贸 siendo el motor de ganancias, generando un ingreso operativo de 359 millones de d贸lares con un margen del 37,4%, mientras que los ingresos de HEYDUDE cayeron un 3,9% y sufrieron una deterioraci贸n no monetaria de 737 millones de d贸lares (430 millones en marcas registradas y 307 millones en fondo de comercio). Estos cargos convirtieron el ingreso operativo consolidado en una p茅rdida de 428 millones de d贸lares y provocaron una p茅rdida neta de 492 millones de d贸lares (-8,82 d贸lares por acci贸n diluida) frente a una ganancia de 229 millones el a帽o pasado.
El efectivo generado por las operaciones se mantuvo positivo en 219 millones de d贸lares, pero disminuy贸 un 41% interanual; el flujo de caja libre financi贸 recompras de acciones por 194 millones en el primer semestre, reduciendo las acciones diluidas a 55,8 millones. El efectivo aument贸 a 201 millones; la deuda bruta subi贸 a 1,38 mil millones, implicando un apalancamiento neto de aproximadamente 1,4 veces el EBITDA de los 煤ltimos doce meses (antes de deterioros). Los intangibles cayeron a 1,34 mil millones tras las depreciaciones.
La direcci贸n se帽ala como principales obst谩culos un consumidor estadounidense m谩s d茅bil, tarifas m谩s altas (19-30%) y un per铆odo de estabilizaci贸n m谩s largo para HEYDUDE. Las demandas colectivas y derivadas en curso a帽aden presi贸n legal. Sin embargo, la empresa mantiene una autorizaci贸n restante para recompras de 1,1 mil millones y una capacidad revolvente de 784 millones, ofreciendo liquidez para navegar desaf铆os macroecon贸micos y espec铆ficos de la marca.
Crocs(CROX)電� 2025雲� 2攵勱赴 毵れ稖鞚� 11鞏� 5觳滊 雼煬搿� 鞝勲厔 雽�牍� 3.4% 歃濌皜頄堨溂氅�, 靻岆箘鞛� 靾橃殧 鞎巾檾鞕� 氙戈淡 鞁犽皽 甏�靹胳棎霃� 攵堦惮頃橁碃 齑濎澊鞚惦鞚� 10bp 靸侅姽頃� 61.7%毳� 旮半頄堨姷雼堧嫟. Crocs 敫岆灉霌滊姅 37.4%鞚� 毵堨鞙茧 3鞏� 5,900毵� 雼煬鞚� 鞓侅梾鞚挫澋鞚� 雮措┌ 靾橃澋鞗� 鞐暊鞚� 頄堨溂雮�, HEYDUDE 毵れ稖鞚� 3.9% 臧愳唽頄堦碃 7鞏� 3,700毵� 雼煬鞚� 牍勴槃旮� 靻愳儊彀啇(靸來憸甓� 4鞏� 3,000毵� 雼煬, 鞓侅梾甓� 3鞏� 700毵� 雼煬)鞚� 旮半頄堨姷雼堧嫟. 鞚措 鞚疙暣 鞐瓣舶 鞓侅梾鞚挫澋鞚� 4鞏� 2,800毵� 雼煬 靻愳嫟搿� 霃岇晞靹瓣碃, 靾滌啇鞁れ潃 4鞏� 9,200毵� 雼煬(頋劃欤茧嫻靾滌啇鞁� -8.82雼煬)毳� 旮半頃� 鞝勲厔 2鞏� 2,900毵� 雼煬 鞚挫澋瓿� 雽�牍勲惄雼堧嫟.
鞓侅梾頇滊彊 順勱笀頋愲鞚� 2鞏� 1,900毵� 雼煬搿� 鞐爠頌� 鞏戫樃頄堨溂雮� 鞝勲厔 雽�牍� 41% 臧愳唽頄堨溂氅�, 鞛夓棳順勱笀頋愲鞚� 靸侂皹旮� 1鞏� 9,400毵� 雼煬鞚� 鞛愳偓欤� 毵れ瀰鞐� 靷毄霅橃柎 頋劃 欤检嫕 靾橂姅 5,580毵� 欤茧 欷勳棃鞀惦媹雼�. 順勱笀鞚� 2鞏� 100毵� 雼煬搿� 歃濌皜頄堦碃, 齑濍秬毂勲姅 13鞏� 8觳滊 雼煬搿� 靻岉彮 歃濌皜頃� 靾滌皑鞛呹笀鞚� 斓滉芳 12臧滌洈 EBITDA(靻愳儊彀啇 鞝�) 雽�牍� 鞎� 1.4氚� 靾橃鞛呺媹雼�. 氍错槙鞛愳偘鞚� 靻愳儊彀啇 鞚错泟 13鞏� 4觳滊 雼煬搿� 臧愳唽頄堨姷雼堧嫟.
瓴届榿歆勳潃 氙戈淡 靻岆箘鞛� 鞁Μ 鞎巾檾, 甏�靹� 鞚胳儊(19~30%), HEYDUDE鞚� 鞎堨爼頇� 旮瓣皠 歆�鞐办潉 欤检殧 鞐拲鞙茧 昙届晿鞀惦媹雼�. 歆勴枆 欷戩澑 歆戨嫧 靻岇啞 氚� 韺岇儩 靻岇啞霃� 氩曥爜 攵�雼挫溂搿� 鞛戩毄頃橁碃 鞛堨姷雼堧嫟. 攴鸽熂鞐愲弰 攵堦惮頃橁碃 須岇偓電� 11鞏� 雼煬鞚� 鞛旍棳 鞛愳偓欤� 毵れ瀰 鞀轨澑瓿� 7鞏� 8,400毵� 雼煬鞚� 毽臣牍� 鞁犾毄 頃滊弰毳� 氤挫湢頃� 瓯办嫓瓴届牅 氚� 敫岆灉霌滊硠 霃勳爠鞚� 攴闺车頃� 鞙犽彊靹膘潉 頇曤炒頃橁碃 鞛堨姷雼堧嫟.
Crocs (CROX) a publi茅 un chiffre d'affaires au deuxi猫me trimestre 2025 de 1,15 milliard de dollars, en hausse de 3,4 % en glissement annuel, avec une marge brute en am茅lioration de 10 points de base 脿 61,7 %, malgr茅 un contexte de consommation plus faible et de nouvelles taxes sur les chaussures aux 脡tats-Unis. La marque Crocs est rest茅e le moteur de profit, g茅n茅rant un r茅sultat op茅rationnel de 359 millions de dollars avec une marge de 37,4 %, tandis que les revenus de HEYDUDE ont diminu茅 de 3,9 % et ont subi une d茅pr茅ciation non mon茅taire de 737 millions de dollars (430 millions pour les marques, 307 millions pour le goodwill). Ces charges ont fait basculer le r茅sultat op茅rationnel consolid茅 vers une perte de 428 millions de dollars et ont entra卯n茅 une perte nette de 492 millions de dollars (-8,82 dollars par action dilu茅e) contre un b茅n茅fice de 229 millions l'ann茅e pr茅c茅dente.
Les flux de tr茅sorerie issus des op茅rations sont rest茅s positifs 脿 219 millions de dollars, mais ont diminu茅 de 41 % en glissement annuel ; le flux de tr茅sorerie disponible a financ茅 194 millions de dollars de rachats d'actions au premier semestre, r茅duisant le nombre d'actions dilu茅es 脿 55,8 millions. La tr茅sorerie a augment茅 脿 201 millions de dollars ; la dette brute a l茅g猫rement augment茅 脿 1,38 milliard, ce qui implique un levier net d'environ 1,4 fois l'EBITDA sur 12 mois glissants (avant d茅pr茅ciation). Les actifs incorporels ont chut茅 脿 1,34 milliard apr猫s les d茅pr茅ciations.
La direction cite comme principaux vents contraires un consommateur am茅ricain plus faible, des taxes plus 茅lev茅es (19-30 %) et un d茅lai de stabilisation plus long pour HEYDUDE. Les poursuites collectives et d茅riv茅es en cours constituent un surcro卯t de risque juridique. N茅anmoins, l'entreprise conserve une autorisation de rachat restante de 1,1 milliard et une capacit茅 de cr茅dit renouvelable de 784 millions, offrant une liquidit茅 pour naviguer 脿 travers les d茅fis macro茅conomiques et sp茅cifiques 脿 la marque.
Crocs (CROX) erzielte im zweiten Quartal 2025 einen Umsatz von 1,15 Mrd. USD, ein Plus von 3,4 % im Jahresvergleich, bei einer um 10 Basispunkte verbesserten Bruttomarge von 61,7 %, trotz eines schw盲cheren Konsumumfelds und neuer US-Schuhz枚lle. Die Marke Crocs blieb die Gewinnquelle und erwirtschaftete einen operativen Gewinn von 359 Mio. USD bei einer Marge von 37,4 %, w盲hrend die Ums盲tze von HEYDUDE um 3,9 % zur眉ckgingen und eine nicht zahlungswirksame Wertminderung von 737 Mio. USD (430 Mio. USD Markenrechte, 307 Mio. USD Gesch盲fts- oder Firmenwert) verbucht wurde. Diese Abschreibungen f眉hrten zu einem konsolidierten operativen Verlust von 428 Mio. USD und einem Nettoverlust von 492 Mio. USD (-8,82 USD verw盲sserter Gewinn je Aktie) gegen眉ber einem Gewinn von 229 Mio. USD im Vorjahr.
Der operative Cashflow blieb mit 219 Mio. USD positiv, sank jedoch um 41 % im Jahresvergleich; der freie Cashflow finanzierte Aktienr眉ckk盲ufe in H枚he von 194 Mio. USD im ersten Halbjahr, wodurch die verw盲sserten Aktien auf 55,8 Mio. reduziert wurden. Die Barmittel stiegen auf 201 Mio. USD; die Bruttoverschuldung stieg leicht auf 1,38 Mrd. USD, was einer Nettoverschuldung von etwa dem 1,4-fachen des EBITDA der letzten zw枚lf Monate (vor Abschreibungen) entspricht. Die immateriellen Verm枚genswerte sanken nach den Abschreibungen auf 1,34 Mrd. USD.
Das Management nennt einen schw盲cheren US-Konsumenten, h枚here Z枚lle (19-30 %) und einen l盲ngeren Stabilisierungszeitraum f眉r HEYDUDE als wesentliche Herausforderungen. Laufende Sammelklagen und Derivatklagen belasten zus盲tzlich rechtlich. Das Unternehmen verf眉gt jedoch weiterhin 眉ber eine verbleibende R眉ckkaufgenehmigung von 1,1 Mrd. USD und eine revolvierende Kreditlinie von 784 Mio. USD, was Liquidit盲t bietet, um makro枚konomische und markenspezifische Herausforderungen zu bew盲ltigen.
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For the quarterly period ended
or
For the transition period from to
Commission file number:
(Exact name of registrant as specified in its charter)
| | |
| ||
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
| | |
| | |
| ||
(Address of principal executive offices) | | (Zip Code) |
(
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
| |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
| | | |
þ | Accelerated filer | ☐ | |
| | | |
Non-accelerated filer | ☐ | Smaller reporting company | |
| | | |
| | Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
As of August 5, 2025, there were
Table of Contents
TABLE OF CONTENTS
PTC Therapeutics, Inc.
| |
| Page No. |
PART I—FINANCIAL INFORMATION | |
| |
Item 1. Financial Statements (unaudited) | 4 |
| |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 40 |
| |
Item 3. Quantitative and Qualitative Disclosures About Market Risk | 60 |
| |
Item 4. Controls and Procedures | 60 |
| |
PART II—OTHER INFORMATION | |
| |
Item 1. Legal Proceedings | 61 |
| |
Item 1A. Risk Factors | 61 |
| |
Item 5. Other Information | 71 |
| |
Item 6. Exhibits | 72 |
i
Table of Contents
FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “aim,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:
| ● | the outcome of pricing, coverage and reimbursement negotiations with third-party payors for our products or product candidates that we commercialize or may commercialize in the future; |
| ● | expectations with respect to Sephience for the treatment of phenylketonuria, including timing of commercialization and of any regulatory submissions and potential approvals, and the potential achievement of regulatory and sales milestones and contingent payments that we may be obligated to make; |
| ● | our ability to maintain our marketing authorization of Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in Brazil, Russia and other regions in which Translarna has been approved; |
| ● | the effect of the European Commission’s adoption of the Committee for Medicinal Products for Human Use’s negative opinion not to renew the conditional marketing authorization for Translarna in the European Economic Area on other regulatory bodies; |
| ● | our ability to use the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, and from our international drug registry study to support a marketing approval for Translarna for the treatment of nmDMD in the United States; |
| ● | whether investigators agree with our interpretation of the results of clinical trials and the totality of clinical data from our trials of Translarna; |
| ● | expectations with respect to our license and collaboration agreement with Novartis Pharmaceuticals Corporation, or Novartis, including our right to receive any development, regulatory and sales milestones, and profit sharing and royalty payments from Novartis; |
| ● | expectations with respect to vatiquinone for the treatment of Friedreich’s ataxia, including any regulatory submissions and potential approvals, commercialization, and the potential achievement of regulatory and sales milestones and contingent payments that we may be obligated to make; |
| ● | expectations with respect to Upstaza/Kebilidi, including commercialization, manufacturing capabilities, and the potential achievement of sales milestones and contingent payments that we may be obligated to make; |
| ● | our expectations with respect to the commercial status of Evrysdi and our program directed against spinal muscular atrophy in collaboration with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. and the Spinal Muscular Atrophy Foundation and our estimates regarding future revenues from sales-based royalty payments or the achievement of milestones in that program; |
| ● | our expectations and the potential financial impact and benefits related to our Collaboration and License Agreement with a subsidiary of Ionis Pharmaceuticals, Inc., including the commercialization of Tegsedi and Waylivra, and our expectations with respect to royalty payments by us based on our potential achievement of certain net sales thresholds; |
1
Table of Contents
| ● | the timing and scope of our commercialization of our products and product candidates; |
| ● | our estimates regarding the potential market opportunity for our products or product candidates, including the size of eligible patient populations and our ability to identify such patients; |
| ● | our ability to obtain additional and maintain existing reimbursed named patient and cohort early access programs for our products on adequate terms, or at all; |
| ● | our estimates regarding expenses, future revenues, third-party discounts and rebates, capital requirements and needs for additional financing, including our ability to maintain the level of our expenses consistent with our internal budgets and forecasts and to secure additional funds on favorable terms or at all; |
| ● | our ability to realize the anticipated benefits of our acquisitions or other strategic transactions, including the possibility that the expected impact of benefits from the acquisitions or strategic transactions will not be realized or will not be realized within the expected time period, significant transaction costs, the integration of operations and employees into our business, our ability to obtain marketing approval of our product candidates we acquired from the acquisitions or other strategic transactions and unknown liabilities; |
| ● | the rate and degree of market acceptance and clinical utility of any of our products or product candidates; |
| ● | the ability and willingness of patients and healthcare professionals to access our products and product candidates through alternative means if pricing and reimbursement negotiations in the applicable territory do not have a positive outcome; |
| ● | the timing of, and our ability to obtain additional marketing authorizations for our products and product candidates; |
| ● | the ability of our products and our product candidates to meet existing or future regulatory standards; |
| ● | the potential receipt of revenues from future sales of our products or product candidates; |
| ● | the expected impact of our loss of market exclusivity for Emflaza for the treatment of Duchenne muscular dystrophy in the United States under the Orphan Drug Act of 1983; |
| ● | our sales, marketing and distribution capabilities and strategy, including the ability of our third-party manufacturers to manufacture and deliver our products and product candidates in clinically and commercially sufficient quantities and the ability of distributors to process orders in a timely manner and satisfy their other obligations to us; |
| ● | our ability to establish and maintain arrangements for the manufacture of our products and product candidates that are sufficient to meet clinical trial and commercial launch requirements; |
| ● | our ability to complete any post-marketing requirements imposed by regulatory agencies with respect to our products; |
| ● | our ability to satisfy our obligations under the terms of our lease agreements; |
| ● | our ability to satisfy our obligations under the indenture governing our 1.50% convertible senior notes due September 15, 2026; |
| ● | our regulatory submissions, including with respect to timing and outcome of regulatory review; |
| ● | the timing and conduct of our ongoing, planned and potential future clinical trials and studies for our splicing and inflammation and ferroptosis programs as well as studies in our products for maintaining authorizations, label |
2
Table of Contents
| extensions and additional indications, including the timing of initiation, enrollment and completion of the trials and the period during which the results of the trials will become available; |
| ● | our plans to advance our earlier stage programs and pursue research and development of other product candidates, including our splicing and inflammation and ferroptosis programs; |
| ● | whether we may pursue business development opportunities, including potential collaborations, alliances, and acquisition or licensing of assets and our ability to successfully develop or commercialize any assets to which we may gain rights pursuant to such business development opportunities; |
| ● | the potential advantages of our products and any product candidate; |
| ● | our intellectual property position; |
| ● | the impact of government laws and regulations; |
| ● | the impact of litigation that has been or may be brought against us or of litigation that we are pursuing against others; and |
| ● | our competitive position. |
We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q, particularly in Part II, Item 1A. Risk Factors as well as in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2024, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.
You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2024 completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
In this Quarterly Report on Form 10-Q, unless otherwise stated or the context otherwise requires, references to “PTC,” “PTC Therapeutics,” “the Company,” “we,” “us,” “our,” and similar references refer to PTC Therapeutics, Inc. and, where appropriate, its subsidiaries. The trademarks, trade names and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.
All website addresses given in this Quarterly Report on Form 10-Q are for information only and are not intended to be an active link or to incorporate any website information into this document.
3
Table of Contents
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
PTC Therapeutics, Inc.
Consolidated Balance Sheets (unaudited)
In thousands (except shares)
| | | | | | | |
| | June 30, | | December 31, | | ||
|
| 2025 |
| 2024 | | ||
Assets | | | | | | | |
Current assets: |
| | |
| |
| |
Cash and cash equivalents | | $ | | | $ | | |
Marketable securities | |
| | |
| | |
Trade and royalty receivables, net | |
| | |
| | |
Inventory, net | |
| | |
| | |
Prepaid expenses and other current assets | |
| | |
| | |
Total current assets | |
| | |
| | |
Fixed assets, net | |
| | |
| | |
Intangible assets, net | |
| | |
| | |
Goodwill | |
| | |
| | |
Operating lease ROU assets | | | | | | | |
Deposits and other assets | |
| | |
| | |
Total assets | | $ | | | $ | | |
Liabilities and stockholders’ deficit | |
|
| |
|
| |
Current liabilities: | |
| | |
|
| |
Accounts payable and accrued expenses | | $ | | | $ | | |
Deferred revenue | |
| | |
| | |
Operating lease liabilities- current | | | | | | | |
Finance lease liabilities- current | | | | | | | |
Liability for sale of future royalties- current | | | | | | | |
Total current liabilities | |
| | |
| | |
Long-term debt | |
| | |
| | |
Contingent consideration payable | |
| — | |
| | |
Operating lease liabilities- noncurrent | | | | | | | |
Finance lease liabilities- noncurrent | | | | | | | |
Liability for sale of future royalties- noncurrent | | | | | | | |
Other long-term liabilities | | | | | | | |
Total liabilities | |
| | |
| | |
Stockholders’ deficit: | |
|
| |
|
| |
Common stock, $ | |
| | |
| | |
Additional paid-in capital | |
| | |
| | |
Accumulated other comprehensive income (loss) | |
| | |
| ( | |
Accumulated deficit | |
| ( | |
| ( | |
Total stockholders’ deficit | |
| ( | |
| ( | |
Total liabilities and stockholders’ deficit | | $ | | | $ | | |
See accompanying unaudited notes.
4
Table of Contents
PTC Therapeutics, Inc.
Consolidated Statements of Operations (unaudited)
In thousands (except shares and per share amounts)
| | | | | | | | | | | | | |
| | Three Months Ended June 30, | | Six Months Ended June 30, | | ||||||||
|
| 2025 |
| 2024 |
| 2025 |
| 2024 | | ||||
Revenues: |
| |
|
| |
| | |
|
| |
| |
Net product revenue | | $ | | | $ | | | $ | | | $ | | |
Collaboration and license revenue | |
| | | | — | |
| | |
| — | |
Royalty revenue | | | | | | | | | | | | | |
Manufacturing revenue | | | — | | | | | | — | | | | |
Total revenues | |
| | |
| | |
| | |
| | |
Operating expenses: | | | | | | | | | | | | | |
Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets | |
| | | | | |
| | |
| | |
Amortization of acquired intangible assets | |
| | | | | |
| | |
| | |
Research and development | |
| | | | | |
| | |
| | |
Selling, general and administrative | |
| | | | | |
| | |
| | |
Change in the fair value of contingent consideration | |
| — | | | | |
| ( | |
| | |
Tangible asset impairment and losses (gains) on transactions, net | | | | | | | | | | | | | |
Total operating expenses | |
| | |
| | |
| | |
| | |
(Loss) income from operations | |
| ( | |
| ( | |
| | |
| ( | |
Interest expense, net | |
| ( | | | ( | |
| ( | |
| ( | |
Other expense, net | |
| ( | | | ( | |
| ( | |
| ( | |
(Loss) income before income tax benefit (expense) | |
| ( | |
| ( | |
| | |
| ( | |
Income tax benefit (expense) | |
| | | | ( | |
| ( | |
| ( | |
Net (loss) income attributable to common stockholders | | $ | ( | | $ | ( | | $ | | | $ | ( | |
Weighted-average shares outstanding: | | | | | | | | | | | | | |
Basic (in shares) | |
| | | | | | | | | | | |
Diluted (in shares) | | | | | | | | | | | | | |
Net (loss) income per share—basic (in dollars per share) | | $ | ( | | $ | ( | | $ | | | $ | ( | |
Net (loss) income per share—diluted (in dollars per share) | | $ | ( | | $ | ( | | $ | | | $ | ( | |
See accompanying unaudited notes.
5
Table of Contents
PTC Therapeutics, Inc.
Consolidated Statements of Comprehensive Income (Loss) (unaudited)
In thousands
| | | | | | | | | | | | | |
| | Three Months Ended June 30, | | Six Months Ended June 30, | | ||||||||
|
| 2025 |
| 2024 |
| 2025 |
| 2024 | | ||||
Net (loss) income | | $ | ( | | $ | ( | | $ | | | $ | ( | |
Other comprehensive income (loss): | |
|
| |
|
| |
| | |
|
| |
Unrealized loss on marketable securities, net of tax | |
| ( | | | ( | |
| ( | |
| ( | |
Foreign currency translation gain (loss), net of tax | |
| | | | ( | |
| | |
| ( | |
Comprehensive (loss) income | | $ | ( | | $ | ( | | $ | | | $ | ( | |
See accompanying unaudited notes.
6
Table of Contents
PTC Therapeutics, Inc.
Consolidated Statements of Stockholders’ Deficit (unaudited)
In thousands (except shares)
| | | | | | | | | | | | | | | | | |
| | | | | |
| | |
| Accumulated |
| | |
| | | |
| | | | | |
| Additional |
| other | | | |
| Total | |||
Three months ended June 30, 2025 | | Common stock | | paid-in |
| comprehensive | | Accumulated | | stockholders’ | |||||||
|
| Shares |
| Amount |
| capital |
| (loss) income |
| deficit |
| deficit | |||||
Balance, March 31, 2025 | | | | $ | | | $ | | | $ | ( | | $ | ( | | $ | ( |
Exercise of options |
| | | | — | | | | | | — | | | — | | | |
Restricted stock vesting and issuance, net |
| | | | — | | | — | | | — | | | — | | | — |
Issuance of common stock in connection with an employee stock purchase plan |
| | | | — | | | | | | — | | | — | | | |
Share-based compensation expense |
| — | | | — | | | | | | — | | | — | | | |
Receivable from investor | | — | | | — | | | | | | — | | | — | | | |
Net loss |
| — | | | — | | | — | | | — | | | ( | | | ( |
Comprehensive income |
| — | | | — | | | — | | | | | | — | | | |
Balance, June 30, 2025 |
| | | $ | | | $ | | | $ | | | $ | ( | | $ | ( |
| | | | | | | | | | | | | | | | | |
| | | | | |
| | |
| Accumulated |
| | |
| | | |
| | | | | |
| Additional |
| other | | | |
| Total | |||
Three months ended June 30, 2024 | | Common stock | | paid-in |
| comprehensive | | Accumulated | | stockholders’ | |||||||
|
| Shares |
| Amount |
| capital |
| loss |
| deficit |
| deficit | |||||
Balance, March 31, 2024 |
| | | $ | | | $ | | | $ | ( | | $ | ( | | $ | ( |
Exercise of options |
| | | | — | | | | | | — | | | — | | | |
Restricted stock vesting and issuance, net |
| | | | — | | | — | | | — | | | — | | | — |
Issuance of common stock in connection with an employee stock purchase plan | | | | | — | | | | | | — | | | — | | | |
Share-based compensation expense |
| — | | | — | | | | | | — | | | — | | | |
Net loss |
| — | | | — | | | — | | | — | | | ( | |
| ( |
Comprehensive loss |
| — | |
| — | |
| — | |
| ( | | | — | |
| ( |
Balance, June 30, 2024 |
| | | $ | | | $ | | | $ | ( | | $ | ( | | $ | ( |
| | | | | | | | | | | | | | | | | |
| | | | | |
| | |
| Accumulated |
| | |
| | | |
| | | | | |
| Additional |
| other | | | |
| Total | |||
Six months ended June 30, 2025 | | Common stock | | paid-in |
| comprehensive | | Accumulated | | stockholders’ | |||||||
|
| Shares |
| Amount |
| capital |
| (loss) income |
| deficit |
| deficit | |||||
Balance, December 31, 2024 |
| | | $ | | | $ | | | $ | ( | | $ | ( | | $ | ( |
Exercise of options |
| | | | — | | | | | | — | | | — | |
| |
Restricted stock vesting and issuance, net |
| | | | | | | — | | | — | | | — | | | |
Issuance of common stock in connection with an employee stock purchase plan |
| | | | — | | | | | | — | | | — | | | |
Share-based compensation expense |
| — | | | — | | | | | | — | | | — | | | |
Receivable from Investor | | — | | | — | | | | | | — | | | — | | | |
Net income |
| — | | | — | | | — | | | — | | | | | | |
Comprehensive income |
| — | | | — | | | — | | | | | | — | | | |
Balance, June 30, 2025 |
| | | $ | | | $ | | | $ | | | $ | ( | | $ | ( |
| | | | | | | | | | | | | | | | | |
| | | | | |
| | |
| Accumulated |
| | |
| | | |
| | | | | |
| Additional |
| other | | | |
| Total | |||
Six months ended June 30, 2024 | | Common stock | | paid-in |
| comprehensive | | Accumulated | | stockholders’ | |||||||
|
| Shares |
| Amount |
| capital |
| loss |
| deficit |
| deficit | |||||
Balance, December 31, 2023 |
| |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | ( |
Exercise of options | | | |
| — | |
| | |
| — | |
| — | | | |
Restricted stock vesting and issuance, net | | | |
| | |
| — | |
| — | |
| — | | | |
Issuance of common stock in connection with an employee stock purchase plan |
| | |
| — | |
| | |
| — | |
| — | |
| |
Share-based compensation expense |
| — | |
| — | |
| | |
| — | |
| — | |
| |
Net loss |
| — | |
| — | |
| — | |
| — | |
| ( | |
| ( |
Comprehensive loss |
| — | |
| — | |
| — | |
| ( | |
| — | |
| ( |
Balance, June 30, 2024 |
| | | $ | | | $ | | | $ | ( | | $ | ( | | $ | ( |
See accompanying unaudited notes.
7
Table of Contents
PTC Therapeutics, Inc.
Consolidated Statements of Cash Flows (unaudited)
In thousands
| | | | | | | |
| | Six Months Ended June 30, | | ||||
|
| 2025 |
| 2024 | | ||
Cash flows from operating activities | | | | | | | |
Net income (loss) | | $ | | | $ | ( | |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |
| | | |
| |
Depreciation and amortization | |
| | | | | |
Non-cash operating lease expense | |
| | | | | |
Non-cash royalty revenue related to sale of future royalties | | | ( | | | ( | |
Non-cash interest expense on liability related to sale of future royalties | | | | | | | |
Change in valuation of contingent consideration | |
| ( | | | | |
Tangible asset impairment | | | | | | | |
Loss on sale of fixed assets | | | | | | | |
Gain on lease terminations | | | — | | | ( | |
Unrealized loss on ClearPoint Equity Investments | |
| | | | | |
Unrealized loss on ClearPoint convertible debt security | | | — | | | | |
Unrealized gain on marketable securities - equity investments | | | ( | | | ( | |
Deferred income taxes | | | — | | | | |
Amortization of discounts on investments, net | |
| ( | | | ( | |
Amortization of debt issuance costs | |
| | | | | |
Share-based compensation expense | |
| | | | | |
Unrealized foreign currency transaction losses (gains), net | |
| | | | ( | |
Changes in operating assets and liabilities: | |
| | | | | |
Inventory, net | |
| ( | | | ( | |
Prepaid expenses and other current assets | |
| ( | | | | |
Trade and royalty receivables, net | |
| ( | | | ( | |
Deposits and other assets | |
| ( | | | | |
Accounts payable and accrued expenses | |
| | | | ( | |
Other liabilities | |
| ( | | | ( | |
Deferred revenue | |
| | | | ( | |
Payments on contingent consideration | | | ( | | | — | |
Net cash provided by (used in) operating activities | | $ | | | $ | ( | |
Cash flows from investing activities | |
| | |
| | |
Purchases of fixed assets | | $ | ( | | $ | ( | |
Proceeds from sale of fixed assets | | | | | | | |
Purchases of marketable securities- available for sale | | | ( | | | ( | |
Purchases of marketable securities- equity investments | | | ( | | | ( | |
Sale and redemption of marketable securities- available for sale | | | | | | | |
Sale and redemption of marketable securities- equity investments | | | | | | | |
Acquisition of product rights and licenses | | | ( | | | ( | |
Net cash used in investing activities | | $ | ( | | $ | ( | |
Cash flows from financing activities | |
| | |
| | |
Proceeds from exercise of options | | $ | | | $ | | |
Proceeds from employee stock purchase plan | | | | | | | |
Proceeds from sale of future royalties | | | — | | | | |
Payments on contingent consideration obligation | | | ( | | | — | |
Payment of finance lease principal | | | — | | | ( | |
Net cash provided by financing activities | | $ | | | $ | | |
Effect of exchange rate changes on cash | |
| | | | ( | |
Net increase in cash and cash equivalents | |
| | |
| | |
Cash and cash equivalents, and restricted cash beginning of period | |
| | | | | |
Cash and cash equivalents, and restricted cash end of period | | $ | | | $ | | |
Supplemental disclosure of cash information | |
| | |
| | |
Cash paid for interest | | $ | | | $ | | |
Cash paid for income taxes | | | | | | | |
Supplemental disclosure of non-cash investing and financing activity | |
| | |
|
| |
Unrealized loss on marketable securities, net of tax | | $ | ( | | $ | ( | |
Right-of-use assets obtained in exchange for operating lease obligations | | | | | | | |
Acquisition of product rights and licenses | | | | | | | |
Fixed asset additions through tenant improvement allowance | | | | | | | |
Milestone payable | | | | | | | |
See accompanying unaudited notes.
8
Table of Contents
PTC Therapeutics, Inc.
Notes to Consolidated Financial Statements (unaudited)
June 30, 2025
In thousands (except share and per share amounts unless otherwise noted)
1. The Company
PTC Therapeutics, Inc. (the “Company” or “PTC”) is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. PTC’s strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for its patients and other stakeholders. PTC has a diversified therapeutic portfolio pipeline that includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism.
The Company has
The Company previously had a marketing authorization for Translarna in the European Economic Area (“EEA”), which had been subject to annual review and renewal by the European Commission (“EC”) following reassessment by the European Medicines Agency (“EMA”) of the benefit-risk balance of the authorization. In September 2022, the Company submitted a Type II variation to the EMA to support conversion of the conditional marketing authorization for Translarna to a standard marketing authorization, which included a report on the placebo-controlled trial of Study 041 and data from the open-label extension. In February 2023, the Company also submitted an annual marketing authorization renewal request to the EMA. In September 2023, the Committee for Medicinal Products for Human Use (“CHMP”), gave a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna for the treatment of nmDMD and a negative opinion on the renewal of the existing conditional marketing authorization of Translarna for the treatment of nmDMD. In January 2024, the CHMP issued a negative opinion for the renewal of the conditional marketing authorization following a re-examination procedure. In May 2024, the EC decided not to adopt the CHMP’s negative opinion for the renewal of the conditional marketing authorization of Translarna and returned such opinion to the CHMP for re-evaluation. In June 2024, following the EC’s request for re-review, the CHMP issued a negative opinion on the renewal of the conditional marketing authorization of Translarna for the treatment of nmDMD. In October 2024, the CHMP maintained its negative opinion for the renewal of the conditional marketing authorization following the requested reexamination procedure. In March 2025, the EC adopted the opinion of the CHMP to not renew the authorization of Translarna for the treatment of nmDMD. However, the EC indicated that individual countries within the European Union (“EU”) can leverage Articles 117(3) and 5(1) of the EU Directive 2001/83 to allow continued commercial use of Translarna.
Translarna is an investigational new drug in the United States. Following the Company’s announcement of top-line results from the placebo-controlled trial of Study 041 in June 2022, the Company submitted a meeting request to the U.S. Food and Drug Administration (“FDA”) to gain clarity on the regulatory pathway for a potential resubmission of a New Drug Application (“NDA”) for Translarna. The FDA provided initial written feedback that Study 041 does not provide substantial evidence of effectiveness to support an NDA resubmission. The Company held a Type C meeting with the FDA in the fourth quarter of 2023 to discuss the totality of Translarna data. Based on feedback from the FDA, the Company resubmitted the NDA in July 2024, based on the results from Study 041 and from the Company’s international drug registry study for nmDMD patients receiving Translarna. In October 2024, the FDA accepted for review the resubmission of the NDA for Translarna for the treatment of nmDMD. As this was an NDA resubmission following a complete response letter
9
Table of Contents
to the NDA which was filed over protest in 2016, the FDA is not obligated to follow the review timelines under Prescription Drug User Fee Act guidelines and an action date has not been provided.
The Company has developed Sephience™ (sepiapterin), a product for the treatment of phenylketonuria (“PKU”), a rare inherited metabolic disease which affects the brain. On July 28, 2025, Sephience™ was approved by the FDA for the treatment of pediatric and adult patients living with PKU in the United States. On June 19, 2025, Sephience was granted marketing authorization by the EC for the treatment of children and adults living with PKU within the EEA. The Company also made a regulatory submission for Sephience for the treatment of PKU in Brazil in the third quarter of 2024, with a regulatory decision expected in the second half of 2025, and in Japan in the fourth quarter of 2024, with a regulatory decision expected in the fourth quarter of 2025.
The Company has developed Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of Aromatic L-Amino Acid Decarboxylase (“AADC”) deficiency (“AADC deficiency”), a rare central nervous system (“CNS”) disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. In July 2022, the EC approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the EEA. In November 2022, the Medicines and Healthcare Products Regulatory Agency approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the United Kingdom. In November 2024, the FDA approved the Company’s gene therapy treatment of AADC deficiency, which is marketed under the brand name Kebilidi™ in the United States.
The Company holds the rights for the commercialization of Tegsedi® (inotersen) and Waylivra® (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to the Collaboration and License Agreement (the “Tegsedi-Waylivra Agreement”), dated August 1, 2018, by and between the Company and Akcea Therapeutics, Inc. (“Akcea”), a subsidiary of Ionis Pharmaceuticals, Inc. Tegsedi has received marketing authorization in the United States, the European Union (the “EU”) and Brazil for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (“hATTR amyloidosis”). In August 2021, ANVISA, the Brazilian health regulatory authority, approved Waylivra as the first treatment for familial chylomicronemia syndrome (“FCS”) in Brazil. In December 2022, ANVISA approved Waylivra for the treatment of familial partial lipodystrophy (“FPL”). Waylivra has also received marketing authorization in the EU for the treatment of FCS.
The Company also has a spinal muscular atrophy (“SMA”) collaboration with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. (referred to collectively as “Roche”) and the Spinal Muscular Atrophy Foundation (“SMA Foundation”). The SMA program has one approved product, Evrysdi® (risdiplam), which was approved by the FDA in August 2020 for the treatment of SMA in adults and children two months and older and by the EC in March 2021 for the treatment of 5q SMA in patients two months and older with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. Evrysdi has also received marketing authorization for the treatment of SMA in over 100 countries. In May 2022, the FDA approved a label expansion for Evrysdi to include infants under two months old with SMA. In August 2023, the EC approved an extension of the Evrysdi marketing authorization to include infants under two months old in the EU.
In addition to the Company’s SMA program, the Company’s splicing platform also includes votoplam (PTC518), which is being developed for the treatment of Huntington’s disease (“HD”). The Company initiated a Phase 2 study of votoplam for the treatment of HD in the first quarter of 2022, which consists of an initial 12-week placebo-controlled phase focused on safety, pharmacology and pharmacodynamic effects followed by a nine-month placebo-controlled phase focused on votoplam biomarker effect. In June 2024, the Company announced interim results from the full Phase 2 study of votoplam. At month 12, votoplam treatment demonstrated durable dose-dependent lowering of mutant HTT (“mHTT”) protein in the blood and dose-dependent lowering of mHTT protein in the cerebrospinal fluid in the interim cohort of stage 2 patients. In addition, favorable trends were demonstrated on several relevant HD clinical assessments. Furthermore, following 12 months of treatment, votoplam continued to be well tolerated. In September 2024, the FDA granted Fast Track designation to the votoplam program for the treatment of HD. In December 2024, the Company held a Type C meeting with the FDA to discuss whether huntingtin protein lowering could be considered a surrogate endpoint for accelerated approval of votoplam. The FDA was aligned on the scientific rationale and asked to see additional data supportive of an association between huntingtin protein lowering and changes in clinical outcome scores. In May 2025, the Company announced that the Phase 2 study of votoplam met its primary endpoints of blood HTT lowering and safety. The results on the full study population are consistent with the previously reported evidence of dose-dependent HTT lowering, favorable safety profile
10
Table of Contents
and early signals of dose-dependent clinical effect at 12 months in Stage 2 patients. In addition, at 24 months of treatment, there were continued trends of dose-dependent favorable clinical effect relative to a propensity-matched natural history cohort as well as dose-dependent NfL lowering. In November 2024, the Company entered into a License and Collaboration Agreement (the “Novartis Agreement”) with Novartis Pharmaceuticals Corporation (“Novartis”), relating to its votoplam HD program which included related molecules. This transaction closed in January 2025, triggering a $
The Company’s inflammation and ferroptosis platform consists of small molecule compounds that target oxidoreductase enzymes that regulate oxidative stress and inflammatory pathways central to the pathology of a number of CNS diseases. The most advanced molecule in the Company’s inflammation and ferroptosis platform is vatiquinone. The Company announced topline results from a registration-directed Phase 3 trial of vatiquinone in children and young adults with Friedreich’s ataxia (“FA”), called MOVE-FA, in May 2023. While the study did not meet its primary endpoint, vatiquinone treatment did demonstrate significant benefit on key disease subscales, including the upright stability subscale, as well as on other disease relevant endpoints. In October 2024, the Company announced that the pre-specified endpoint for two different FA long-term extension studies was met, with statistically significant evidence of durable treatment benefit on disease progression. In December 2024, the Company submitted an NDA to the FDA for vatiquinone for the treatment of children and adults living with FA. In February 2025, the FDA accepted for filing the NDA and granted priority review with a target regulatory action date of August 19, 2025.
In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas for rare diseases.
As of June 30, 2025, the Company had an accumulated deficit of approximately $
2. Summary of significant accounting policies
The Company’s complete listing of significant accounting policies is set forth in Note 2 of the notes to the Company’s audited financial statements as of December 31, 2024 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 27, 2025 (the "2024 Form 10-K"). Selected significant accounting policies are discussed in further detail below.
Basis of presentation
The accompanying financial information as of June 30, 2025 and for the three and six months ended June 30, 2025 and 2024 has been prepared by the Company, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rules and
11
Table of Contents
regulations. These interim financial statements should be read in conjunction with the Company’s audited financial statements as of December 31, 2024 and notes thereto included in the 2024 Form 10-K.
In the opinion of management, the unaudited financial information as of June 30, 2025 and for the three and six months ended June 30, 2025 and 2024 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations, stockholders’ deficit, and cash flows. The results of operations for the three and six months ended June 30, 2025 are not necessarily indicative of the results to be expected for the year ended December 31, 2025 or for any other interim period or for any other future year.
Use of estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, royalty revenue, certain accruals related to the Company’s research and development expenses, valuation procedures for liability for sale of future royalties, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Restricted cash
Restricted cash included in deposits and other assets on the consolidated balance sheet contains an unconditional, irrevocable and transferable letter of credit of $
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same amounts shown in the consolidated statement of cash flows:
| | | | | | |
|
| End of |
| Beginning of | ||
|
| period- |
| period- | ||
|
| June 30, |
| December 31, | ||
|
| 2025 | | 2024 | ||
Cash and cash equivalents | | $ | | | $ | |
Restricted cash included in deposits and other assets | |
| | |
| |
Total Cash, cash equivalents and restricted cash per consolidated statement of cash flows | | $ | | | $ | |
Segment information
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (“CODM”), or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s CODM consists of the chief executive officer, the chief financial officer, and the chief business officer. The Company views its operations and manages its business in
12
Table of Contents
The measure of segment assets is reported on the balance sheet as total consolidated assets. The Company derives its revenues through its worldwide net sales of its commercial products, collaboration agreements and license agreements, and royalty revenues. Refer to Note 11 for further segment information on revenues.
The Company expects to continue to incur significant expenses as it advances product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval. As such, the CODM uses cash forecast models in deciding how to invest into the life science segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net (loss) income is used to monitor planned versus actual results. Monitoring planned versus actual results is used in assessing performance of the segment and in establishing management’s compensation, along with the cash forecast models. Refer to Note 13 for segment information on significant segment expenses.
Marketable securities
The Company’s marketable securities consists of both debt securities and equity investments. The Company considers its investments in debt securities with original maturities of greater than 90 days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. For the three and six months ended June 30, 2025 and 2024,
Marketable securities that are equity investments are measured at fair value, as it is readily available, and as such are classified as Level 1 assets. Unrealized holding gains and losses for these equity investments are components of other (expense) income, net within the consolidated statement of operations.
Inventory and cost of product, collaboration and license sales
Inventory
Inventories are stated at the lower of cost and net realizable value, utilizing standard costing, which approximates average costs by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for marketing efforts are charged to selling, general and administrative expense. Amounts related to clinical development programs and marketing efforts are immaterial.
13
Table of Contents
The following table summarizes the components of the Company’s inventory for the periods indicated:
| | | | | | |
|
| June 30, 2025 |
| December 31, 2024 | ||
Raw materials | | $ | | | $ | |
Work in progress | |
| | |
| |
Finished goods | |
| | |
| |
Total inventory | | $ | | | $ | |
The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. For the three and six months ended June 30, 2025, the Company recorded inventory write-downs of $
Cost of product, collaboration and license sales
Cost of product, collaboration and license sales consists of the cost of inventory sold, manufacturing and supply chain costs, storage costs, amortization of the acquired intangible asset, royalty payments associated with net product sales, royalty payments to collaborative partners associated with royalty revenues and collaboration revenue related to milestones, and costs related to performance of services associated with license agreement revenues. Production costs are expensed as cost of product, collaboration and license sales when the related products are sold or royalty revenues and collaboration revenue milestones are earned.
Revenue recognition
Net product revenue
The Company’s net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD. The Company recognizes revenue when its performance obligations with its customers have been satisfied and if it is probable that a significant revenue reversal will not occur. The Company’s performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies. The performance obligations are satisfied at a point in time when the Company’s customer obtains control of the product, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of the invoice date. The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to product sales. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month.
The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government pricing programs, and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained.
14
Table of Contents
In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. The Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.
Collaboration, license, and royalty revenue
The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.
At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 808 “Collaborative Arrangements” to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer. If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations.
For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation. The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.
For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved. If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved. Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Company’s control. If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method. The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement. The Company recognizes royalties from product sales at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied. If it is probable that a significant revenue reversal will not occur, the Company will estimate the royalty payments using the most likely amount method.
The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.
Allowance for doubtful accounts
The Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customer’s financial condition and current economic trends. The Company also assesses whether an allowance for expected credit losses may be required which includes a review of the Company’s receivables portfolio, which are pooled on a customer basis or country basis. In making its assessment of whether an allowance for credit losses is required, the Company considers its historical experience with customers, current balances, levels of delinquency, regulatory and legal environments, and other relevant current and future forecasted economic conditions. For the three and six months ended June 30, 2025 and 2024,
15
Table of Contents
doubtful accounts was $
Liability for sale of future royalties
The Company has a royalty purchase agreement with Royalty Pharma Investments 2019 ICAV (“Royalty Pharma”) in which the Company sold its right to receive sales-based royalty payments on worldwide net sales of Evrysdi in exchange for upfront cash consideration from Royalty Pharma. In accordance with the guidance in ASC 470-10-25-2, the Company determined that cash consideration obtained pursuant to the royalty purchase agreement should be classified as debt and is recorded as “liability for sale of future royalties-current” and “liability for sale of future royalties-noncurrent” on the Company’s consolidated balance sheet based on the timing of the expected payments to be made to Royalty Pharma. The liability is amortized using the effective interest method over the life of the arrangement, in accordance with the respective guidance, utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to Royalty Pharma and the Company updates the effective interest rate on a quarterly basis. Refer to Note 9 for further details.
Goodwill
Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassesses its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount.
Income Taxes
On December 15, 2022, the EU Member States formally adopted the EU’s Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates were January 1, 2024, and January 1, 2025, for different aspects of the directive. A significant number of other countries are also implementing similar legislation. As a result, the tax laws in the U.S. and other countries in which PTC and its affiliates do business could change on a prospective or retroactive basis and any such changes could materially adversely affect the Company’s business. The Company is continuing to evaluate the potential impact on future periods of the Pillar Two Framework, pending legislative adoption by additional individual countries, including those within the EU.
On December 22, 2017, the U.S. government enacted the 2017 Tax Cuts and Jobs Act (“TCJA”), which significantly revised U.S. tax law by, among other provisions, lowering the U.S. federal statutory corporate income tax rate to
Since 2022, TCJA amendments to Internal Revenue Code (“IRC”) Section 174 no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over either a five- or 15-year period, depending on the location of the activities performed. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year five for activities conducted in the United States or year 15 in the case of development conducted on
16
Table of Contents
foreign soil. This tax law change is anticipated to result in an increased current taxable income of the Company by $
On July 4, 2025, the U.S. government enacted the One Big Beautiful Bill Act which generally extends the tax provisions enacted by the TCJA that were set to expire at the end of 2025, as well as making other changes to federal tax law for multinational corporations. The Company is currently evaluating the impact of the new legislation and the impact on its financial statements.
Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.
Leases
The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating and finance leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating and finance lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments.
Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company’s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.
Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.
A lessee is required to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates.
The lease term for all of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. Refer to Note 3 for further details.
Tangible asset impairment and losses (gains) on transactions, net
Tangible asset impairment and losses (gains) on transactions, net includes impairments identified on fixed assets, losses and gains on sales of fixed assets, and gains on lease terminations. For the three months ended June 30, 2025, these amounts consisted of a $
17
Table of Contents
consisted of a $
Recently issued accounting standards
In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. ASU 2023-09 enhances the transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The guidance is effective for public business entities for annual periods beginning after December 15, 2024. For entities other than public business entities, the amendments are effective for annual periods beginning after December 15, 2025. Early adoption is permitted. The Company is currently planning to adopt this guidance when effective. The Company is assessing the impact of the adoption on the Company’s consolidated financial statements and accompanying footnotes, but expects the impact will be enhanced disclosures related to income taxes.
In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. ASU 2024-03 enhances financial reporting by requiring additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The guidance is effective for public business entities for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently planning to adopt this guidance when effective. The Company is assessing the impact of the adoption on the Company’s consolidated financial statements and accompanying footnotes but expects the impact will be enhanced disclosures related to income statement expenses.
3. Leases
The Company’s principal office space is a facility located in Warren, New Jersey, which is approximately
The Company also has a finance lease related to its commercial manufacturing agreement with MassBiologics of the University of Massachusetts Medical School (“MassBio”). As of June 30, 2025, the balance of the finance lease liabilities-current and finance lease liabilities-noncurrent are $
The Company also leases certain vehicles, lab equipment, and office equipment under operating leases. The Company’s leases have remaining operating lease terms ranging from
18
Table of Contents
The components of operating lease expense were as follows:
| | | | | | | | | | | | | |
|
| Three Months Ended |
| Three Months Ended |
| Six Months Ended |
| Six Months Ended | | ||||
| | | June 30, 2025 | | | June 30, 2024 | | | June 30, 2025 | | | June 30, 2024 | |
Operating Lease Cost |
| |
| | |
| | |
| | |
| |
Fixed lease cost | | $ | | | $ | | | $ | | | $ | | |
Variable lease cost | |
| | |
| | |
| | |
| | |
Short-term lease cost | |
| | |
| | |
| | |
| | |
Total operating lease cost | | $ | | | $ | | | $ | | | $ | | |
Total operating lease cost is a component of operating expenses on the consolidated statements of operations.
Supplemental lease term and discount rate information related to leases was as follows as of June 30, 2025 and December 31, 2024:
| | | | | |
|
| June 30, 2025 |
| December 31, 2024 |
|
Weighted-average remaining lease terms - operating leases (years) |
| | | ||
Weighted-average discount rate - operating leases | | | % | | % |
Weighted-average remaining lease terms - finance lease (years) |
| | | ||
Weighted-average discount rate - finance lease |
| | % | | % |
Supplemental cash flow information related to leases was as follows as of June 30, 2025 and 2024:
| | | | | | | |
|
| Six Months Ended June 30, | | ||||
|
| 2025 |
| 2024 | | ||
Cash paid for amounts included in the measurement of lease liabilities: |
| |
| | |
| |
Operating cash flows from operating leases | | $ | | | $ | | |
Financing cash flows from finance lease | | | — | | | | |
Operating cash flows from finance lease | | | — | | | | |
| | | | | | | |
Right-of-use assets obtained in exchange for lease obligations: | |
| | |
|
| |
Operating leases | | $ | | | $ | | |
| | | | | | | |
Changes due to lease modification and termination: | | | | | | | |
Net decrease in right-of-use assets | | $ | — | | $ | | |
Net decrease in operating lease liabilities | | | — | | | | |
Future minimum lease payments under non-cancelable leases as of June 30, 2025 were as follows:
| | | | | | | |
|
| Operating Leases |
| Finance Lease | | ||
2025 (excludes the six months ended June 30, 2025) | | $ | | | $ | | |
2026 | |
| | |
| | |
2027 | |
| | |
| | |
2028 | |
| | |
| | |
2029 and thereafter | |
| | |
| | |
Total lease payments | |
| | |
| | |
Less: Imputed Interest expense | |
| | |
| | |
Total | | $ | | | $ | | |
4. Fair value of financial instruments and marketable securities
The Company follows the fair value measurement rules, which provideguidance on the use of fair value in accounting and disclosure for assets and liabilities when such accounting and disclosure is called for by other accounting literature. These rules establish a fair value hierarchy for inputs to be used to measure fair value of financial assets and liabilities.
19
Table of Contents
This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).
| ● | Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the balance sheet date. |
| ● | Level 2—Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). |
| ● | Level 3—Inputs are unobservable and reflect the Company’s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. |
Cash equivalents and marketable securities are reflected in the accompanying financial statements at fair value. The carrying amount of receivables and accounts payable and accrued expenses approximates fair value due to the short-term nature of those instruments.
The Company owns common stock in ClearPoint Neuro, Inc. (“ClearPoint”) (formerly MRI Interventions, Inc.), a publicly traded medical device company. The ClearPoint equity investments (collectively, the “ClearPoint Equity Investments”) represent financial instruments, and therefore, are recorded at fair value, which is readily determinable. The ClearPoint Equity Investments are components of prepaids and other current assets on the consolidated balance sheet as of June 30, 2025 and December 31, 2024. The Company classifies the ClearPoint Equity Investments as Level 1 assets within the fair value hierarchy, as the value is based on a quoted market price in an active market, which is not adjusted. Other than the ClearPoint Equity Investments, no other items included in prepaids and other current assets on the consolidated balance sheets are fair valued.
In January 2020, the Company purchased a $
The Company has an investment in mutual funds that is denominated in a foreign currency and is classified as marketable securities on the Company’s consolidated balance sheets. This equity investment is reported at fair value, as it is readily available, and as such is classified as a Level 1 asset. Unrealized holding gains and losses for this equity investment are included as components of interest expense, net within the consolidated statement of operations.
The tables presented below are a summary of changes in the fair value for the Company’s marketable securities – equity investments, ClearPoint Equity Investments, and ClearPoint convertible debt security for the three and six months ended June 30, 2025 and June 30, 2024:
20
Table of Contents
| | | | | | | | | | | | | | | | | | |
| | Ending | | | | | Foreign | | | | | | | | Ending | |||
| | Balance at | | | | | Currency | | | | | | | | Balance at | |||
| | March 31, | | Unrealized | | Unrealized | | Investments | | Redemptions/ | | June 30, | ||||||
|
| 2025 |
| Gain |
| Gain |
| Purchased |
| Sale |
| 2025 | ||||||
Marketable securities - equity investments | | $ | | | | | | | | | | | | | ( | | | |
ClearPoint Equity Investments | | | | | | | | | — | | | — | | | — | | | |
Total Fair Value | | $ | | | $ | | | $ | | | $ | | | $ | ( | | $ | |
| | | | | | | | | | | | | | | | | | |
| | Ending | | | | | Foreign | | | | | | | | Ending | |||
| | Balance at | | | | | Currency | | | | | | | | Balance at | |||
| | March 31, | | Unrealized | | Unrealized | | Investments | | Redemptions/ | | June 30, | ||||||
|
| 2024 |
| Gain/(Loss) | | Loss |
| Purchased |
| Sale |
| 2024 | ||||||
Marketable securities - equity investments | | $ | | | | | | | ( | | | | | | ( | | $ | |
ClearPoint Equity Investments | | | | | | ( | | | — | | | — | | | — | | | |
ClearPoint convertible debt security | | | | | | ( | | | — | | | — | | | — | | | |
Total Fair Value | | $ | | | $ | ( | | $ | ( | | $ | | | $ | ( | | $ | |
| | | | | | | | | | | | | | | | | | | |
| | Ending | | | | | Foreign | | | | | | | | Ending | | |||
| | Balance at | | | | | Currency | | | | | | | | Balance at | | |||
| | December 31, | | Unrealized | | Unrealized | | Investments | | Redemptions/ | | June 30, | | ||||||
|
| 2024 |
| Gain/(Loss) |
| Gain |
| Purchased |
| Sale |
| 2025 | | ||||||
Marketable securities - equity investments | | $ | | | | | | | | | | | | | ( | | | | |
ClearPoint Equity Investments | | | | | | ( | | | — | | | — | | | — | | | | |
Total Fair Value | | $ | | | $ | ( | | $ | | | $ | | | $ | ( | | $ | | |
| | | | | | | | | | | | | | | | | | |
| | Ending | | | | | Foreign | | | | | | | | Ending | |||
| | Balance at | | | | | Currency | | | | | | | | Balance at | |||
| | December 31, | | Unrealized | | Unrealized | | Investments | | Redemptions/ | | June 30, | ||||||
|
| 2023 |
| Gain/(Loss) |
| Loss |
| Purchased |
| Sale |
| 2024 | ||||||
Marketable securities - equity investments | | $ | | | | | | | ( | | | | | | ( | | $ | |
ClearPoint Equity Investments | | | | | | ( | | | — | | | — | | | — | | | |
ClearPoint convertible debt security | | | | | | ( | | | — | | | — | | | — | | | |
Total Fair Value | | $ | | | $ | ( | | $ | ( | | $ | | | $ | ( | | $ | |
Fair value of marketable securities that are classified as available for sale debt securities is based upon market prices using quoted prices in active markets for identical assets quoted on the last day of the period. In establishing the estimated fair value of the remaining available for sale debt securities, the Company used the fair value as determined by its investment advisors using observable inputs other than quoted prices.
The following represents the fair value using the hierarchy described above for the Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of June 30, 2025 and December 31, 2024:
| | | | | | | | | | | | |
| | June 30, 2025 | ||||||||||
|
| | |
| Quoted prices |
| Significant |
| | | ||
| | | |
| in active |
| other |
| Significant | |||
| | | |
| markets for |
| observable |
| unobservable | |||
| | | |
| identical assets |
| inputs |
| inputs | |||
|
| Total |
| (level 1) |
| (level 2) |
| (level 3) | ||||
Marketable securities - available for sale | | $ | | | $ | — | | $ | | | $ | — |
Marketable securities - equity investments | | $ | | | $ | | | $ | — | | $ | — |
ClearPoint Equity Investments | | $ | | | $ | | | $ | — | | $ | — |
21
Table of Contents
| | | | | | | | | | | | |
| | December 31, 2024 | ||||||||||
|
| | |
| Quoted prices |
| Significant |
| | | ||
| | | |
| in active |
| other |
| Significant | |||
| | | |
| markets for |
| observable |
| unobservable | |||
| | | |
| identical assets |
| inputs |
| inputs | |||
|
| Total |
| (level 1) |
| (level 2) |
| (level 3) | ||||
Marketable securities - available for sale | | $ | | | $ | — | | $ | | | $ | — |
Marketable securities - equity investments | | $ | | | $ | | | $ | — | | $ | — |
ClearPoint Equity Investments | | $ | | | $ | | | $ | — | | $ | — |
Contingent consideration payable- net sales milestones | | $ | | | $ | — | | $ | — | | $ | |
The following is a summary of marketable securities accounted for as available for sale debt securities at June 30, 2025 and December 31, 2024:
| | | | | | | | | | | | |
| | June 30, 2025 | ||||||||||
|
| Amortized |
| Gross Unrealized | | | | |||||
|
| Cost |
| Gains |
| Losses |
| Fair Value | ||||
Commercial paper | | $ | | | $ | — | | $ | ( | | $ | |
Corporate debt securities | | | | | | | | | ( | | | |
Government obligations | | | | | | | | | ( | | | |
Total | | $ | | | $ | | | $ | ( | | $ | |
| | | | | | | | | | | | |
| | December 31, 2024 | ||||||||||
|
| Amortized |
| Gross Unrealized | | | | |||||
|
| Cost |
| Gains |
| Losses |
| Fair Value | ||||
Commercial paper | | $ | | | $ | — | | $ | ( | | $ | |
Corporate debt securities | |
| | | | | | | ( | | | |
Government obligations | | | | | | | | | — | | | |
Total | | $ | | | $ | | | $ | ( | | $ | |
For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. For the three and six months ended June 30, 2025 and 2024,
For the three and six months ended June 30, 2025, realized gains from the sale of available for sale debt securities were immaterial. For the three and six months ended June 30, 2024, the Company did
22
Table of Contents
The unrealized losses and fair values of available for sale debt securities that have been in an unrealized loss position for a period of less than and greater than or equal to 12 months as of June 30, 2025 are as follows:
| | | | | | | | | | | | | | | | | | |
| | June 30, 2025 | ||||||||||||||||
|
| Securities in an unrealized loss |
| Securities in an unrealized loss |
| | | | | | ||||||||
|
| position less than 12 months |
| position greater than or equal to 12 months | | Total | ||||||||||||
|
| Unrealized losses |
| Fair Value |
| Unrealized losses |
| Fair Value |
| Unrealized losses |
| Fair Value | ||||||
Commercial paper | | $ | ( | | | | | | — | | | — | | | ( | | $ | |
Corporate debt securities | | $ | ( | | | | | | — | | | — | | | ( | | $ | |
Government obligations | | $ | ( | | | | | | — | | | — | | | ( | | $ | |
Total | | $ | ( | | $ | | | $ | — | | $ | — | | $ | ( | | $ | |
The unrealized losses and fair values of available for sale debt securities that have been in an unrealized loss position for a period of less than and greater than or equal to 12 months as of December 31, 2024 are as follows:
| | | | | | | | | | | | | | | | | | |
| | December 31, 2024 | ||||||||||||||||
|
| Securities in an unrealized loss |
| Securities in an unrealized loss |
| | | | | | ||||||||
|
| position less than 12 months |
| position greater than or equal to 12 months | | Total | ||||||||||||
|
| Unrealized losses |
| Fair Value |
| Unrealized losses |
| Fair Value |
| Unrealized losses |
| Fair Value | ||||||
Commercial paper | | $ | ( | | | | | | — | | | — | | | ( | | $ | |
Corporate debt securities | | $ | ( | | | | | | — | | | — | | | ( | | $ | |
Total | | $ | ( | | $ | | | $ | — | | $ | — | | $ | ( | | $ | |
Available for sale debt securities at June 30, 2025 and December 31, 2024 mature as follows:
| | | | | | |
| | June 30, 2025 | ||||
|
| Less Than |
| More Than | ||
|
| 12 Months |
| 12 Months | ||
Commercial paper | | $ | | | $ | — |
Corporate debt securities | | | | | | — |
Government obligations | | | | | | — |
Total | | $ | | | $ | — |
| | | | | | |
| | December 31, 2024 | ||||
|
| Less Than |
| More Than | ||
|
| 12 Months |
| 12 Months | ||
Commercial paper | | $ | | | $ | — |
Corporate debt securities | |
| | |
| — |
Government obligations | | | | | | — |
Total | | $ | | | $ | — |
The Company classifies all of its marketable securities as current as they are all either available for sale debt securities or equity investments and are available for current operations.
Convertible senior notes
In September 2019, the Company issued $
23
Table of Contents
Level 3 valuation
The contingent consideration payable is fair valued each reporting period with the change in fair value recorded as a gain or loss within the change in the fair value of contingent consideration on the consolidated statements of operations. During the first quarter of 2025, the probability of triggering the remaining contingent consideration was determined to be remote, and therefore the balance was written down to
5. Accounts payable and accrued expenses
Accounts payable and accrued expenses at June 30, 2025 and December 31, 2024 consist of the following:
| | | | | | | |
| | June 30, | | December 31, | | ||
|
| 2025 |
| 2024 | | ||
Employee compensation, benefits, and related accruals | | $ | | | $ | | |
Income tax payable | | | | | | | |
Consulting and contracted research | |
| | |
| | |
Sales allowance | |
| | |
| | |
Sales rebates | |
| | |
| | |
Royalties | | | | | | | |
Accounts payable | |
| | |
| | |
Milestone payable | | | | | | | |
Other | |
| | |
| | |
Total | | $ | | | $ | | |
As of June 30, 2025, the Company does
6. Capitalization
In August 2019, the Company entered into an At the Market Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald and RBC Capital Markets, LLC (together, the “Sales Agents”), pursuant to which, the Company may offer and sell shares of its common stock, having an aggregate offering price of up to $
24
Table of Contents
7. Net (loss) income per share
Basic and diluted net (loss) income per share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding.
The following tables set forth the computation of basic and diluted net (loss) income per share:
| | | | | | | | | | | | | | | |
| | Three Months Ended June 30, | | | Six Months Ended June 30, | | |||||||||
|
| 2025 |
| 2024 |
| | 2025 |
| 2024 |
| |||||
Numerator: | | | | | | | | | | | | | | | |
Net (loss) income, basic | | $ | ( |
| $ | ( | |
| | $ | |
| $ | ( |
|
Add: Interest expense, net of tax, on the Company's 2026 Convertible Notes | | | — | | | — | | | | | | | | — | |
Net (loss) income, diluted | | $ | ( | | $ | ( | | | | | | | | ( | |
Denominator: | | | | | | | | | | | | | | | |
Weighted-average number of shares outstanding, basic | | | |
| | | |
| |
| |
|
| |
|
Effect of dilutive securities: | | | | | | | | | | | | | | | |
Common stock issuable under the Company's equity incentive plans | |
| — | |
| — | | | | | | | | — | |
Common stock issuable under the Company's 2026 Convertible Notes | | | — | | | — | | | | | | | | — | |
Weighted-average common shares outstanding, diluted | | | | | | | | | | | | | | | |
Net (loss) income per common share, basic | | $ | ( | * | $ | ( | * | | | $ | | | | ( | * |
Net (loss) income per common share, diluted | | $ | ( | * | $ | ( | * | | | $ | | | $ | ( | * |
* In the three months ended June 30, 2025, and the three and six months ended June 30, 2024, the Company experienced a net loss and therefore did not report any dilutive share impact.
The following table shows historical common share equivalents outstanding, which are not included in the above calculation, as the effect of their inclusion is anti-dilutive during each period. The anti-dilutive shares are calculated as the unweighted outstanding shares as of the reporting period end date that are antidilutive using the treasury stock method.
| | | | | |
| | As of June 30, | | ||
|
| 2025 |
| 2024 |
|
Stock options | | | | | |
Unvested restricted stock units |
| |
| |
|
Total |
| |
| |
|
8. Stock award plan
In May 2013, the Company’s Board of Directors and stockholders approved the 2013 Long-Term Incentive Plan, which became effective upon the closing of the Company’s initial public offering. On June 8, 2022 (the “Restatement Effective Date”), the Company’s stockholders approved the Amended and Restated 2013 Long-Term Incentive Plan (the “Amended 2013 LTIP”). The Amended 2013 LTIP provides for the grant of incentive stock options, nonstatutory stock options, restricted stock units and other stock-based awards. The number of shares of common stock reserved for issuance under the Amended 2013 LTIP is the sum of (A) the number of shares of the Company’s common stock (up to
25
Table of Contents
Common Stock. As of June 30, 2025, awards for
In January 2020, the Company’s Board of Directors approved the 2020 Inducement Stock Incentive Plan. The 2020 Inducement Stock Incentive Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards and other stock-based awards for, initially, up to at the time, an aggregate of
The Board of Directors has the authority to select the individuals to whom options are granted and determine the terms of each option, including (i) the number of shares of common stock subject to the option; (ii) the date on which the option becomes exercisable; (iii) the option exercise price, which, in the case of incentive stock options, must be at least
Inducement stock option awards
From January 1, 2025 through June 30, 2025, the Company issued a total of
Stock option activity—A summary of stock option activity is as follows:
| | | | | | | | | | | |
|
| |
| | |
| Weighted- |
|
| | |
| | | | Weighted- | | average | | | Aggregate | ||
| | | | average | | remaining | | | intrinsic | ||
| | Number of | | exercise | | contractual | | | value(in | ||
| | options | | price | | term | | | thousands) | ||
| | | | | | | |
| | | |
Outstanding at December 31, 2024 |
| | | $ | |
|
|
| | |
|
Granted |
| | | $ | |
|
|
| | |
|
Exercised |
| ( | | $ | |
|
|
| | |
|
Forfeited/Cancelled |
| ( | | $ | |
|
|
| | |
|
Outstanding at June 30, 2025 |
| | | $ | |
| years | | $ | | |
Expected to vest at June 30, 2025 |
| | | $ | |
| years | | $ | | |
Exercisable at June 30, 2025 |
| | | $ | |
| years | | $ | | |
The fair value of grants made in the six months ended June 30, 2025 was contemporaneously estimated on the date of grant using the following assumptions:
| | | |
|
| Six months ended |
|
|
| June 30, 2025 |
|
Risk-free interest rate |
|
| |
Expected volatility |
|
| |
Expected term |
|
|
26
Table of Contents
The Company assumed
The expected term of options was estimated based on the Company’s historical exercise data and the expected volatility of options was estimated based on the Company’s historical stock volatility. The risk-free rate of the options was based on U.S. Government Securities Treasury Constant Maturities yields at the date of grant for a term similar to the expected term of the option.
Restricted Stock Units—Restricted stock units are granted subject to certain restrictions, including in some cases service or time conditions (restricted stock). The grant-date fair value of restricted stock units, which have been determined based upon the market value of the Company’s shares on the grant date, are expensed over the vesting period. From January 1, 2025, through June 30, 2025, the Company issued a total of
The following table summarizes information on the Company’s restricted stock units:
| | | | | |
| | Restricted Stock Units | |||
| | | | Weighted | |
| | | | Average | |
| | | | Grant | |
| | Number of | | Date | |
|
| Shares |
| Fair Value | |
Unvested at December 31, 2024 | | | | $ | |
Granted |
| | | | |
Vested |
| ( | | | |
Forfeited |
| ( | | | |
Unvested at June 30, 2025 |
| | | $ | |
Performance-based Restricted Stock Units—In December 2023, the Company granted
Employee Stock Purchase Plan—In June 2016, the Company established an Employee Stock Purchase Plan (as amended, the “ESPP” or the "Plan”), for certain eligible employees. The Plan is administered by the Company’s Board of Directors or a committee appointed by the Company’s Board of Directors. In June 2021, the Plan was amended to increase the total number of shares available for purchase under the Plan from
27
Table of Contents
The Company recorded share-based compensation expense in the statement of operations related to incentive stock options, nonstatutory stock options, restricted stock units and the ESPP as follows:
| | | | | | | | | | | | |
| | Three Months Ended June 30, | | Six Months Ended June 30, | ||||||||
|
| 2025 |
| 2024 |
| 2025 |
| 2024 | ||||
Research and development | | $ | | | $ | | | $ | | | $ | |
Selling, general and administrative | |
| | |
| | |
| | |
| |
Total | | $ | | | $ | | | $ | | | $ | |
As of June 30, 2025, there was approximately $
9. Debt
Liability for sale of future royalties
On July 17, 2020, the Company, RPI Intermediate Finance Trust (“RPI”), and, for the limited purposes set forth in the agreement, Royalty Pharma plc, entered into a royalty purchase agreement (the “Original Royalty Purchase Agreement”). Pursuant to the Original Royalty Purchase Agreement, the Company sold to RPI
Pursuant to the guidance in ASC 470-10-25-2, the Company determined that the $
On October 18, 2023, the Company, Royalty Pharma, and, for the limited purposes set forth in the agreement, Royalty Pharma plc, entered into an Amended and Restated Royalty Purchase Agreement (the “A&R Royalty Purchase Agreement”), which amends and restates in its entirety the Original Royalty Purchase Agreement. Pursuant to the A&R Royalty Purchase Agreement, the Company has sold or agreed to sell to Royalty Pharma certain portions of the Company’s remaining Royalty on worldwide net sales of Evrysdi and any other product (the “Products”) developed pursuant to the SMA License Agreement (all such retained Royalty rights of the Company, the “Retained Royalty Rights,” and all such Royalty rights that are sold to Royalty Pharma pursuant to the A&R Royalty Purchase Agreement, the “A&R Assigned Royalty Rights”). At closing, Royalty Pharma paid the Company $
28
Table of Contents
fewer of the put options, Royalty Pharma may exercise a call option during the period from and after January 1, 2026 until and including March 31, 2026 for up to
The change in rights and obligations from the A&R Royalty Purchase Agreement resulted in a change in the terms of the liability for sale of future royalties, which was evaluated by the Company in accordance with ASC 470-50, Debt — Modifications and Extinguishments. The Company determined that the present value of the cash flows under the A&R Royalty Purchase Agreement were substantially different from the present value of the cash flows under the Original Royalty Purchase Agreement. This resulted in the derecognition of the old liability for sale of future royalties and the new liability for sale of future royalties being recorded at fair value, which was determined to be $
The fair value for the new liability for sale of future royalties on the date of the A&R Royalty Purchase Agreement was based on the Company’s estimates of future royalties expected to be paid to Royalty Pharma over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. The liability is being amortized using the effective interest method over the life of the arrangement, in accordance with ASC 470 and ASC 835. The initial annual effective interest rate was determined to be
In June 2024, the Company, Royalty Pharma and Royalty Pharma plc, entered into an amendment to the A&R Royalty Purchase Agreement. Under the A&R Royalty Purchase Agreement, the Company exercised a put option in June 2024, resulting in the Company receiving $
To date, the Company has sold to Royalty Pharma a total of
29
Table of Contents
The following table shows the activity within the “liability for sale of future royalties- current” and “liability for sale of future royalties- noncurrent” accounts for the six months ended June 30, 2025:
| | | | |
|
| Six Months Ended June 30, | | |
Liability for sale of future royalties- (current and noncurrent) | | 2025 | | |
Beginning balance as of December 31, 2024 | | $ | | |
Less: Non-cash royalty revenue payable to Royalty Pharma | | | ( | |
Plus: Non-cash interest expense recognized | | | | |
Ending balance | | $ | | |
Effective interest rate as of June 30, 2025 | |
| | |
Non-cash interest expense is recorded in the statement of operations within “Interest expense, net”.
2026 Convertible Notes
In September 2019, the Company issued the 2026 Convertible Notes, which included an option to purchase up to an additional $
The 2026 Convertible Notes are governed by an indenture (the “2026 Convertible Notes Indenture") with U.S. Bank National Association as trustee (the "2026 Convertible Notes Trustee").
Holders of the 2026 Convertible Notes may convert their 2026 Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2026 only under the following circumstances:
| ● | during any calendar quarter commencing on or after December 31, 2019 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least |
| ● | during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price (as defined in the 2026 Convertible Notes Indenture) per $1,000 principal amount of 2026 Convertible Notes for each trading day of the measurement period was less than |
| ● | during any period after the Company has issued notice of redemption until the close of business on the scheduled trading day immediately preceding the relevant redemption date; or |
| ● | upon the occurrence of specified corporate events. |
On or after March 15, 2026, until the close of business on the business day immediately preceding the maturity date, holders may convert their 2026 Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock or any combination thereof at the Company’s election.
30
Table of Contents
The conversion rate for the 2026 Convertible Notes was initially, and remains,
The Company was not permitted to redeem the 2026 Convertible Notes prior to September 20, 2023. The Company may redeem for cash all or any portion of the 2026 Convertible Notes, at its option, if the last reported sale price of its common stock has been at least
If the Company undergoes a “fundamental change” (as defined in the 2026 Convertible Notes Indenture), subject to certain conditions, holders of the 2026 Convertible Notes may require the Company to repurchase for cash all or part of their 2026 Convertible Notes at a repurchase price equal to
The 2026 Convertible Notes represent senior unsecured obligations and will rank senior in right of payment to the Company’s future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment to the Company’s existing and future unsecured indebtedness that is not so subordinated, effectively junior in right of payment to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness, and structurally subordinated to all existing and future indebtedness and other liabilities (including trade payables) incurred by the Company’s subsidiaries. The 2026 Convertible Notes Indenture contains customary events of default with respect to the 2026 Convertible Notes, including that upon certain events of default (including the Company’s failure to make any payment of principal or interest on the 2026 Convertible Notes when due and payable) occurring and continuing, the 2026 Convertible Notes Trustee by notice to the Company, or the holders of at least
The 2026 Convertible Notes consist of the following:
| | | | | | | |
|
| | | | | | |
| | June 30, 2025 | | December 31, 2024 | | ||
Principal | | $ | | | $ | | |
Less: Debt issuance costs | |
| ( | |
| ( | |
Net carrying amount | | $ | | | $ | | |
As of June 30, 2025, the remaining contractual life of the 2026 Convertible Notes is approximately
The following table sets forth total interest expense recognized related to the 2026 Convertible Notes:
| | | | | | | | | | | | | |
| | | Three Months Ended June 30, | | | Six Months Ended June 30, | | ||||||
|
| 2025 | | 2024 |
| 2025 | | 2024 | | ||||
Contractual interest expense | | $ | | | $ | | | $ | | | $ | | |
Amortization of debt issuance costs | |
| | | | | | | | | | | |
Total | | $ | | | $ | | | $ | | | $ | | |
Effective interest rate | |
| | % | | | % | | | % | | | % |
31
Table of Contents
10. Commitments and contingencies
Under various agreements, the Company will be required to pay royalties and milestone payments upon the successful development and commercialization of products.
Pursuant to the Agreement and Plan of Merger (the “Agilis Merger Agreement”), dated as of July 19, 2018 by and among the Company, Agilis Biotherapeutics, Inc. (“Agilis”) and Agility Merger Sub, Inc. (such merger pursuant thereto, the “Agilis Merger”), Agilis equityholders were previously entitled to receive contingent consideration payments from the Company based on (i) the achievement of certain development milestones up to an aggregate maximum amount of $
As of June 30, 2025, all of the milestones have either been paid or settled, with the exception of the regulatory milestones and net sales milestones related to FA and Angelman syndrome and the net sales milestones related to Upstaza/Kebilidi. In May 2023, as part of the Company’s strategic portfolio prioritization, the Company decided to discontinue its preclinical and early research programs in its gene therapy platform, which included FA and Angelman syndrome. As a result, the Company does not expect the milestones related to FA and Angelman syndrome to be achieved. In addition, the Company does not expect to pay the
On October 25, 2019, the Company completed the acquisition of substantially all of the assets of BioElectron Technology Corporation (“BioElectron”), a Delaware corporation, including certain compounds that the Company has begun to develop as part of its inflammation and ferroptosis platform, pursuant to an asset purchase agreement by and between the Company and BioElectron, dated October 1, 2019 (the “BioElectron Asset Purchase Agreement”). BioElectron was a private company with a pipeline focused on inflammatory CNS disorders. The lead program, vatiquinone, is in late stage development for FA with substantial unmet need and significant commercial opportunity that are complementary to PTC’s existing pipeline.
Subject to the terms and conditions of the BioElectron Asset Purchase Agreement, BioElectron may become entitled to receive contingent milestone payments of up to $
Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of May 5, 2020 (the “Censa Merger Agreement”) by and among the Company, Censa Pharmaceuticals, Inc. (“Censa”), Hydro Merger Sub, Inc., the Company’s wholly owned, indirect subsidiary, and, solely in its capacity as the representative, agent and attorney-in-fact of the securityholders of Censa, Shareholder Representative Services LLC (such merger pursuant thereto, the “Censa Merger”), former Censa securityholders may become entitled to receive contingent payments from the Company based on (i) the achievement of certain development and regulatory milestones up to an aggregate maximum amount of $
32
Table of Contents
In June 2025, Sephience™ (sepiapterin) was granted marketing authorization by the EC for the treatment of children and adults living with PKU. Pursuant to the Censa Merger Agreement, the acceptance triggered a $
The Company also has the Tegsedi-Waylivra Agreement for the commercialization of Tegsedi and Waylivra, and products containing those compounds in countries in Latin America and the Caribbean. Akcea is entitled to receive royalty payments subject to certain terms set forth in the Tegsedi-Waylivra Agreement.
The Company has employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control or termination without cause, occur. Additionally, the Company has royalty payments associated with Translarna, Emflaza, and Upstaza net product revenue, payable quarterly or annually in accordance with the terms of the related agreements.
From time to time in the ordinary course of its business, the Company is subject to claims, legal proceedings and disputes. The Company is not currently aware of any material legal proceedings against it.
11. Revenue recognition
Net product sales
The Company views its operations and manages its business in
During the three and six months ended June 30, 2025 and 2024, net product revenues consisted of the following:
| | | | | | | | | | | | | | | | | | |
| | Three Months Ended June 30, | ||||||||||||||||
| | | 2025 | | 2024 | |||||||||||||
| | | United States | | | International | | | Total | | | United States | | | International | | | Total |
Translarna | | $ | — | | $ | | | $ | | | $ | — | | $ | | | $ | |
Emflaza | | | | | | — | | | | | | | | | — | | | |
Upstaza/Kebilidi | | | — | | | | | | | | | — | | | | | | |
All other products | | | — | | | | | | | | | — | | | | | | |
Total net product revenue | | $ | | | $ | | | $ | | | $ | | | $ | | | $ | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | Six Months Ended June 30, | ||||||||||||||||
| | 2025 | | 2024 | ||||||||||||||
| | | United States | | | International | | | Total | | | United States | | | International | | | Total |
Translarna | | $ | — | | $ | | | $ | | | $ | — | | $ | | | $ | |
Emflaza | | | | | | — | | | | | | | | | — | | | |
All other products | | | — | | | | | | | | | — | | | | | | |
Total net product revenue | | $ | | | $ | | | $ | | | $ | | | $ | | | $ | |
33
Table of Contents
Disaggregated net product revenues by country for the three and six months ended June 30, 2025 and 2024 are as follows:
| | | | | | | | | | | | |
| | Three Months Ended June 30, | | Six Months Ended June 30, | ||||||||
| | 2025 | | 2024 | | 2025 | | 2024 | ||||
United States | | $ | | | $ | | | $ | | | $ | |
Russia | | | | | | | | | | | | |
Brazil | | | | | | | | | | | | |
All other countries | | | | | | | | | | | | |
Total net product revenue | | $ | | | $ | | | $ | | | $ | |
For the three months ended June 30, 2025,
As of June 30, 2025 and December 31, 2024, the Company does
Collaboration and License revenue
In November 2011, the Company and the SMA Foundation entered into a licensing and collaboration agreement with Roche. Under the terms of the SMA License Agreement, Roche acquired an exclusive worldwide license to the Company’s SMA program.
Under the agreement, the Company is eligible to receive additional payments from Roche if specified events are achieved with respect to each licensed product, including up to $
The SMA program currently has
For the three and six months ended June 30, 2025, collaboration revenue related to the SMA License Agreement with Roche was immaterial. For the three and six months ended June 30, 2024, the Company did
In addition to research and development and sales milestones, the Company is eligible to receive up to double-digit royalties on worldwide annual net sales of a commercial product under the SMA License Agreement. For the three and six months ended June 30, 2025, the Company has recognized $
In November 2024, the Company entered into the Novartis Agreement with Novartis related to the Company’s votoplam HD program. The transaction contemplated by the Novartis Agreement closed in January 2025. Under the Novartis Agreement, and upon the closing of the transaction, the Company received an upfront nonrefundable payment of $
The Company evaluated the Novartis Agreement in order to determine the proper accounting treatment and concluded that the arrangement was not subject to ASC 730 or ASC 808, as the upfront payment was nonrefundable with no obligation
34
Table of Contents
for the Company to repay it and as the Company is not exposed to significant risks. The Company evaluated the arrangement under ASC 606, as a contract with a customer was determined to exist.
Pursuant to the Novartis Agreement, the Company was required to transfer the applicable licenses and related manufacturing and other know how to Novartis and to complete the ongoing Phase 2A clinical trial and continue the ongoing open label extension (“OLE”) clinical trial pursuant to its existing development plan, with the goal of transitioning the ongoing OLE clinical trial to Novartis within 12 months after the effective date of the Novartis Agreement. Novartis will be responsible for all other development of licensed compounds and licensed products and the manufacture and commercialization of licensed compounds and licensed products worldwide. Therefore, the Company determined that there were three material and distinct performance obligations: the transfer of the licenses and know-how, completion of the Phase 2A clinical trial, and continuing the OLE clinical trial until transitioned to Novartis. As of June 30, 2025, the first two performance obligations were considered to be substantially complete. The OLE clinical trial is still ongoing and is expected to be fully transitioned to Novartis by the end of 2025.
The Company determined that the transaction included the fixed consideration of the $
During the three and six months ended June 30, 2025, the Company recognized $
Manufacturing Revenue
For the three and six months ended June 30, 2025, the Company did
As of June 30, 2025 and December 31, 2024, the Company does
In June 2024, the Company sold its gene therapy manufacturing business in Hopewell Township, New Jersey. Accordingly, the Company does not expect to have manufacturing revenue going forward.
35
Table of Contents
12. Intangible assets and goodwill
Definite-lived intangibles
Definite-lived intangible assets consisted of the following at June 30, 2025 and December 31, 2024:
| | | | | | | | | | | | |
| | | Ending Balance at | | | | | | Foreign | | | Ending Balance at |
Definite-lived | | | December 31, | | | | | | currency | | | June 30, |
intangible assets, gross |
| | 2024 |
| | Additions |
| | translation | | | 2025 |
Waylivra | | | | | | | | | | | | |
Tegsedi | | | | | | | | | | | | |
Kebilidi | | | | | | — | | | — | | | |
Upstaza | | | | | | — | | | — | | | |
Sephience | | | — | | | | | | — | | | |
Total definite-lived intangibles, gross | | $ | | | $ | | | $ | | | $ | |
| | | | | | | | | | | | |
| | | Ending Balance at | | | | | | Foreign | | | Ending Balance at |
Definite-lived | | | December 31, | | | | | | currency | | | June 30, |
intangible assets, accumulated amortization |
| | 2024 |
| | Amortization |
| | translation |
| | 2025 |
Waylivra | | | ( | | | ( | | | ( | | | ( |
Tegsedi | | | ( | | | ( | | | ( | | | ( |
Kebilidi | | | ( | | | ( | | | — | | | ( |
Upstaza | | | ( | | | ( | | | — | | | ( |
Sephience | | | — | | | ( | | | — | | | ( |
Total definite-lived intangibles, accumulated amortization | | $ | ( | | $ | ( | | $ | ( | | $ | ( |
| | | | | | | | | | | | |
Total definite-lived intangibles, net | | | | | | | | | | | $ | |
Akcea is entitled to receive royalty payments subject to certain terms set forth in the Tegsedi-Waylivra Agreement related to sales of Waylivra and Tegsedi. In accordance with the guidance for an asset acquisition, the Company records royalty payments when they become payable to Akcea and increase the cost basis for the Waylivra and Tegsedi intangible assets. For the six months ended June 30, 2025, royalty payments of $
Pursuant to the Censa Merger Agreement, in June 2025, a $
The former Censa securityholders may also be entitled to receive other contingent payments subject to certain terms set forth in the Censa Merger Agreement related to sales of Sephience. In accordance with the guidance for an asset acquisition, the Company will record such payments when they become payable to the former Censa securityholders and increase the cost basis for the Sephience intangible asset.
36
Table of Contents
For the three months ended June 30, 2025 and 2024, the Company recognized amortization expense of $
| | | |
|
| As of June 30, 2025 | |
2025 | | $ | |
2026 | |
| |
2027 | |
| |
2028 | |
| |
2029 and thereafter | |
| |
Total | | $ | |
The weighted average remaining amortization period of the definite-lived intangibles as of June 30, 2025 is
Goodwill
As a result of the Agilis Merger on August 23, 2018, the Company recorded $
13. Segment information
The Company views its operations and manages its business in
| | | | | | | | | | | | | |
| | | Three months ended June 30, | | Six months ended June 30, | ||||||||
| | 2025 | | 2024 | | 2025 | | 2024 | | ||||
Total revenues | | $ | | $ | | $ | | $ | | ||||
Less: | | | | | | | | | | | | | |
Cost of product, collaboration and license sales | | | | | | | | | | | | | |
Program spend | | | | | | | | | | | | | |
Employee costs | | | | | | | | | | | | | |
Manufacturing costs | | | | | | | | | | | | | |
Administrative costs | | | | | | | | | | | | | |
Occupancy costs | | | | | | | | | | | | | |
Milestones | | | — | | | | | | — | | | | |
Other segment items (a) | | | | | | | | | | | | | |
Segment net (loss) income | | $ | ( | | $ | ( | | $ | | | $ | ( | |
Reconciliation of profit or loss | | | | | | | | | | | | | |
Adjustments and reconciling items | | | — | | | — | | | — | | | — | |
Consolidated net (loss) income | | $ | ( | | $ | ( | | $ | | | $ | ( | |
37
Table of Contents
| (a) | Other segment items includes the following: |
| | | | | | | | | | | | |
| | | Three months ended June 30, | | | Six months ended June 30, | ||||||
| | | 2025 | | 2024 | | | 2025 | | 2024 | ||
Interest income | | $ | ( | | $ | ( | | $ | ( | | $ | ( |
Interest expense | | | | | | | | | | | | |
Income tax (benefit) expense | | | ( | | | | | | | | | |
Depreciation | | | | | | | | | | | | |
Amortization | | | | | | | | | | | | |
All other (b) | | | | | | | | | | | | |
Total other segment items | | $ | | | $ | | | $ | | | $ | |
| (b) | All other includes cost of goods sold, royalty, travel and expense, distribution costs, bad debt expense, finance costs, contract labor costs, stock compensation expense, change in the fair value of contingent consideration, and other expense. |
14. Subsequent events
Sephience FDA Approval
On July 28, 2025, Sephience™ was approved by the FDA for the treatment of pediatric and adult patients living with PKU in the United States. Pursuant to the Censa Merger Agreement, the approval triggered a $
Censa Rights Satisfaction Agreement
On August 5, 2025, the Company, certain of the former securityholders of Censa, and, for the limited purposes set forth in the agreement, Shareholder Representative Services LLC, a Colorado limited liability company, entered into a Rights Satisfaction Agreement (“the Rights Satisfaction Agreement”) pursuant to which such former securityholders of Censa (the “Participating Rightsholders”) agreed to the cancellation and forfeiture of their rights to receive certain payments based on worldwide annual net sales by the Company of products containing sepiapterin (“Net Sales of Product”) under the Censa Merger Agreement, in exchange for the consideration set forth in the Rights Satisfaction Agreement and further detailed below.
Pursuant to the terms of the Rights Satisfaction Agreement, the Participating Rightsholders have canceled and forfeited their rights under the Censa Merger Agreement to receive a percentage of annual net sales during the applicable payment term equal to (i)
In consideration of the foregoing, the Company agreed to pay to the Participating Rightsholders an aggregate amount in cash up to $
At the Closing, based on the participation of former Censa securityholders holding approximately
38
Table of Contents
an aggregate amount of Upfront Consideration in cash of approximately $
The Rights Satisfaction Agreement has no effect on the Censa Merger Agreement other than to provide for the cancellation and forfeiture of the Participating Rightsholders’ rights to receive the Net Sales Payments described above. As a result, all other rights and obligations under the Censa Merger Agreement remain in effect pursuant to their terms, including, without limitation, the Company's obligation to pay certain contingent payments upon the achievement of certain development and Net Sales of Product milestones.
The Rights Satisfaction Agreement contains customary representations, warranties and covenants of the Company and the Participating Rightsholders and provided for a simultaneous signing and closing.
39
Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis is meant to provide material information relevant to an assessment of the financial condition and results of operations of our company, including an evaluation of the amounts and certainty of cash flows from operations and from outside resources, so as to allow investors to better view our company from management’s perspective. The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the notes to those financial statements appearing elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto and management’s discussion and analysis of financial condition and results of operations for the year ended December 31, 2024 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 27, 2025, or our 2024 Annual Report. This discussion contains forward-looking statements that involve significant risks and uncertainties. As a result of many factors, such as those set forth in Part II, Item 1A. (Risk Factors) of this Quarterly Report on Form 10-Q and Part I, Item 1A. (Risk Factors) of our 2024 Annual Report, our actual results may differ materially from those anticipated in these forward-looking statements.
Our Company
We are a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. We are advancing a robust and diversified pipeline of transformative medicines as part of our mission to provide access to best-in-class treatments for patients with unmet medical needs. Our strategy is to leverage our scientific expertise and global commercial infrastructure to optimize value for our patients and other stakeholders. We have a diversified therapeutic portfolio pipeline that includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism.
Corporate Updates
Sephience™ (sepiapterin)
Sephience (sepiapterin) is a product for the treatment of phenylketonuria, or PKU, a rare inherited metabolic disease which affects the brain. On July 28, 2025, Sephience was approved by the FDA for the treatment of pediatric and adult patients living with PKU in the United States. On June 19, 2025, Sephience was granted marketing authorization by the EC for the treatment of children and adults living with PKU within the EEA. We also made a regulatory submission for Sephience for the treatment of PKU in Brazil in the third quarter of 2024, with a regulatory decision expected in the second half of 2025, and in Japan in the fourth quarter of 2024, with a regulatory decision expected in the fourth quarter of 2025.
Censa Rights Satisfaction Agreement
On August 5, 2025, we, certain of the former securityholders of Censa, and, for the limited purposes set forth in the agreement, Shareholder Representative Services LLC, a Colorado limited liability company, entered into a Rights Satisfaction Agreement, or the Rights Satisfaction Agreement, pursuant to which such former securityholders of Censa, or the Participating Rightsholders, agreed to the cancellation and forfeiture of their rights to receive certain payments based on worldwide annual net sales by us of products containing sepiapterin, or Net Sales of Product, under the Agreement and Plan of Merger, dated as of May 5, 2020, or the Censa Merger Agreement, by and among us, Hydro Merger Sub, Inc., our wholly owned, indirect subsidiary, Censa and, solely in its capacity as the representative, agent and attorney-in-fact of the securityholders of Censa, Shareholder Representative Services LLC, in exchange for the consideration set forth in the Rights Satisfaction Agreement and further detailed below.
Pursuant to the terms of the Rights Satisfaction Agreement, the Participating Rightsholders have canceled and forfeited their rights under the Censa Merger Agreement to receive a percentage of annual net sales during the applicable payment term equal to (i) 8% of annual Net Sales of Product for that portion of annual Net Sales of Product less than or equal to $250.0 million, (ii) 10% of annual Net Sales of Product for that portion of annual Net Sales of Product greater than
40
Table of Contents
$250.0 million but less than $500.0 million and (iii) 12% of annual Net Sales of Product for that portion of annual Net Sales of Product greater than $500.0 million, which we refer to collectively as the Net Sales Payments.
In consideration of the foregoing, we agreed to pay to the Participating Rightsholders an aggregate amount in cash up to $250.0 million, or the Upfront Consideration, upon the consummation of the transactions contemplated by the Rights Satisfaction Agreement, or the Closing, and potential milestone payments, each, an Additional Milestone Payment, of up to $100.0 million each (or up to $500.0 million in the aggregate) based on the achievement of specified Net Sales Thresholds (as defined in the Censa Merger Agreement). The amount of the Upfront Consideration and the Additional Milestone Payments was subject to adjustment in the Rights Satisfaction Agreement based on the number of Participating Rightsholders.
At the Closing, based on the participation of former Censa securityholders holding approximately 90% of Censa’s equity securities prior to the consummation of the transactions contemplated by the Censa Merger Agreement, we paid an aggregate amount of Upfront Consideration in cash of approximately $225.0 million. Additionally, we are obligated to make Additional Milestone Payments in an amount equal to approximately $90.0 million upon achievement of each of the (i) first occurrence of a three or fewer consecutive calendar year period in which aggregate Net Sales of Product are greater than $3.0 billion, (ii) first occurrence of a five or fewer consecutive calendar year period in which aggregate Net Sales of Product are greater than $5.0 billion, (iii) first occurrence of a seven or fewer consecutive calendar year period in which aggregate Net Sales of Product are greater than $7.0 billion, (iv) first occurrence of a nine or fewer consecutive calendar year period in which aggregate Net Sales of Product are greater than $9.0 billion and (v) first occurrence of an 11 or fewer consecutive calendar year period in which aggregate Net Sales of Product are greater than $11.0 billion. If, after the Closing, any additional former securityholder of Censa executes and delivers a joinder to the Rights Satisfaction Agreement and becomes a party thereto, we will pay such former securityholder an amount in cash equal to such former securityholder’s applicable pro rata share of the Upfront Consideration (less any Net Sale Payments previously received) and any Additional Milestone Payments that become payable to Participating Rightsholders under the Rights Satisfaction Agreement.
In addition to the Additional Milestone Payments, and pursuant to the terms of the Censa Merger Agreement, we will make payments of $30.0 million for the first occurrence of a four consecutive calendar quarter period in which aggregate Net Sales of Product (as defined in the Censa Merger Agreement) exceed $250.0 million, $50.0 million for the first occurrence of a four consecutive calendar quarter period in which aggregate Net Sales of Product exceed $500.0 million, and $80.0 million for the first occurrence of a four consecutive calendar quarter period in which aggregate Net Sales of Product exceed $1.0 billion.
The Rights Satisfaction Agreement has no effect on the Censa Merger Agreement other than to provide for the cancellation and forfeiture of the Participating Rightsholders’ rights to receive the Net Sales Payments described above. As a result, all other rights and obligations under the Censa Merger Agreement remain in effect pursuant to their terms, including, without limitation, our obligation to pay certain contingent payments upon the achievement of certain development and Net Sales of Product milestones.
The Rights Satisfaction Agreement contains customary representations, warranties and covenants of us and the Participating Rightsholders and provided for a simultaneous signing and closing.
Global Commercial Footprint
Global DMD Franchise
We have two products, Translarna™ (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy, or DMD, a rare, life-threatening disorder. Translarna has marketing authorization in Russia for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in patients aged two years and older, and in Brazil for the treatment of nmDMD in ambulatory patients two years and older and for continued treatment of patients that become non-ambulatory, as well as in various other countries. During the quarter ended June 30, 2025, we recognized $59.5 million in net sales of Translarna. We hold worldwide commercialization rights to Translarna for all indications in all territories.
41
Table of Contents
Emflaza is approved in the United States for the treatment of DMD in patients two years and older. During the quarter ended June 30, 2025, we recognized $36.4 million in net sales of Emflaza.
We previously had a marketing authorization for Translarna in the European Economic Area, or EEA, which had been subject to annual review and renewal by the European Commission, or EC, following reassessment by the European Medicines Agency, or EMA, of the benefit-risk balance of the authorization. In September 2022, we submitted a Type II variation to the EMA to support conversion of the conditional marketing authorization for Translarna to a standard marketing authorization, which included a report on the placebo-controlled trial of Study 041 and data from the open-label extension as further described below. Study 041 was an 18-month, placebo-controlled trial, followed by an 18-month open-label extension of Translarna in the treatment of ambulatory patients with nmDMD aged five years or older. In February 2023, we also submitted an annual marketing authorization renewal request to the EMA. In September 2023, the Committee for Medicinal Products for Human Use, or CHMP, gave a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna for the treatment of nmDMD and a negative opinion on the renewal of the existing conditional marketing authorization of Translarna for the treatment of nmDMD. In January 2024, the CHMP issued a negative opinion for the renewal of the conditional marketing authorization following a re-examination procedure. In May 2024, the EC decided not to adopt the CHMP’s negative opinion for the renewal of the conditional marketing authorization of Translarna and returned such opinion to the CHMP for re-evaluation. In June 2024, following the EC’s request for re-review, the CHMP issued a negative opinion on the renewal of the conditional marketing authorization of Translarna for the treatment of nmDMD. In October 2024, the CHMP maintained its negative opinion for the renewal of the conditional marketing authorization following the requested reexamination procedure. In March 2025, the EC adopted the opinion of the CHMP to not renew the authorization of Translarna for the treatment of nmDMD. However, the EC indicated that individual countries within the European Union, or EU, can leverage Articles 117(3) and 5(1) of the EU Directive 2001/83 to allow continued commercial use of Translarna. There is a substantial risk that as a result of the EC’s adoption of the CHMP’s negative opinion we will lose a significant portion of our ability to generate revenue from sales of Translarna in the EEA.
Translarna is an investigational new drug in the United States. During the first quarter of 2017, we filed a New Drug Application, or NDA, for Translarna for the treatment of nmDMD over protest with the United States Food and Drug Administration, or FDA. In October 2017, the Office of Drug Evaluation I of the FDA issued a Complete Response Letter, or CRL, for the NDA, stating that it was unable to approve the application in its current form. In response, we filed a formal dispute resolution request with the Office of New Drugs of the FDA. In February 2018, the Office of New Drugs of the FDA denied our appeal of the CRL. In its response, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway. This would involve a resubmission of an NDA containing the current data on effectiveness of ataluren with new data to be generated on dystrophin production in nmDMD patients’ muscles. We followed the FDA’s recommendation and collected, using newer technologies via procedures and methods that we designed, such dystrophin data in a new study, Study 045, and announced the results of Study 045 in February 2021. Study 045 did not meet its pre-specified primary endpoint. In June 2022, we announced top-line results from the placebo-controlled trial of Study 041. Following this announcement, we submitted a meeting request to the FDA to gain clarity on the regulatory pathway for a potential resubmission of an NDA for Translarna. The FDA provided initial written feedback that Study 041 does not provide substantial evidence of effectiveness to support an NDA resubmission. We held a Type C meeting with the FDA in the fourth quarter of 2023 to discuss the totality of Translarna data. Based on feedback from the FDA, we resubmitted the NDA in July 2024, based on the results from Study 041 and from our international drug registry study for nmDMD patients receiving Translarna. In October 2024, the FDA accepted for review the resubmission of the NDA for Translarna for the treatment of nmDMD. As this was an NDA resubmission following a complete response letter to the NDA which was filed over protest in 2016, the FDA is not obligated to follow the review timelines under Prescription Drug User Fee Act guidelines and an action date has not been provided.
We have previously relied on Emflaza’s seven-year marketing exclusivity period in the United States for its approved indications under the provisions of the Orphan Drug Act of 1983, or the Orphan Drug Act, when commercializing Emflaza. Emflaza’s seven-year period of orphan drug exclusivity related to the treatment of DMD in patients five years and older expired in February 2024. We expect the expiration of this orphan drug exclusivity to potentially have a significant negative impact on Emflaza net product revenue. Emflaza’s orphan drug exclusivity related to the treatment of DMD in patients two years of age to less than five expires in June 2026.
42
Table of Contents
Upstaza™ (eladocagene exuparvovec) / Kebilidi™ (eladocagene exuparvovec-tneq)
Upstaza/Kebilidi is a gene therapy for the treatment of Aromatic L Amino Acid Decarboxylase, or AADC, deficiency, a rare central nervous system, or CNS, disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. In July 2022, the EC approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the EEA. In November 2022, the Medicines and Healthcare Products Regulatory Agency approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the United Kingdom. In November 2024, the FDA granted accelerated approval of our gene therapy for the treatment of children and adults with AADC deficiency, which is marketed with the brand name Kebilidi in the United States.
Tegsedi® (inotersen) and Waylivra™ (volanesorsen)
We hold the rights for the commercialization of Tegsedi and Waylivra for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to a Collaboration and License Agreement, or the Tegsedi-Waylivra Agreement, dated August 1, 2018, by and between us and Akcea Therapeutics, Inc., or Akcea, a subsidiary of Ionis Pharmaceuticals, Inc. Tegsedi has received marketing authorization in the United States, European Union, or EU, and Brazil for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis, or hATTR amyloidosis. In August 2021, ANVISA, the Brazilian health regulatory authority, approved Waylivra as the first treatment for familial chylomicronemia syndrome, or FCS, in Brazil. In December 2022, ANVISA approved Waylivra for the treatment of familial partial lipodystrophy, or FPL. Waylivra has also received marketing authorization in the EU for the treatment of FCS.
Evrysdi® (risdiplam)
We also have a spinal muscular atrophy, or SMA, collaboration with F. Hoffman-La Roche Ltd. and Hoffman La Roche Inc., which we refer to collectively as Roche, and the Spinal Muscular Atrophy Foundation, or SMA Foundation. The SMA program has one approved product, Evrysdi (risdiplam), which was approved by the FDA in August 2020 for the treatment of SMA in adults and children two months and older and by the EC in March 2021 for the treatment of 5q SMA in patients two months and older with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. Evrysdi also received marketing authorization for the treatment of SMA in over 100 countries. In May 2022, the FDA approved a label expansion for Evrysdi to include infants under two months old with SMA. In August 2023, the EC approved an extension of the Evrysdi marketing authorization to include infants under two months old in the EU.
Diversified Development Pipeline
Splicing Platform
In addition to our SMA program, our splicing platform also includes votoplam (PTC518), which is being developed for the treatment of Huntington’s disease, or HD. We announced the results from our Phase 1 study of votoplam in healthy volunteers in September 2021 demonstrating dose-dependent lowering of huntingtin messenger ribonucleic acid and protein levels, that votoplam efficiently crosses blood brain barrier at significant levels and that votoplam was well tolerated. We initiated a Phase 2 study of votoplam for the treatment of HD in the first quarter of 2022, which consists of an initial 12-week placebo-controlled phase focused on safety, pharmacology and pharmacodynamic effects followed by a nine-month placebo-controlled phase focused on votoplam biomarker effect. In June 2024, we announced interim results from the full Phase 2 study of votoplam. At month 12, votoplam treatment demonstrated durable dose-dependent lowering of mHTT protein in the blood and dose-dependent lowering of mHTT protein in the cerebrospinal fluid in the interim cohort of stage 2 patients. In addition, favorable trends were demonstrated on several relevant HD clinical assessments. Furthermore, following 12 months of treatment, votoplam continued to be well tolerated. In September 2024, the FDA granted Fast Track designation to the votoplam program for the treatment of HD. In December 2024, we held a Type C meeting with the FDA to discuss whether huntingtin protein lowering could be considered a surrogate endpoint for accelerated approval of votoplam. The FDA was aligned on the scientific rationale and asked to see additional data supportive of an association between huntingtin protein lowering and changes in clinical outcome scores. In May 2025, we announced that the Phase 2 study of votoplam met its primary endpoints of blood HTT lowering and safety. The results on the full study population are consistent with the previously reported evidence of dose-dependent HTT lowering,
43
Table of Contents
favorable safety profile and early signals of dose-dependent clinical effect at 12 months in Stage 2 patients. In addition, at 24 months of treatment, there were continued trends of dose-dependent favorable clinical effect relative to a propensity-matched natural history cohort as well as dose-dependent NfL lowering. In November 2024, we entered into the License and Collaboration Agreement, or the Novartis Agreement, with Novartis Pharmaceuticals Corporation, or Novartis, relating to our votoplam program. This transaction closed in January 2025. Pursuant to the Novartis Agreement, we are responsible for completing the ongoing Phase 2A clinical trial and continuing the ongoing open label extension, or OLE, clinical trial pursuant to its existing development plan, with the goal of transitioning the ongoing OLE clinical trial to Novartis within 12 months after the effective date of the Novartis Agreement. Novartis will be responsible for all other development of licensed compounds and licensed products and the manufacture and commercialization of licensed compounds and licensed products worldwide. We continue to collaborate with Novartis on next steps and aim to meet with FDA in the fourth quarter of 2025 to discuss Phase 3 clinical trial design and potential accelerated approval pathway.
Inflammation and Ferroptosis Platform
Our inflammation and ferroptosis platform consists of small molecule compounds that target oxidoreductase enzymes that regulate oxidative stress and inflammatory pathways central to the pathology of a number of CNS diseases. The most advanced molecule in our inflammation and ferroptosis platform is vatiquinone. We announced topline results from a registration-directed Phase 3 trial of vatiquinone in children and young adults with Friedreich’s Ataxia, called MOVE-FA, in May 2023. While the study did not meet its primary endpoint of statistically significant change in modified Friedreich Ataxia Rating Scale, or mFARS, score at 72 weeks in the primary analysis population, vatiquinone treatment did demonstrate significant benefit on key disease subscales and secondary endpoints. In addition, in the population of subjects that completed the study protocol, significance was reached in the mFARS endpoint and several secondary endpoints, including the upright stability subscale. Furthermore, vatiquinone was well tolerated. In October 2024, we announced that the pre-specified endpoint for two different FA long-term extension studies was met, with statistically significant evidence of durable treatment benefit on disease progression. In December 2024, we submitted an NDA to the FDA for vatiquinone for the treatment of children and adults living with FA. In February 2025, the FDA accepted for filing the NDA and granted priority review with a target regulatory action date of August 19, 2025.
Multi-Platform Discovery
In addition, we have a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas for rare diseases.
Funding
The success of our products and any other product candidates we may develop depends largely on obtaining and maintaining reimbursement from governments and third-party insurers. Our revenues are primarily generated from sales of Translarna for the treatment of nmDMD in countries where we were able to obtain acceptable commercial pricing and reimbursement terms and in select countries where we are permitted to distribute Translarna under our early access programs, or EAP, programs or through similar styled programs, and from sales of Emflaza for the treatment of DMD in the United States. We also generate revenue from sales of Upstaza for the treatment of AADC deficiency in the EEA, we have recognized revenue associated with milestone and royalty payments from Roche pursuant to a License and Collaboration Agreement, or the SMA License Agreement, by and among us, Roche and, for the limited purposes set forth therein, the SMA Foundation, under our SMA program and we have recognized license revenues related to performance obligations already completed pursuant to the Novartis Agreement.
We have financed our operations to date primarily through the private offerings of convertible senior notes, public and “at the market offerings” of common stock, proceeds from royalty purchase agreements, private placements of our convertible preferred stock and common stock, collaborations, bank and institutional lender debt, other convertible debt, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by our product candidates. We have relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States since 2014, Emflaza for the treatment of DMD in the United States since 2017 and Upstaza for the treatment of AADC deficiency in the EEA since 2022. We have also relied
44
Table of Contents
on revenue associated with milestone and royalty payments from Roche pursuant to the SMA License Agreement under our SMA program, revenue generated from net sales of Tegsedi and Waylivra in Latin America and the Caribbean, and license revenues related to performance obligations already completed pursuant to the Novartis Agreement.
In June 2024, we entered into an amendment with Royalty Pharma Investments 2019 ICAV, or Royalty Pharma, and Royalty Pharma plc, to the Amended and Restated Royalty Purchase Agreement, dated October 18, 2023, or the A&R Royalty Purchase Agreement, which amends and restated in its entirety the Royalty Purchase Agreement by and among us, RPI Intermediate Finance Trust, and for the limited purposes set forth in the agreement, Royalty Pharma plc, dated as of July 17, 2020, or the Original Royalty Purchase Agreement, and we exercised our first put option in exchange for $241.8 million in cash consideration. To date, Royalty Pharma has paid to us cash consideration of $1.9 billion (less payments on our right to receive sales-based royalty payments, or the Royalty, on worldwide net sales of Evrysdi and any other product in development pursuant to the SMA License Agreement received by us with respect to assigned Royalties, or the Assigned Royalty Rights) in exchange for 90.49% of the Royalty, which will be reduced to 83.33% after Royalty Pharma receives $1.3 billion in aggregate payments, or the Assigned Royalty Cap, from the Royalty assigned under the Original Royalty Purchase Agreement. We currently retain 9.51% of the Royalty, which increases to 16.67% after the Assigned Royalty Cap has been met. We have the option to sell our retained portions of the Royalty to Royalty Pharma in up to three tranches for the following payments: (1) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, (2) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, and (3) $50.0 million in exchange for 1.90% of the Royalty, which increases to 3.33% after the Assigned Royalty Cap has been met, in each case less Royalty payments received by us with respect to the Assigned Royalty Rights.
In November 2024, we entered into the Novartis Agreement relating to our votoplam HD program which includes related molecules. Pursuant to the Novartis Agreement, we are responsible for completing the ongoing Phase 2A clinical trial and continuing the ongoing OLE clinical trial pursuant to its existing development plan, with the goal of transitioning the ongoing OLE clinical trial to Novartis within 12 months after the effective date. Novartis will be responsible for all other development of licensed compounds and licensed products and the manufacture and commercialization of licensed compounds and licensed products worldwide. Under the Novartis Agreement, and upon the closing of the transaction contemplated by the Novartis Agreement in January 2025, we received an upfront payment of $1.0 billion on the effective date and can receive up to $1.9 billion in development, regulatory and sales milestones, a 40% share of U.S. profits and losses, and tiered double-digit royalties on ex-U.S. sales.
In August 2019, we entered into an At the Market Offering Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald and RBC Capital Markets, LLC, or together, the Sales Agents, pursuant to which, we may offer and sell shares of our common stock, having an aggregate offering price of up to $125.0 million from time to time through the Sales Agents by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. During the three and six months ended June 30, 2025, we did not issue or sell any shares of common stock pursuant to the Sales Agreement. The remaining shares of our common stock available to be issued and sold, under the Sales Agreement, have an aggregate offering price of up to $93.0 million as of June 30, 2025.
As of June 30, 2025, we had an accumulated deficit of $2,845.2 million. We had a net income of $801.7 million and a net loss of $190.8 million for the six months ended June 30, 2025 and 2024, respectively.
We anticipate that we will continue to incur significant expenses in connection with our commercialization efforts in the United States, the EEA, Latin America and other territories, including expenses related to our commercial infrastructure and corresponding sales and marketing, legal and regulatory, and distribution and manufacturing undertakings as well as administrative and employee-based expenses. In addition to the foregoing, we expect to continue to incur significant costs in connection with ongoing, planned and potential future clinical trials and studies for our splicing and inflammation and ferroptosis programs as well as studies in our products for maintaining authorizations, label extensions and additional indications. We continue to seek marketing authorization for Translarna for the treatment of nmDMD in territories in which we do not currently have marketing authorization. We have submitted an NDA to the FDA for vatiquinione for the treatment of FA in the fourth quarter of 2024. These efforts may significantly impact the timing and extent of our commercialization and manufacturing expenses.
45
Table of Contents
We may seek to expand and diversify our product pipeline through opportunistically in-licensing or acquiring the rights to products, product candidates or technologies and we may incur expenses, including with respect to transaction costs, subsequent development costs or any upfront, milestone or other payments or other financial obligations associated with any such transaction, which would increase our future capital requirements.
With respect to our outstanding 1.50% convertible senior notes due September 15, 2026, or the 2026 Convertible Notes,
cash interest payments are payable on a semi-annual basis in arrears, which will require total funding of $4.3 million
annually.
We expect to make payments to the former Censa Pharmaceuticals, Inc., or Censa, securityholders of $25.0 million in the aggregate in cash for the marketing authorization granted by the EC for Sephience for the treatment of children and adults living with PKU in the EEA, and $32.5 million in the aggregate in cash for the approval by the FDA of Sephience for the treatment of pediatric and adult patients living with PKU in the United States, pursuant to the Censa Merger Agreement.
Upon the potential achievement in 2025 of certain regulatory milestones relating to vatiquinone, which milestones would be payable in 2026, we expect to make payments to BioElectron Technology Corporation, or BioElectron, of $75.0 million in the aggregate, in cash or shares of our common stock, as determined by us, pursuant to an asset purchase agreement by and between the Company and BioElectron, dated October 1, 2019, or the BioElectron Asset Purchase Agreement.
We also have certain significant contractual obligations and commercial commitments that require funding and we have disclosed these items under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Funding Obligations” in our 2024 Annual Report. There were no material changes to these obligations and commitments during the period ended June 30, 2025. Furthermore, since we are a public company, we have incurred and expect to continue to incur additional costs associated with operating as such including significant legal, accounting, investor relations and other expenses.
We will need to generate significant revenues to achieve and sustain profitability, and we may never do so. Accordingly, we may need to obtain substantial additional funding in connection with our continuing operations. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or our commercialization efforts.
Financial operations overview
Revenues
Net product revenues. To date, our net product revenues have consisted primarily of sales of Translarna for the treatment of nmDMD in territories outside of the United States and sales of Emflaza for the treatment of DMD in the United States. We recognize revenue when performance obligations with customers have been satisfied and if it is probable that a significant revenue reversal will not occur. Our performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies. The performance obligations are satisfied at a point in time when our customer obtains control of the product, which is typically upon delivery. We invoice customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of invoice date. We determine the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods not yet provided. As we have identified only one distinct performance obligation, the transaction price is allocated entirely to the product sale. In determining the transaction price, a significant financing component does not exist since the timing from when we deliver product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month.
We record product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government pricing programs, and distribution fees. We use the expected value or most likely amount method when estimating variable consideration, unless discount or rebate terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are
46
Table of Contents
recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained.
During the three and six months ended June 30, 2025 and 2024, net product revenues consisted of the following:
| | | | | | | | | | | | | | | | | | |
| | Three Months Ended June 30, | ||||||||||||||||
| | | 2025 | | 2024 | |||||||||||||
| | | United States | | | International | | | Total | | | United States | | | International | | | Total |
Translarna | | $ | — | | $ | 59,470 | | $ | 59,470 | | $ | — | | $ | 70,350 | | $ | 70,350 |
Emflaza | | | 36,353 | | | — | | | 36,353 | | | 47,296 | | | — | | | 47,296 |
Upstaza/Kebilidi | | | — | | | 11,889 | | | 11,889 | | | — | | | 1,589 | | | 1,589 |
All other products | | | — | | | 10,617 | | | 10,617 | | | — | | | 13,985 | | | 13,985 |
Total net product revenue | | $ | 36,353 | | $ | 81,976 | | $ | 118,329 | | $ | 47,296 | | $ | 85,924 | | $ | 133,220 |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | Six Months Ended June 30, | ||||||||||||||||
| | 2025 | | 2024 | ||||||||||||||
| | | United States | | | International | | | Total | | | United States | | | International | | | Total |
Translarna | | $ | — | | $ | 145,624 | | $ | 145,624 | | $ | — | | $ | 173,934 | | $ | 173,934 |
Emflaza | | | 84,142 | | | — | | | 84,142 | | | 104,777 | | | — | | | 104,777 |
All other products | | | — | | | 41,989 | | | 41,989 | | | — | | | 32,113 | | | 32,113 |
Total net product revenue | | $ | 84,142 | | $ | 187,613 | | $ | 271,755 | | $ | 104,777 | | $ | 206,047 | | $ | 310,824 |
Disaggregated net product revenues by country for the three and six months ended June 30, 2025 and 2024 are as follows:
| | | | | | | | | | | | |
| | Three Months Ended June 30, | | Six Months Ended June 30, | ||||||||
| | 2025 | | 2024 | | 2025 | | 2024 | ||||
United States | | $ | 36,353 | | $ | 47,296 | | $ | 84,142 | | $ | 104,777 |
Russia | | | 18,124 | | | 2,146 | | | 56,638 | | | 54,751 |
Brazil | | | 40,951 | | | 30,375 | | | 50,456 | | | 39,085 |
All other countries | | | 22,901 | | | 53,403 | | | 80,519 | | | 112,211 |
Total net product revenue | | $ | 118,329 | | $ | 133,220 | | $ | 271,755 | | $ | 310,824 |
For the three months ended June 30, 2025, three of our distributors each accounted for over 10% of our net product sales. For the three months ended June 30, 2024, two of our distributors each accounted for over 10% of our net product sales. For the six months ended June 30, 2025 and 2024, two of our distributors each accounted for over 10% of our net product sales.
In relation to customer contracts, we incur costs to fulfill a contract but do not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. We consider any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.
Roche and the SMA Foundation Collaboration. In November 2011, we entered into the SMA License Agreement pursuant to which we are collaborating with Roche and the SMA Foundation to further develop and commercialize compounds identified under our SMA program with the SMA Foundation. The research component of this agreement terminated effective December 31, 2014. We are eligible to receive additional payments from Roche if specified events are achieved with respect to each licensed product, including up to $135.0 million in research and development event milestones, up to $325.0 million in sales milestones upon achievement of specified sales events, and up to double digit royalties on worldwide annual net sales of a commercial product. As of June 30, 2025, we had recognized a total of $310.0 million in
47
Table of Contents
milestone payments and $639.6 million royalties on net sales pursuant to the SMA License Agreement. As of June 30, 2025, there are no remaining research and development event milestones that we can receive. The remaining potential sales milestones as of June 30, 2025 are $150.0 million upon achievement of certain sales events.
For the three and six months ended June 30, 2025, collaboration revenue related to the SMA License Agreement with Roche was immaterial. For the three and six months ended June 30, 2024, we did not recognize collaboration revenue related to the SMA License Agreement with Roche.
For the three and six months ended June 30, 2025, we recognized $57.6 million and $94.0 million of royalty revenue, respectively, related to Evrysdi. For the three and six months ended June 30, 2024, we recognized $53.2 million and $84.3 million of royalty revenue, respectively, related to Evrysdi.
Novartis Collaboration for votoplam HD. In November 2024, we entered into the Novartis Agreement with Novartis related to our votoplam HD program. Upon the closing of the transaction contemplated by the Novartis Agreement in January 2025, we received an upfront payment of $1.0 billion on the effective date and can receive up to $1.9 billion in development, regulatory and sales milestones, a 40% share of U.S. profits and losses, and tiered double-digit royalties on ex-U.S. sales
During the three and six months ended June 30, 2025, we recognized $2.9 million and $992.7 million, respectively, in license revenues related to performance obligations for Novartis already completed. The remaining $7.3 million is recorded as deferred revenue on the consolidated balance sheet as of June 30, 2025 and will be recognized over time as the work related to the OLE clinical trial is performed. Collaboration and license revenue during the six months ended June 30, 2025 was partially offset by $3.5 million related to a refund for a prior collaboration arrangement in relation to votoplam.
Pursuant to the A&R Royalty Purchase Agreement, Royalty Pharma has paid to us aggregate cash consideration of $1.9 billion (less Royalty payments received by us with respect to the Assigned Royalty Rights) in exchange for 90.49% of the Royalty, which will be reduced to 83.33% of the Royalty after Royalty Pharma receives $1.3 billion in aggregate payments from the Royalty assigned at the closing of the Original Purchase Agreement. We currently retain 9.51% of the Royalty, which increases to 16.67% after the Assigned Royalty Cap has been met, and all economic rights to receive the remaining potential regulatory and sales milestone payments under the SMA License Agreement.
We have the option to sell our retained portions of the Royalty to Royalty Pharma in up to three tranches for the following payments: (1) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, (2) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, and (3) $50.0 million in exchange for 1.90% of the Royalty, which increases to 3.33% after the Assigned Royalty Cap has been met, in each case less Royalty payments received by us with respect to the Assigned Royalty Rights. See “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and capital resources—Sources of liquidity” for additional information.
Research and development expense
Research and development expenses consist of the costs associated with our research activities, as well as the costs associated with our drug discovery efforts, conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings. Our research and development expenses consist of:
48
Table of Contents
We use our employee and infrastructure resources across multiple research projects, including our drug development programs. We track expenses related to our clinical programs and certain preclinical programs on a per project basis.
We expect our research and development expenses to fluctuate in connection with our ongoing activities, particularly in connection with our activities under our splicing and inflammation and ferroptosis programs and performance of our post-marketing requirements imposed by regulatory agencies with respect to our products. The timing and amount of these expenses will depend upon the outcome of our ongoing clinical trials and the costs associated with our planned clinical trials. The timing and amount of these expenses will also depend on the costs associated with potential future clinical trials of our products or product candidates and the related expansion of our research and development organization, regulatory requirements, advancement of our preclinical programs, and product candidate manufacturing costs.
The following tables provides research and development expense for our most advanced principal product development programs, for the three and six months ended June 30, 2025 and 2024.
| | | | | | | |
| | | | | | | |
| | Three Months Ended June 30, | | ||||
|
| 2025 |
| 2024 | | ||
| | (in thousands) | | ||||
Development | | $ | 51,150 | | $ | 49,931 | |
Research | | | 15,691 | | | 18,204 | |
Milestones | | | — | | | 15,000 | |
Payroll, benefits, and share-based stock compensation | | | 36,995 | | | 37,302 | |
Facilities and other | |
| 9,154 | |
| 11,732 | |
Total research and development | | $ | 112,990 | | $ | 132,169 | |
| | | | | | |
| | Six Months Ended June 30, | ||||
|
| 2025 |
| 2024 | ||
| | (in thousands) | ||||
Development | | $ | 98,999 | | $ | 103,355 |
Research | |
| 29,538 | |
| 31,703 |
Milestones | | | — | | | 15,000 |
Payroll, benefits, and share-based stock compensation | |
| 75,229 | |
| 76,654 |
Facilities and other | |
| 18,197 | |
| 21,586 |
Total research and development | | $ | 221,963 | | $ | 248,298 |
Development. Consists of costs incurred for product candidates following initiation of a clinical trial.
For the three and six months ended June 30, 2025, compared to the three and six months ended June 30, 2024, the changes reflect progressing through different phases of studies as we continue to focus our resources on our differentiated, high potential research and development programs.
Research. Consists of costs incurred for product candidates before initiation of a clinical trial.
For the three and six months ended June 30, 2025, compared to the three and six months ended June 30, 2024, the decrease in research expenses primarily reflected our continued focus of our resources on product candidates approaching approval during the current year periods.
Milestones. Consists of development and regulatory milestone expenses incurred in connection with our collaborative arrangements.
For the three and six months ended June 30, 2025, compared to the three and six months ended June 30, 2024, the decrease in milestone expenses related to the achievement of a $15.0 million success-based regulatory milestone for the validation and acceptance of a marketing authorization application for sepiapterin for PKU in May 2024.
49
Table of Contents
Payroll, benefits, and share-based stock compensation. Consists of costs incurred for salaries and wages, bonus, payroll taxes, benefits and share-based stock compensation associated with employees involved in research and development activities. Share-based stock compensation may fluctuate from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued.
For the three and six months ended June 30, 2025 compared to the three and six months ended June 30, 2024, the change in payroll, benefits, and share-based stock compensation expenses was relatively flat.
Facilities and other. Consists of indirect costs incurred for the benefit of multiple programs, including information technology, and other facility-based expenses, such as rent expense.
For the three and six months ended June 30, 2025 compared to the three and six months ended June 30, 2024, the decrease in facilities and other expenses primarily related to decreases in facility-based expenses at our facility in Hopewell Township, New Jersey as a result of an amendment and restatement of our lease for such facility in June 2024 and at our facility in Warren, New Jersey as a result of an amendment to our lease for such facility in December 2024.
The successful development of our products and product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:
| ● | the scope, rate of progress and expense of our clinical trials and other research and development activities; |
| ● | the potential benefits of our products and product candidates over other therapies; |
| ● | our ability to market, commercialize and achieve market acceptance for any of our products or product candidates that we are developing or may develop in the future, including our ability to negotiate pricing and reimbursement terms acceptable to us; |
| ● | clinical trial results; |
| ● | the terms and timing of regulatory approvals; and |
| ● | the expense of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights. |
A change in the outcome of any of these variables with respect to the development of our products or product candidates could mean a significant change in the costs and timing associated with the development of those products or product candidates. For example, if the EMA or FDA or other regulatory authority were to require us to conduct clinical trials beyond those which we currently anticipate will be required for the completion of clinical development of any of our products or product candidates or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.
Selling, general and administrative expense
Selling, general and administrative expenses consist primarily of salaries and other related costs for personnel, including share-based compensation expenses, in our executive, legal, business development, commercial, finance, accounting, information technology and human resource functions. Other selling, general and administrative expenses include facility-related costs not otherwise included in research and development expense; advertising and promotional expenses; costs associated with industry and trade shows; and professional fees for legal services, including patent-related expenses, accounting services and miscellaneous selling costs.
We expect that selling, general and administrative expenses will increase in future periods in connection with our continued efforts to commercialize our products, including increased payroll, expanded infrastructure, commercial operations, increased consulting, legal, accounting and investor relations expenses.
50
Table of Contents
Interest expense, net
Interest expense, net consists of interest expense from the liability for the sale of future royalties related to the A&R Royalty Purchase Agreement and the 2026 Convertible Notes outstanding, offset by interest income earned on investments.
Critical accounting policies and significant judgments and estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions.
During the three and six months ended June 30, 2025, there were no material changes to our critical accounting policies as reported in our 2024 Annual Report.
Results of operations
Three months ended June 30, 2025 compared to three months ended June 30, 2024
The following table summarizes revenues and selected expense and other income data for the three months ended June 30, 2025 and 2024.
| | | | | | | | | |
| | Three Months Ended | | | | ||||
| | June 30, | | Change | |||||
(in thousands) |
| 2025 |
| 2024 |
| 2025 vs. 2024 | |||
Net product revenue | | $ | 118,329 | | $ | 133,220 | | $ | (14,891) |
Collaboration and license revenue | | | 2,941 | | | — | | | 2,941 |
Royalty revenue | | | 57,605 | | | 53,183 | | | 4,422 |
Manufacturing revenue | | | — | | | 301 | | | (301) |
Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets | |
| 11,420 | |
| 15,527 | | | (4,107) |
Amortization of acquired intangible assets | |
| 4,061 | |
| 2,865 | | | 1,196 |
Research and development expense | |
| 112,990 | |
| 132,169 | | | (19,179) |
Selling, general and administrative expense | |
| 85,262 | |
| 69,500 | | | 15,762 |
Change in the fair value of contingent consideration | |
| — | |
| 5,100 | | | (5,100) |
Tangible asset impairment and losses (gains) on transactions, net | | | 99 | | | 1,761 | | | (1,662) |
Interest expense, net | |
| (30,358) | |
| (43,490) | | | 13,132 |
Other expense, net | |
| (5,737) | |
| (2,025) | | | (3,712) |
Income tax benefit (expense) | | | 6,203 | | | (13,446) | | | 19,649 |
Net product revenue. Net product revenue was $118.3 million for the three months ended June 30, 2025, a decrease of $14.9 million, or 11%, from $133.2 million for the three months ended June 30, 2024. The decrease in net product revenue was primarily due to a decrease in net product sales of Emflaza and Translarna. Emflaza net product revenue was $36.4 million for the three months ended June 30, 2025, a decrease of $10.9 million, or 23%, compared to $47.3 million for the three months ended June 30, 2024. These results were driven by additional generic competition. Translarna net product revenues were $59.5 million for the three months ended June 30, 2025, a decrease of $10.9 million, or 15%, compared to $70.4 million for the three months ended June 30, 2024. These results were primarily due to the EC’s adoption of the CHMP’s negative opinion.
Collaboration and license revenue. Collaboration and license revenue was $2.9 million for the three months ended June 30, 2025, an increase of $2.9 million, or 100%, from $0.0 million for the three months ended June 30, 2024. The increase in collaboration and license revenue was due to the receipt of the $1.0 billion upfront payment upon the effective
51
Table of Contents
date of the license and collaboration agreement with Novartis related to our votoplam HD program. For the three months ended June 30, 2025, we recognized $2.9 million related to license revenue from the Novartis Agreement for performance obligations completed during the period. For the three months ended June 30, 2024, we did not recognize any collaboration or license revenue.
Royalty revenue. Royalty revenue was $57.6 million for the three months ended June 30, 2025, an increase of $4.4 million, or 8%, from $53.2 million for the three months ended June 30, 2024. The increase in royalty revenue was due to higher Evrysdi sales in the three months ended June 30, 2025 as compared to the three months ended June 30, 2024. In accordance with the SMA License Agreement, we are entitled to royalties on worldwide annual net sales of the product.
Manufacturing revenue. Manufacturing revenue was $0.0 million for the three months ended June 30, 2025, a decrease of $0.3 million, or 100%, from $0.3 million for the three months ended June 30, 2024. The decrease was due to the prior completion of all manufacturing services related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. In June 2024, we sold our gene therapy manufacturing business in Hopewell Township, New Jersey. Accordingly, we do not expect to have manufacturing revenue going forward.
Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets. Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets was $11.4 million for the three months ended June 30, 2025, a decrease of $4.1 million, or 26%, from $15.5 million for the three months ended June 30, 2024. Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets consisted primarily of royalty payments associated with Emflaza, Translarna, and Upstaza net product sales, costs associated with Emflaza, Translarna, and Upstaza products sold during the period, and inventory reserves. The decrease in cost of product, collaboration and license sales, excluding amortization of acquired intangible assets, was primarily due to decreases in royalty costs driven by Emflaza as a result of the completion of the royalty agreement with Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC), which was partially offset by costs associated with the Novartis Agreement.
Amortization of acquired intangible assets. Amortization of acquired intangible assets was $4.1 million for the three months ended June 30, 2025, an increase of $1.2 million, or 42%, from $2.9 million for the three months ended June 30, 2024. These amounts are related to the Waylivra, Tegsedi, Upstaza/Kebilidi, and Sephience intangible assets, which are all being amortized on a straight-line basis over their estimated useful lives. The amortization increase was driven by multiple approvals during the year ended 2024 related to PTC-AADC. In October 2024, we received regulatory approval for Upstaza in Brazil, and in November 2024, the BLA for our gene therapy treatments of AADC deficiency was approved by the FDA, marketed under the brand name Kebilidi. With these approvals, $10.7 million and $17.4 million for Kebilidi and Upstaza, respectively, was reclassed from the PTC-AADC indefinite lived intangible asset to definite lived intangible assets. We will amortize these allocated balances of $10.7 million and $17.4 million over their expected useful lives of 12 years on a straight-line basis. In June 2025, the EC granted marketing authorization to Sephience for the treatment of children and adults living with PKU in the EEA, which triggered a $25.0 million milestone to the former Censa securityholders. The milestone was recorded as an intangible asset and is being amortized to cost of product sales over its expected useful life on a straight-line basis.
Research and development expense. Research and development expense was $113.0 million for the three months ended June 30, 2025, a decrease of $19.2 million, or 15%, from $132.2 million for the three months ended June 30, 2024. The decrease in research and development expenses primarily related to a $15.0 million regulatory success-based milestone payable to the former Censa securityholders for the three months ended June 30, 2024.
Selling, general and administrative expense. Selling, general and administrative expense was $85.3 million for the three months ended June 30, 2025, an increase of $15.8 million, or 23%, from $69.5 million for the three months ended June 30, 2024. The increase reflected our continued investment to support our commercial activities including our expanding commercial portfolio.
Change in the fair value of contingent consideration. The change in the fair value of contingent consideration was $0.0 million for the three months ended June 30, 2025, a change of $5.1 million, or 100%, from a loss of $5.1 million for the
52
Table of Contents
three months ended June 30, 2024. During the first quarter of 2025, the probability of triggering the remaining contingent consideration was determined to be remote, and therefore the balance was written down to zero.
Tangible asset impairment and losses (gains) on transactions, net. Tangible asset impairment and losses (gains) on transactions, net was $0.1 million for the three months ended June 30, 2025, a decrease of $1.7 million, or 94%, from $1.8 million for the three months ended June 30, 2024. This decrease was primarily related to the loss on sale of $4.2 million of certain assets related to gene therapy manufacturing and $0.2 million of fixed asset impairments during the three months ended June 30, 2024. These amounts were partially offset by a gain of $2.2 million on lease terminations and a $0.4 million gain on sales of fixed assets during the three months ended June 30, 2024. During the three months ended June 30, 2025, we recorded $0.1 million related to fixed asset impairments.
Interest expense, net. Interest expense, net was $30.4 million for the three months ended June 30, 2025, a decrease of $13.1 million, or 30%, from $43.5 million for the three months ended June 30, 2024. The decrease in interest expense, net was directly related to the increase in marketable securities – available for sale, resulting in investment income on our marketable securities – available for sale of $18.4 million and $6.8 million for the three months ended June 30, 2025 and 2024, respectively.
Other expense, net. Other expense, net was $5.7 million for the three months ended June 30, 2025, an increase of $3.7 million, or over 100%, from other expense, net of $2.0 million for the three months ended June 30, 2024. The increase in other expense, net primarily relates to net realized and unrealized losses from foreign currency of $8.7 million for the three months ended June 30, 2025, compared to net unrealized losses of $3.4 million from our ClearPoint Neuro. Inc. debt and equity investments, offset by a net realized and unrealized gain from foreign currency of $0.9 million for the three months ended June 30, 2024.
Income tax benefit (expense). Income tax benefit was $6.2 million for the three months ended June 30, 2025, a change of $19.6 million, or over 100%, compared to income tax expense of $13.4 million for the three months ended June 30, 2024. The change in income tax benefit (expense) was driven by the projected utilization of additional tax attributes in 2025.
Six months ended June 30, 2025 compared to six months ended June 30, 2024
The following table summarizes revenues and selected expense and other income data for the six months ended June 30, 2025 and 2024.
| | | | | | | | | |
| | Six Months Ended | | | | ||||
| | June 30, | | Change | |||||
(in thousands) |
| 2025 |
| 2024 |
| 2025 vs. 2024 | |||
Net product revenue | | $ | 271,755 | | $ | 310,824 | | $ | (39,069) |
Collaboration and license revenue | |
| 989,172 | |
| — | | | 989,172 |
Royalty revenue | | | 94,044 | | | 84,337 | | | 9,707 |
Manufacturing revenue | | | — | | | 1,661 | | | (1,661) |
Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets | |
| 24,282 | |
| 30,267 | | | (5,985) |
Amortization of acquired intangible assets | |
| 7,859 | |
| 54,395 | | | (46,536) |
Research and development expense | |
| 221,963 | |
| 248,298 | | | (26,335) |
Selling, general and administrative expense | |
| 166,223 | |
| 142,772 | | | 23,451 |
Change in the fair value of contingent consideration | |
| (800) | |
| 5,000 | | | (5,800) |
Tangible asset impairment and losses (gains) on transactions, net | | | 176 | | | 1,761 | | | (1,585) |
Interest expense, net | |
| (64,450) | |
| (84,324) | | | 19,874 |
Other expense, net | |
| (12,042) | |
| (434) | | | (11,608) |
Income tax expense | | | (57,063) | | | (20,326) | | | (36,737) |
53
Table of Contents
Net product revenue. Net product revenue was $271.8 million for the six months ended June 30, 2025, a decrease of $39.1 million, or 13%, from $310.8 million for the six months ended June 30, 2024. The decrease in net product revenue was primarily due to a decrease in net product sales of Emflaza and Translarna. Emflaza net product revenue was $84.1 million for the six months ended June 30, 2025, a decrease of $20.7 million, or 20%, compared to $104.8 million for the six months ended June 30, 2024. These results were driven by additional generic competition. Translarna net product revenues were $145.6 million for the six months ended June 30, 2025, a decrease of $28.3 million, or 16%, compared to $173.9 million for the six months ended June 30, 2024. These results were primarily due to the EC’s adoption of the CHMP’s negative opinion.
Collaboration and license revenue. Collaboration and license revenue was $989.2 million for the six months ended June 30, 2025, an increase of $989.2 million, or 100%, from $0.0 million for the six months ended June 30, 2024. The increase in collaboration and license revenue was due to the receipt of the $1.0 billion upfront payment upon the effective date of the license and collaboration agreement with Novartis related to our votoplam HD program. For the six months ended June 30, 2025, we recognized $992.7 million related to license revenue from the Novartis Agreement which was partially offset by $3.5 million related to a refund for a prior collaboration arrangement in relation to votoplam. For the six months ended June 30, 2024, we did not recognize any collaboration or license revenue.
Royalty revenue. Royalty revenue was $94.0 million for the six months ended June 30, 2025, an increase of $9.7 million, or 12%, from $84.3 million for the six months ended June 30, 2024. The increase in royalty revenue was due to higher Evrysdi sales in the six months ended June 30, 2025 as compared to the six months ended June 30, 2024. In accordance with the SMA License Agreement, we are entitled to royalties on worldwide annual net sales of the product.
Manufacturing revenue. Manufacturing revenue was $0.0 million for the six months ended June 30, 2025, a decrease of $1.7 million, or 100%, from $1.7 million for the six months ended June 30, 2024. The decrease was due to the prior completion of all manufacturing services related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. In June 2024, we sold our gene therapy manufacturing business in Hopewell Township, New Jersey. Accordingly, we do not expect to have manufacturing revenue going forward.
Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets. Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets was $24.3 million for the six months ended June 30, 2025, a decrease of $6.0 million, or 20%, from $30.3 million for the six months ended June 30, 2024. Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets consisted primarily of royalty payments associated with Emflaza, Translarna, and Upstaza net product sales, costs associated with Emflaza, Translarna, and Upstaza products sold during the period, and inventory reserves. The decrease in cost of product, collaboration and license sales, excluding amortization of acquired intangible assets, was primarily due to decreases in royalty costs driven by Emflaza as a result of the completion of the royalty agreement with Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC), which was partially offset by costs associated with the Novartis Agreement.
Amortization of acquired intangible assets. Amortization of acquired intangible assets was $7.9 million for the six months ended June 30, 2025, a decrease of $46.5 million, or 86%, from $54.4 million for the six months ended June 30, 2024. These amounts are related to the Emflaza rights acquisition, as well as the Waylivra, Tegsedi, Upstaza/Kebilidi, and Sephience intangible assets, which are all being amortized on a straight-line basis over their estimated useful lives. The amortization decrease was driven by the Emflaza rights intangible asset being fully amortized as of February 2024. As a result, there is no further amortization for Emflaza as of February 2024.
Research and development expense. Research and development expense was $222.0 million for the six months ended June 30, 2025, a decrease of $26.3 million, or 11%, from $248.3 million for the six months ended June 30, 2024. The decrease in research and development expenses related to decreases in program spend as we continued to focus our resources on our differentiated, high potential research and development programs. For the six months ended June 30, 2024, research and development expense also includes a $15.0 million regulatory success-based milestone paid to the former Censa securityholders.
54
Table of Contents
Selling, general and administrative expense. Selling, general and administrative expense was $166.2 million for the six months ended June 30, 2025, an increase of $23.5 million, or 16%, from $142.8 million for the six months ended June 30, 2024. The increase reflected our continued investment to support our commercial activities including our expanding commercial portfolio.
Change in the fair value of contingent consideration. The change in the fair value of contingent consideration was a gain of $0.8 million for the six months ended June 30, 2025, a change of $5.8 million, or over 100%, from a loss of $5.0 million for the six months ended June 30, 2024. During the first quarter of 2025, the probability of triggering the remaining contingent consideration was determined to be remote, and therefore the balance was written down to zero.
Tangible asset impairment and losses (gains) on transactions, net. Tangible asset impairment and losses (gains) on transactions, net was $0.2 million for the six months ended June 30, 2025, a decrease of $1.6 million, or 90%, from $1.8 million for the six months ended June 30, 2024. This decrease was primarily related to the loss on sale of $4.2 million of certain assets related to gene therapy manufacturing and $0.2 million of fixed asset impairments during the six months ended June 30, 2024. These amounts were partially offset by a gain of $2.2 million on lease terminations and a $0.4 million gain on sales of fixed assets during the six months ended June 30, 2024. During the six months ended June 30, 2025, we recorded $0.1 million related to fixed asset impairments and $0.1 million related to losses on the sale of fixed assets.
Interest expense, net. Interest expense, net was $64.5 million for the six months ended June 30, 2025, a decrease of $19.9 million, or 24%, from $84.3 million for the six months ended June 30, 2024. The decrease in interest expense, net was directly related to the increase in investments on our marketable securities – available for sale, resulting in investment income on our marketable securities – available for sale of $32.5 million and $13.7 million for the six months ended June 30, 2025 and 2024, respectively.
Other expense, net. Other expense, net was $12.0 million for the six months ended June 30, 2025, an increase of $11.6 million, or over 100%, from other expense, net of $0.4 million for the six months ended June 30, 2024. The increase in other expense, net, primarily relates to net realized and unrealized losses from foreign currency of $15.0 million for the six months ended June 30, 2025 compared to net realized and unrealized gains from foreign currency of $2.1 million for the six months ended June 30, 2024.
Income tax expense. Income tax expense was $57.1 million for the six months ended June 30, 2025, an increase of $36.7 million, or over 100%, compared to income tax expense of $20.3 million for the six months ended June 30, 2024. The increase in income tax expense was attributable to the recognition of the revenue associated with the Novartis Agreement in 2025. Additionally, we incur income tax expenses in various foreign jurisdictions, and our foreign tax liabilities are largely dependent upon the distribution of pre-tax earnings among these different jurisdictions.
Liquidity and capital resources
Sources of liquidity
While we have generated net income in the six months ended June 30, 2025, we have historically incurred significant operating losses.
As a growing commercial-stage biopharmaceutical company, we are engaging in significant commercialization efforts for our products while also devoting a substantial portion of our efforts on research and development related to our products, product candidates and other programs. To date, our product revenue has primarily consisted of sales of Translarna for the treatment of nmDMD in territories outside of the United States and from Emflaza for the treatment of DMD in the United States. Our ongoing ability to generate revenue from sales of Translarna for the treatment of nmDMD is dependent upon our ability to maintain our marketing authorizations in Brazil and Russia and secure market access through commercial programs following the conclusion of pricing and reimbursement terms at sustainable levels in the member states of the EEA or through EAP programs or similar styled programs in the EEA and other territories. In March 2025, the EC adopted the opinion of the CHMP to not renew the authorization of Translarna for the treatment of nmDMD. However, the EC indicated that individual countries within the EU can leverage Articles 117(3) and 5(1) of the EU Directive 2001/83 to allow continued use of Translarna. Our ability to generate product revenue from Emflaza will largely depend on the
55
Table of Contents
coverage and reimbursement levels set by governmental authorities, private health insurers and other third-party payors. Additionally, Emflaza’s seven-year period of orphan drug exclusivity related to the treatment of DMD in patients five years and older expired in February 2024. We have previously relied on this exclusivity period to commercialize Emflaza in the United States. We expect the expiration of this orphan drug exclusivity to potentially have a significant negative impact on Emflaza net product revenue. Emflaza’s orphan drug exclusivity related to the treatment of DMD in patients two years of age to less than five expires in June 2026.
We have financed our operations to date primarily through the private offerings of convertible senior notes, public offerings and “at the market offerings” of common stock, proceeds from royalty purchase agreements, private placements of our preferred stock and common stock, collaborations, bank and institutional lender debt, other convertible debt, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by our product candidates. We expect to continue to incur significant expenses and operating losses for at least the next fiscal year. The net income and losses we incur may fluctuate significantly from quarter to quarter.
In August 2019, we entered into the Sales Agreement, pursuant to which, we may offer and sell shares of our common stock, having an aggregate offering price of up to $125.0 million from time to time through the Sales Agents by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act. See “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Corporate Updates—Funding” for additional information.
In September 2019, we closed a private offering of $287.5 million aggregate principal amount of 2026 Convertible Notes, which included an option to purchase up to an additional $37.5 million in aggregate principal amount of the 2026 Convertible Notes, which was fully exercised by the initial purchasers. The 2026 Convertible Notes bear cash interest at a rate of 1.50% per year, payable semi-annually on March 15 and September 15 of each year, beginning on March 15, 2020. The 2026 Convertible Notes will mature on September 15, 2026, unless earlier repurchased or converted. We received net proceeds of $279.3 million after deducting the initial purchasers’ discounts and commissions and the offering expenses payable by us.
We have received fundings from Royalty Pharma under the A&R Royalty Purchase Agreement in July 2020, October 2023 and June 2024 totaling $1.9 billion (less Royalty payments received by us with respect to the Assigned Royalty Rights). In exchange for these fundings, we sold Royalty Pharma 90.49% of the Royalty, which will be reduced to 83.33% after Royalty Pharma receives the Assigned Royalty Cap from the Royalty assigned under the Original Royalty Purchase Agreement. We currently retain 9.51% of the Royalty, which increases to 16.67% after the Assigned Royalty Cap has been met. We have the option to sell our retained portions of the Royalty to Royalty Pharma in up to three tranches for the following payments: (1) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, (2) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, and (3) $50.0 million in exchange for 1.90% of the Royalty, which increases to 3.33% after the Assigned Royalty Cap has been met, in each case less Royalty payments received by us with respect to the Assigned Royalty Rights.
In November 2024, we and Novartis entered into the Novartis Agreement relating to our votoplam HD program which includes related molecules. Pursuant to the Novartis Agreement, we are responsible for completing the ongoing Phase 2A clinical trial and continuing the ongoing OLE clinical trial pursuant to its existing development plan, with the goal of transitioning the ongoing OLE clinical trial to Novartis within 12 months after the effective date. Novartis will be responsible for all other development of licensed compounds and licensed products and the manufacture and commercialization of licensed compounds and licensed products worldwide. Under the Novartis Agreement, and upon the closing of the transaction contemplated by the Novartis Agreement in January 2025, we received an upfront payment of $1.0 billion on the effective date and can receive up to $1.9 billion in development, regulatory and sales milestones, a 40% share of U.S. profits and losses, and tiered double-digit royalties on ex-U.S. sales.
Cash flows
As of June 30, 2025, we had cash, cash equivalents and marketable securities of $1.99 billion.
56
Table of Contents
The following table provides information regarding our cash flows and our capital expenditures for the periods indicated.
| | | | | |
| | Six Months Ended | | ||
| | June 30, | | ||
(in thousands) |
| 2025 |
| 2024 | |
Cash provided (used in) by: |
|
|
|
| |
Operating activities | | 811,770 | | (692) | |
Investing activities | | (606,369) | | (180,855) | |
Financing activities | | 13,371 | | 247,022 | |
Net cash provided by operating activities was $811.8 million for the six months ended June 30, 2025, compared to net cash used in operating activities of $0.7 million for the six months ended June 30, 2024. The net cash provided by operating activities for the six months ended June 30, 2025, was primarily related to the upfront payment of $1.0 billion in cash received upon the closing of the transaction contemplated by the Novartis Agreement in January 2025, partially offset by spend supporting clinical development and commercial activities. The net cash used in operating activities for the six months ended June 30, 2024 was primarily related to spend supporting clinical development and commercial activities, partially offset by the cash received from the sales milestone of $100.0 million for the achievement of $1.5 billion in worldwide net sales from Evrysdi.
Net cash used in investing activities was $606.4 million for the six months ended June 30, 2025, compared to $180.9 million for the six months ended June 30, 2024. Cash used in investing activities for the six months ended June 30, 2025 and 2024, were primarily related to the acquisition of product rights, purchases of marketable securities, and purchases of fixed assets, partially offset by net sales and redemption of marketable securities and proceeds from sale of fixed assets.
Net cash provided by financing activities was $13.4 million for the six months ended June 30, 2025, compared to $247.0 million for the six months ended June 30, 2024. Cash provided by financing activities for the six months ended June 30, 2025 was primarily attributable to proceeds from our employee stock purchase plan and proceeds from the exercise of options, partially offset by payments on contingent consideration obligation. Cash provided by financing activities for the six months ended June 30, 2024 was primarily attributable to proceeds from sales of future royalties, proceeds from our employee stock purchase plan, and proceeds from the exercise of options, partially offset by payments on our finance lease principal.
Funding requirements
We anticipate that we will continue to incur significant expenses in connection with our commercialization efforts in the United States, the EEA, Latin America and other territories, including expenses related to our commercial infrastructure and corresponding sales and marketing, legal and regulatory, and distribution and manufacturing undertakings as well as administrative and employee-based expenses. In addition to the foregoing, we expect to continue to incur significant costs in connection with ongoing, planned and potential future clinical trials and studies for our splicing and inflammation and ferroptosis programs as well as studies in our products for maintaining authorizations, label extensions and additional indications. We continue to seek marketing authorization for Translarna for the treatment of nmDMD in territories that we do not currently have marketing authorization in. We submitted an NDA to the FDA for vatiquinone for the treatment of FA in December 2024. These efforts may significantly impact the timing and extent of our commercialization and manufacturing expenses.
In addition, our expenses will increase if and as we:
| ● | seek to satisfy contractual and regulatory obligations that we assumed through our acquisitions and collaborations; |
| ● | execute our commercialization strategy for our products, including initial commercialization launches of our products, label extensions or entering new markets; |
57
Table of Contents
| ● | are required to complete any additional clinical trials, non-clinical studies or Chemistry, Manufacturing and Controls, or CMC, assessments or analyses in order to advance our products or product candidates in the United States or elsewhere; |
| ● | are required to take other steps to maintain our current marketing authorization in Brazil and Russia for Translarna for the treatment of nmDMD or to obtain further marketing authorizations for Translarna for the treatment of nmDMD or other indications; |
| ● | initiate or continue the research and development of sepiapterin and our splicing and inflammation and ferroptosis programs as well as studies in our products for maintaining authorizations, label extensions and additional indications; |
| ● | seek to discover and develop additional product candidates; |
| ● | seek to expand and diversify our product pipeline through strategic transactions; |
| ● | maintain, expand and protect our intellectual property portfolio; and |
| ● | add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts. |
We believe that our cash flows from product sales, together with existing cash and cash equivalents, and marketable securities, will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.
Our future capital requirements will depend on many factors, including:
| ● | our ability to maintain the marketing authorization for Translarna and our other products in territories outside of the EEA; |
| ● | our ability to commercialize and market our products and product candidates that may receive marketing authorization; |
| ● | our ability to negotiate, secure and maintain adequate pricing, coverage and reimbursement terms, on a timely basis, with third-party payors for our products and products candidates; |
| ● | the amount of generic drug competition that we face for Emflaza for the treatment of DMD in patients five years and older; |
| ● | our ability to obtain marketing authorization for Translarna for the treatment of nmDMD in the United States; |
| ● | our ability to obtain marketing authorization for vatiquinone for the treatment of FA in the United States; |
| ● | our ability to successfully complete all post-marketing requirements imposed by regulatory agencies with respect to our products; |
| ● | the progress and results of activities for Sephience and our splicing and inflammation and ferroptosis programs as well as studies in our products for maintaining authorizations, label extensions and additional indications; |
| ● | the scope, costs and timing of our commercialization activities, including product sales, marketing, legal, regulatory, distribution and manufacturing, for any of our products and for any of our other product candidates |
58
Table of Contents
| that may receive marketing authorization or any additional territories in which we receive authorization to market Sephience or Translarna; |
| ● | the costs, timing and outcome of regulatory review of our splicing and inflammation and ferroptosis programs and Sephience, Translarna and Upstaza/Kebilidi in other territories; |
| ● | our ability to satisfy our obligations under the indenture governing the 2026 Convertible Notes; |
| ● | the timing and scope of any potential future growth in our employee base; |
| ● | the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our other product candidates, including those in our splicing and inflammation and ferroptosis programs; |
| ● | revenue received from commercial sales of our products or any of our product candidates; |
| ● | our ability to obtain additional and maintain existing reimbursed named patient and cohort EAP programs for Translarna for the treatment of nmDMD on adequate terms, or at all; |
| ● | the ability and willingness of patients and healthcare professionals to access Translarna through alternative means if pricing and reimbursement negotiations in the applicable territory do not have a positive outcome; |
| ● | the costs of preparing, filing and prosecuting patent applications, maintaining, and protecting our intellectual property rights and defending against intellectual property-related claims; |
| ● | the extent to which we acquire or invest in other businesses, products, product candidates, and technologies, including the success of any acquisition, in-licensing or other strategic transaction we may pursue, and the costs of subsequent development requirements and commercialization efforts, including with respect to our acquisitions of Emflaza, Agilis, our inflammation and ferroptosis platform and Censa and our licensing of Tegsedi and Waylivra; |
| ● | our ability to establish and maintain collaborations, including our collaborations with Roche and the SMA Foundation, and our ability to obtain research funding and achieve milestones under these agreements. |
| ● | the progress and results of activities for our votoplam program, including our right to receive any development, regulatory and sales milestones, profit sharing and royalty payments from Novartis; and |
| ● | unexpected decreases in revenue or increase in expenses resulting from potential widespread outbreaks of contagious disease. |
With respect to our outstanding 2026 Convertible Notes, cash interest payments are payable on a semi-annual basis in arrears, which will require total funding of $4.3 million annually.
We expect to make payments to the former Censa securityholders of $25 million in the aggregate in cash for the marketing authorization granted by the EC for Sephience for the treatment of children and adults living with PKU, and $32.5 million in the aggregate in cash for approval by the FDA of Sephience for the treatment of pediatric and adult patients living with PKU in the United States, pursuant to the Censa Merger Agreement.
Upon the potential achievement in 2025 of certain regulatory milestones relating to vatiquinone, which milestones would be payable in 2026, we expect to make payments to BioElectron of $75.0 million in the aggregate, in cash or shares of our common stock, as determined by us, pursuant to the BioElectron Asset Purchase Agreement.
We also have certain significant contractual obligations and commercial commitments that require funding and we have disclosed these items under the heading “Management’s Discussion and Analysis of Financial Condition and Results of
59
Table of Contents
Operations-Funding Obligations” in our 2024 Annual Report. There were no material changes to these obligations and commitments during the period ended June 30, 2025.
We will need to generate significant revenues to achieve and sustain profitability, and we may never do so. We may need to obtain substantial additional funding in connection with our continuing operations. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs primarily through a combination of equity offerings, debt financings, collaborations, strategic alliances, grants and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by our product and product candidates and marketing, distribution or licensing arrangements. Adequate additional financing may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our shareholders ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.
If we are unable to raise additional funds through equity, debt or other financings when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
During the period ended June 30, 2025, there were no material changes in our market risk or how our market risk is managed, compared to those disclosed under the heading “Quantitative and Qualitative Disclosures about Market Risk” in our 2024 Annual Report.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2025. The term “disclosure controls and procedures”, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2025, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
No change in our internal control over financial reporting occurred during the quarter ended June 30, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
60
Table of Contents
PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time in the ordinary course of our business, we are subject to claims, legal proceedings and disputes, including as a result of patients seeking to participate in our clinical trials or otherwise gain access to our product candidates. We are not currently aware of any material legal proceedings to which we are a party or of which any of our property is subject.
Item 1A. Risk Factors.
We have set forth in Item 1A to our Annual Report on Form 10-K for the year ended December 31, 2024, risk factors relating to our business, our industry, our structure and our common stock. Readers of this Quarterly Report on Form 10-Q are referred to such Item 1A for a more complete understanding of risks concerning us. The risk factor disclosure in our Annual Report on Form 10-K for the year ended December 31, 2024 is qualified by the additional information that is described in this Quarterly Report on Form 10-Q, including the updated risk factor disclosure set forth below.
A substantial portion of our commercial sales currently occurs in territories outside of the United States which subjects us to additional business risks that could adversely affect our revenue and results of operations.
We commercialize Sephience, Translarna, Upstaza, Tegsedi and Waylivra outside of the United States. We have operations in multiple European countries, Latin America and other territories. We expect that we will continue to expand our international operations in the future, including in emerging growth markets, pending successful completion of the applicable regulatory processes. International operations inherently subject us to a number of risks and uncertainties, including:
| ● | political, regulatory, compliance and economic developments that could restrict our ability to manufacture, market and sell our products, including the Russia-Ukraine conflict and related sanctions that have been imposed by various countries in response thereto; |
| ● | financial risks such as longer payment cycles, difficulty collecting accounts receivable, potentially high inflation rates, sustained high interest rates and exposure to fluctuations in foreign currency exchange rates; |
| ● | difficulty in staffing and managing international operations; |
| ● | potentially negative consequences from changes in or interpretations of tax laws; |
| ● | changes in international medical reimbursement policies and programs; |
| ● | unexpected changes in healthcare policies of ex-U.S. jurisdictions; |
| ● | trade protection measures, including import or export licensing requirements and tariffs; |
| ● | our ability to develop relationships with qualified local distributors and trading companies; |
| ● | political and economic instability in particular ex-U.S. economies and markets, in particular in emerging markets, for example in Brazil; |
| ● | diminished protection of intellectual property in some countries outside of the United States; |
| ● | differing labor regulations and business practices; |
| ● | regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors’ and service providers’ activities that may fall within the purview of the Foreign Corrupt Practices Act, UK Bribery Act or similar local regulation; and |
61
Table of Contents
| ● | various effects and responsive measures relating to outbreaks of contagious disease. |
For example, the Brazilian Ministry of Health has previously experienced significant administrative delays processing centralized group purchase orders. Almost all of our product revenue for Translarna in Brazil is attributable to such purchase orders. These centralized group purchase order delays have caused, and may continue to cause, fluctuations in our ability to generate revenue in Brazil.
In addition, some countries in which a product candidate is not approved allow patients access to the product candidate through other legal mechanisms, including court intervention or EAP programs, if the product is approved in another jurisdiction. The price that is ultimately approved by governmental authorities in any country pursuant to commercial pricing and reimbursement processes may be significantly lower than the price we are able to charge for sales under such legal mechanisms and we may become obligated to repay such excess amount.
Some of the countries in which our products are available for sale are in emerging markets. Some countries within emerging markets, including those in Latin America, may be especially vulnerable to periods of global or regional financial instability or may have very limited resources to spend on. We also may be required to increase our reliance on third-party agents within less developed markets. In addition, many emerging market countries have currencies that fluctuate substantially and if such currencies devalue and we cannot offset the devaluations, our financial performance within such countries could be adversely affected.
Furthermore, in some countries, including Brazil and Russia, orders for named patient sales may be for multiple months of therapy, which can lead to an unevenness in orders which could result in significant fluctuations in quarterly net product sales. Other factors may also contribute to fluctuations in quarterly net product sales including a product’s availability in any particular territory, government actions, economic pressures, political unrest and other factors. Net product sales are impacted by factors such as the timing of decisions by regulatory authorities and our ability to successfully negotiate favorable pricing and reimbursement processes on a timely basis in the countries in which we have or may obtain regulatory approval, including the United States, EEA and other territories.
Any of these factors may, individually or as a group, have a material adverse effect on our business and results of operations. As we continue to expand our existing international operations, we may encounter new risks.
Our products or product candidates may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.
We may not obtain adequate coverage or reimbursement for our products, or we may be required to sell our products at an unsatisfactory price. In addition, obtaining pricing, coverage and reimbursement approvals can be a time consuming and expensive process. Our business would be materially adversely affected if we do not receive these approvals on a timely basis.
The regulations and practices that govern marketing authorizations, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries, including almost all of the member states of the EEA, require approval of the sale (list) price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some ex-U.S. markets, including the European market, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing authorization for a product in a particular country, but then be subject to price regulations, in some countries at national as well as regional levels, that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more products or other product candidates, even following marketing authorization.
Our ability to successfully commercialize our products or product candidates that may receive marketing authorization will depend in large part on the extent to which coverage and reimbursement for these products and related treatments will
62
Table of Contents
be available from government health administration authorities, private health insurers, managed healthcare organizations and other third-party payors and organizations. Government authorities and other third-party payors, such as private health insurers and managed healthcare organizations, decide which medications they will pay for and establish reimbursement conditions and rates. A primary trend in the EU and U.S. healthcare industries and elsewhere is cost containment. Government authorities, including the United States government and state legislatures, and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Prices at which our products are reimbursed can be subject to challenge, reduction or denial by the government and other payers. Increasingly, third-party payors are requiring that drug companies provide them with discounts off the products’ sale (list) prices and are challenging the prices manufacturers charge for medical products. We cannot be sure that coverage will be available for any product or product candidate that we may commercialize and, if coverage is available, the level of reimbursement is also uncertain.
Reimbursement levels may impact the demand for, or the price of, any product or product candidate for which we obtain marketing authorization. Obtaining reimbursement for our products has been and is expected to continue to be, particularly difficult due to price considerations typically associated with drugs that are developed to treat conditions that affect a small population of patients. In addition, third-party payors are likely to impose strict requirements for reimbursement of a higher priced drug, such as prior authorization and the requirement to try other therapies first (i.e., step edits), or high co-payments which can result in patient rejection. Decreases in third-party reimbursement for a product or a decision by a third-party payor to not cover a product could reduce physician usage of the product. If reimbursement is not available or is available only on a limited basis, we may not be able to successfully commercialize any product or product candidate for which we have obtained or may obtain marketing authorization.
There may be significant delays in obtaining coverage for newly approved drugs, and coverage may be more limited than the drug’s approved indications as determined by the applicable regulatory authority. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent, and programs intended to provide patient assistance until coverage is established can be very costly and limited in duration by law. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs, and may be incorporated into existing payments for other services. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.
Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws, enforcement policies or administrative determinations with respect to the importation of drugs into the United States from other countries where they may be sold at lower prices.
In the United States, third-party payors include federal healthcare programs, such as Medicare, Medicaid, TRICARE, and Veterans Health Administration programs; managed care providers, private health insurers and other organizations. Several of the U.S. federal healthcare programs establish ceiling prices or require that drug manufacturers extend discounts or pay rebates to certain programs in order for their products to be covered and reimbursed. For example, the Medicaid Drug Rebate Program requires pharmaceutical manufacturers of covered outpatient drugs to enter into and have in effect a national rebate agreement with the federal government as a condition for coverage of the manufacturer’s covered outpatient drug(s) by state Medicaid programs. The amount of the rebate for each product is based on a statutory formula and may be subject to an additional discount if certain pricing increases more than inflation. State Medicaid programs and Medicaid managed care plans can seek additional “supplemental” rebates from manufacturers in connection with states’ establishment of preferred drug lists. A further requirement for Medicaid coverage is that manufacturers of single source and innovator multiple source drugs enter into a Master agreement and Federal Supply Schedule, or FSS, agreement with the Secretary for Veterans Affairs and charge no more than statutory ceiling prices to the Department of Veteran Affairs, the Department of Defense and certain other federal agencies.
Similarly, in order for a covered outpatient drug to receive federal reimbursement under the Medicare Part B and Medicaid programs, the manufacturer must extend discounts on the covered outpatient drug to entities that are enrolled and
63
Table of Contents
participating in the 340B drug pricing program, which is a federal program that requires manufacturers to provide discounts to certain statutorily-defined safety-net providers. The 340B discount for each product is calculated based on certain Medicaid Drug Rebate Program metrics that manufacturers are required to report to CMS.
Sephience and Emflaza are also eligible for reimbursement under the Medicare Part D program. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities, which will provide coverage of outpatient prescription drugs. Part D prescription drug formularies are required to include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any negotiated prices for our products covered by a Part D prescription drug plan likely will be lower than the prices we might otherwise obtain, and payment of Medicare Coverage Gap discounts may further reduce realization on Part D drugs. Further, CMS is proposing to relax Part D coverage requirements to give plans more leverage in negotiating their formularies.
With respect to drugs eligible for reimbursement under Medicare Part B, on November 27, 2020, CMS issued an interim final rule implementing a Most Favored Nations payment model under which reimbursement for certain Medicare Part B drugs and biologicals will be based on a price that reflects the lowest per capita Gross Domestic Product-adjusted (GDP-adjusted) price of any non-U.S. member country of the Organisation for Economic Co-operation and Development (OECD) with a GDP per capita that is at least sixty percent of the U.S. GDP per capita. This rule now has been rescinded but other measures, including the Inflation Reduction Act of 2022, or IRA, have been enacted to address the costs of pharmaceuticals. The Inflation Reduction Act of 2022 requires manufacturers of selected drugs to negotiate discounted prices with the Secretary of the Department of Health and Human Services (HHS). Failure to reach an agreement can subject manufacturers to an excise tax or withdraw of all drug products from coverage under Medicare and Medicaid. Drug price negotiations and other program implementation measures could potentially be affected by the Executive Order, Initial Rescissions of Harmful Executive Orders and Actions, issued on January 20, 2025 and/or the anticipated change in leadership at Health and Human Services and the Centers for Medicare and Medicaid Services (CMS) under the new administration. Such rules and any additional healthcare reform measures could further constrain our business or limit the amounts that federal and state governments will pay for healthcare products and services, which could result in additional pricing pressures.
In addition, U.S. private health insurers often rely upon Medicare coverage policies and payment limitations in setting their own coverage and reimbursement policies. Any such coverage or payment limitations may result in a similar reduction in payments from non-governmental payors. Payment by private payors is also subject to payor-determined coverage and reimbursement policies that vary considerably and are subject to change without notice. We expect that coverage and reimbursement of Emflaza in the United States will vary from commercial payor to commercial payor. Many commercial payors, such as managed care plans, manage access to prescription drugs partly to control costs to their plans, and may use drug formularies and medical policies to limit their exposure. Exclusion from policies can directly reduce product usage in the payor’s patient population and may negatively impact utilization in other payor plans, as well.
There has been recent negative publicity and increasing legislative and public scrutiny around pharmaceutical drug pricing in the U.S., in particular with respect to orphan drugs and specifically with respect to Emflaza. Moreover, U.S. government authorities and third-party payors are increasingly attempting to limit or regulate drug prices and reimbursement, often with particular focus on orphan drugs. For example, certain drugs with an orphan designation may become subject to price negotiations under the IRA. These dynamics may give rise to heightened attention and potential negative reactions to pricing decisions for Emflaza and products for which we may receive regulatory approval in the future, possibly limiting our ability to generate revenue and attain profitability.
Moreover, in 2017, the U.S. Congress modified and amended certain provisions of the 2010 U.S. healthcare reform legislation (the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, known collectively as the Affordable Care Act), which could have an impact on coverage and reimbursement for healthcare items and services covered by the federal and state healthcare programs as well as plans in the private health insurance market. The so-called “individual mandate” was repealed as part of tax reform legislation adopted in December 2017. Legal challenges to the Affordable Care Act continue to arise and there may be future efforts to modify, repeal, or otherwise invalidate all, or certain provisions of the Affordable Care Act. We cannot assure that the Affordable Care Act, as currently enacted or as amended in the future, will not adversely affect our business and financial
64
Table of Contents
results and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.
Additionally, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. Failure of the Joint Select Committee on Deficit Reduction to reach required deficit reduction goals triggered the legislation’s automatic reduction to several government programs. This legislation resulted in aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2031. However, pursuant to the CARES Act and subsequent legislation, these Medicare sequester reductions were suspended through the end of March 2022 and from April 2022 through June 2022, a 1% cut was in effect, with the full 2% cut remaining thereafter. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidates is prescribed or used.
In the EU, reference pricing systems and other measures may lead to cost containment and reduced prices with respect to Sephience for the treatment of PKU, Translarna for the treatment of nmDMD, Upstaza for the treatment of AADC deficiency and other product candidates that might receive marketing authorization in the future. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for our product or any of our product candidates that may receive marketing authorization, or a reduction in coverage for payment rates for our product or any such product candidates, could have a material adverse effect on our business, results of operations and financial condition. In addition, in the EU, an authorized trader, such as a wholesaler, can purchase a medicine in one EU member state and obtain a license to import the product into another EU member state. This process is called “parallel distribution”. As a result, a purchaser in one EU member state may seek to import Translarna from another EU member state where Translarna is sold at a lower price. This could have a negative impact on our business, financial condition, results of operations and growth.
Similarly, sales of Sephience, Emflaza or our other products in the United States could also be reduced if they, or products similar to them, are imported into the United States from lower-priced markets, whether legally or illegally. For example, in the United States, prices for pharmaceuticals are generally higher than in the bordering nations of Mexico and Canada. In October 2020, the Department of Health and Human Services, or HHS, and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. Certain states have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for review and approval by the FDA. Florida received approval for its SIP from the FDA. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The effective date of the new safe harbors and the revision to the discount safe harbor was delayed by court order until January 1, 2023. Recent legislation further delayed implementation of the new safe harbors and the revision to the discount safe harbor until January 1, 2032.
Commercialization of Sephience, Translarna and Upstaza has been in, and is expected to continue to take place in, countries that tend to impose strict price controls, which may adversely affect our revenues. Failure to obtain and maintain acceptable pricing and reimbursement terms for Sephience for PKU, Translarna for the treatment of nmDMD, or Upstaza for the treatment of AADC deficiency in the EEA and other countries where these products are available would delay or prevent us from marketing our product in such regions, which would adversely affect our business, results of operations, and financial condition. In addition, the recent decision of the European Commission to withdraw Translarna’s marketing authorization materially limits our ability to make Translarna available in the EEA on a reimbursed basis and may impact our revenues in the EEA and regions that relied on the EEA marketing authorization. In addition, some countries in the EEA may require us to make payments based on the withdrawal of the Translarna marketing authorization and related actions by regulatory authorities overseeing market access systems in those countries.
65
Table of Contents
In some countries, particularly the member states of the EEA, the pricing of prescription pharmaceuticals is subject to strict governmental control. Each country in the EEA has its own pricing and reimbursement regulations and may have other regulations related to the marketing and sale of pharmaceutical products in the country. We generally will not be able to commence commercial sales of Sephience for the treatment of PKU, Translarna for the treatment of nmDMD, or Upstaza for the treatment of AADC deficiency pursuant to the marketing authorization granted by the EC in any particular member state of the EEA until we conclude the applicable pricing and reimbursement negotiations and comply with any licensing, employment or related regulatory requirements in that country. In some countries we may be required to conduct additional clinical trials or other studies of our product, including trials that compare the cost-effectiveness of our product to other available therapies in order to obtain reimbursement or pricing approval. We may not be able to conclude pricing and reimbursement negotiations or comply with additional regulatory requirements in the countries in which we seek to commercialize Sephience, Translarna, or Upstaza on a timely basis, or at all.
The pricing and reimbursement process varies from country to country and can take a substantial amount of time from initiation to completion. Pricing negotiations may continue after reimbursement has been obtained. We cannot predict the timing of the commercial launch of our products in countries where we are awaiting pricing and reimbursement guidelines. While we have submitted pricing and reimbursement dossiers with respect to Sephience for the treatment of PKU, Translarna for the treatment of nmDMD, and Upstaza for the treatment of AADC deficiency in many EEA countries, we have only received both pricing and reimbursement approval on terms that are acceptable to us in a limited number of countries.
The price that is approved by governmental authorities in any country pursuant to commercial pricing and reimbursement processes may be significantly lower than the price we are able to charge for sales under our reimbursed EAP programs and various forms of national “market access agreements” may need to be entered into to achieve reimbursement. In some instances, reimbursement may be subject to challenge, reduction or denial by the government and other payors. In some countries, EAP and commercial sales of a product can begin while pricing and reimbursement rates are under discussion with the applicable government health programs. In the event that the negotiated price of the product is lower than the amount reimbursed for sales made prior to the conclusion of price negotiations, we may become obligated to repay such excess amount to the applicable government health program. We will make such retroactive reimbursement, if any, following the conclusion of price negotiations with the applicable government health authority.
In addition, the recent decision of the European Commission to not renew Translarna’s marketing authorization for the treatment of nonsense mutation Duchenne muscular dystrophy following the negative opinion of the CHMP materially limits our ability to make Translarna available in the EEA or to receive reimbursement in connection with such continued availability. While the unprecedented EC decision referenced the possibility for individual countries within the European Union to leverage Articles 117(3) and 5(1) of the EU Directive 2001/83 to allow continued use of Translarna, many EEA countries have not adopted a mechanism for reimbursed access, and those that have done so have placed time restrictions and other conditions on patients. Some countries may never do so, or may request price adjustments or even seek to collect funds from us based on the nonrenewal of the Translarna MAA. For example, in France, the relevant regulatory authorities published a formal decree removing Translarna from the list of medicines available, which triggered a process to determine any payment we may owe based on an analysis of the difference between the price at which Translarna was reimbursed historically and a comparator product. It is possible that this process may result in the French authorities demanding a payment that is materially different than our prior estimates in France for the applicable period. Our ability to oppose such a demand may be limited to actions in the French court system, which may take years and may not be resolved in our favor, and may require advance payment of any disputed payment amount.
Political, economic and regulatory developments may further complicate pricing and reimbursement negotiations and there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. In addition, adverse clinical and regulatory developments may exacerbate these risks.
Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices and revenues. Publication of discounts by third-party payors or authorities may lead to further pressure on prices or reimbursement levels within the country of publication and other countries.
66
Table of Contents
If we fail to successfully secure and maintain pricing and reimbursement coverage for Sephience, Translarna or Upstaza or are significantly delayed in doing so or if burdensome conditions are imposed by private payers, government authorities or other third-party payors on such reimbursement, planned launches in the affected countries will be delayed and our business, results of operations and financial condition could be adversely affected.
We contract with third parties for the manufacture and distribution of our products and certain of our product candidates, which may increase the risk that we will not have sufficient quantities of our products or product candidates, such quantities may not meet the applicable regulatory quality standards, or such quantities at an acceptable cost, which could delay, prevent or impair our commercialization or development efforts.
We have limited personnel with experience in drug manufacturing and currently rely on third parties to manufacture our products and certain product candidates on a clinical or commercial scale. We currently rely on third parties for supply of the active pharmaceutical ingredients used in all of our products and product candidates. We outsource most of the manufacturing, packaging, labeling and distribution of our products and certain of our product candidates to third parties, including our commercial supply of Sephience, Translarna, Emflaza and Upstaza/Kebilidi.
We do not directly control manufacturing for our products and product candidates and we are dependent on and will continue to be dependent on, our contract manufacturers for compliance with cGMP or good distribution practice, or GDP, or similar regulatory requirements outside the EU and the United States for manufacture of both active drug substances and finished drug products. Should we or our contract manufacturers fail to comply with these requirements, we and they could face significant regulatory and commercial consequences. For example, regulatory authorities routinely inspect manufacturing and other drug/biologic facilities. Our manufacturers and manufacturing facilities must also be approved by such regulatory authorities pursuant to inspections that will be conducted after we submit our marketing applications and will be subject to continuing regulatory authority inspections should we receive marketing approval. If we or our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the EU member state regulatory authorities, FDA, or other ex-U.S. regulatory agencies, we and they will not be able to secure and/or maintain regulatory approval for the manufacturing facilities, and we would not be able to secure and/or maintain, or may be delayed in securing regulatory approval of marketing applications or supplements for the applicable products or product candidates. We may also have to repeat studies that used product that did not conform with applicable requirements. In addition, we or third-party manufacturers or distributors may not be able to comply with generally accepted worker safety standards, cGMP, GDP or similar regulatory requirements outside the EU and the United States. Our failure, or the failure of our third-party manufacturers or distributors, over whom we have no direct control, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, clinical holds or termination of clinical studies, warning or untitled letters, regulatory communications warning the public about safety issues with a product, import or export refusals, license revocation, seizures, detentions, or recalls of product candidates or products, operating restrictions, criminal prosecutions or debarment, suits under the civil False Claims act, corporate integrity agreements, or consent decrees, any of which could significantly and adversely affect our reputation and supplies of our products or product candidates and our business, results of operations and financial condition could be materially adversely affected.
In addition, we have no direct control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. Furthermore, all of our contract manufacturers are engaged with other companies to supply and/or manufacture materials or products for such companies, which exposes our manufacturers to regulatory risks for the production of such other materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may generally affect the regulatory status of our contract manufacturers’ facilities and our products or product candidates. If the FDA, EU member state regulatory authorities or a comparable ex-U.S. regulatory agency do not approve these or our facilities for the manufacture of our products or product candidates or if it withdraws its approval in the future, we may need to find alternative manufacturing facilities, which would negatively impact our ability to develop, obtain regulatory approval for or market our products or product candidates, if approved. There is also no guarantee that we would be able to find alternative manufacturing facilities or enter into agreements with alternative manufacturers on favorable terms. There may be limited manufacturers who would have the ability to manufacture our products and product candidates, especially our gene therapy product candidates, particularly as the pharmaceutical manufacturing industry becomes increasingly more consolidated. Moreover, any alternative manufacturers would need to be approved by the relevant regulatory authority, which approval is not
67
Table of Contents
guaranteed. We, accordingly, may not be able to make alternative manufacturing arrangements, which could adversely affect our products, product candidates, and our business, results of operations and financial condition. See “Item 1. Business—Manufacturing” for additional information regarding the manufacturing of our products and product candidates.
Even if we are able to establish and maintain arrangements with third-party manufacturers, distributors and other third parties, reliance on such third parties entails additional risks, including:
| ● | reliance on the third party for regulatory compliance and quality assurance; |
| ● | the possible breach of the agreements by the third party; |
| ● | the possible misappropriation of our proprietary information, including our trade secrets and know-how; |
| ● | the possibility of commercial supplies of our products not being distributed to commercial vendors or end users in a timely manner, resulting in lost sales; |
| ● | the possibility of clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions; |
| ● | the possibility of third-party resources not being devoted in the manner necessary to satisfy our requirements within the expected time frame; |
| ● | the possibility of third parties not providing us with accurate or timely information regarding their inventories, the number of patients who are using our products, or serious adverse events and/or product complaints regarding our products; |
| ● | the possibility of third parties being unable to satisfy their financial obligations to us or to others; and |
| ● | the possible termination or nonrenewal of a critical agreement by the third party at a time that is costly or inconvenient to us. |
Many additional factors could cause production or distribution interruptions with the manufacture and distribution of any of our products and product candidates, including human error, natural disasters, labor disputes, acts of terrorism or war, equipment malfunctions, contamination, supply chain disruption, including disruptions caused by outbreaks of contagious disease, any new tariffs imposed in the jurisdictions in which we operate, or raw material and component shortages. For example, we have previously experienced delays in receiving certain raw materials in connection with supply chain disruptions caused by the COVID-19 pandemic, however, these delays did not affect or delay our manufacturing given our inventories for such materials at the time. If future supply chain disruptions create prolonged delays, the supplies of our products or products candidates may be significantly and adversely affected and our business, results of operations and financial condition could be materially adversely affected.
Our products and product candidates and any other products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. In addition, changes in cGMP regulations could negatively impact our ability or the ability of our contract manufacturers to complete the manufacturing process of our products and our product candidates in a compliant manner on the schedule we require for commercial and clinical trial use, respectively.
If we or the third parties that we engage to manufacture product for our commercial sales, preclinical tests and clinical trials should, prior to the time that we have validated alternative providers, cease to continue to do so for any reason, we likely would experience delays in our ability to supply our products or product candidates to patients or in our ability to advance our clinical trials while we identify and qualify replacement suppliers and we may be unable to obtain replacement
68
Table of Contents
supplies on terms that are favorable to us. In addition, if we are not able to obtain adequate supplies of our products or product candidates or the drug substances used to manufacture them, we will lose commercial sales revenue and it will be more difficult for us to develop our product candidates and compete effectively.
In addition, to the extent that any contract manufactures that we engage develop proprietary manufacturing processes or procedures, should we need to change manufacturers, we may not be able to transfer know-how to a new manufacturer. In such a case, the new manufacturer would need to invest substantial time, money, and effort to develop its own processes and procedures, which would require regulatory authority approval.
Third parties might illegally distribute and sell counterfeit or unfit versions of our products that do not meet our rigorous manufacturing and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. In addition, thefts of inventory at warehouses, plants or while in-transit, which are not properly stored and which are sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.
Our current and anticipated future dependence upon others for the manufacture and distribution of Sephience, Translarna, Emflaza, Upstaza, Kebilidi, Tegsedi, Waylivra and our product candidates may adversely affect our business, financial condition, results of operations and limit our ability to grow including our ability to develop product candidates and commercialize our products that receive regulatory approval on a timely and competitive basis.
We currently depend, and expect to continue to depend, on collaborations with third parties for the development and commercialization of some of our products and product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these products and product candidates.
For each of our product candidates, we plan to evaluate the merits of retaining commercialization rights for ourselves or entering into selective collaboration arrangements with leading pharmaceutical or biotechnology companies, such as our collaborations with Roche and the SMA Foundation, for our SMA program, including Evrysdi. We have entered into arrangements with certain third parties to market or distribute Sephience for the treatment of PKU and Translarna for the treatment of nmDMD in certain countries and, as we continue to implement our commercialization plans for Sepience and Translarna, we anticipate that we will engage additional third parties to perform these functions for us in other countries. We generally plan to seek collaborators for the development and commercialization of product candidates that have high anticipated development costs, are directed at indications for which a potential collaborator has a particular expertise, or involve markets that require a large sales and marketing organization to serve effectively. Our likely collaborators for any marketing, distribution, development, licensing or broader collaboration arrangements may include: large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and/or biotechnology companies.
We will have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates and our collaborators will be subject to the same product development and commercialization risks that we are subject to. Our ability to generate revenues from these arrangements will depend on our collaborators’ desire and ability to successfully perform the functions assigned to them in these arrangements in a compliant manner. In particular, the commercial success of Evrysdi will depend on the success of Roche’s commercialization program. Furthermore, the successful development of another product candidate from our spinal muscular atrophy program will depend on the success of our collaborations with the SMA Foundation and Roche, including whether Roche pursues clinical development of any other compounds identified under the collaborations.
Collaborations involving our products and product candidates, including our collaborations with the SMA Foundation and Roche, pose the following risks to us:
| ● | collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; |
| ● | collaborators may not pursue development and commercialization of our products and product candidates or may elect not to continue or renew development or commercialization programs, based on clinical trial results, changes |
69
Table of Contents
| in the collaborators’ strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities; |
| ● | collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; |
| ● | collaborators could independently develop, or develop with third parties, products that replace or compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; |
| ● | collaborators may fail to comply with the applicable regulatory requirements, subjecting them or us to potential regulatory enforcement action; |
| ● | a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products; |
| ● | collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; |
| ● | collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; |
| ● | disputes may arise between the collaborator and us as to the ownership of intellectual property arising during the collaboration; |
| ● | we may grant exclusive rights for our products or product candidates to our collaborators, which would prevent us from collaborating with others, or from using our products or product candidates ourselves; |
| ● | disputes may arise between the collaborators and us that result in the delay or termination of the collaboration, which may include ending research, development or commercialization activities for our products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and |
| ● | collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. |
Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated.
There may be future changes in legal and regulatory requirements that may materially impact our results of operation.
Future changes in legal and regulatory requirements may introduce new risks into our operations and future prospects, which we are not able to currently anticipate. By example, changes taking place in the United States associated with a new federal administration, as well as changes in legal standards, including the reduced level of judicial deference due to administrative agencies following a 2024 Supreme Court decision, may introduce uncertainties with respect to our current and future operations and our future likelihood of success. It is possible that new federal or state laws or regulations may be passed, or laws and regulations may be enforced differently than they were before, which may expose us to additional legal and regulatory risk or uncertainty and require the expenditure of additional resources to ensure that we are able to comply. Such actions could also adversely restrict our business and operations. There could also be changes in the FDA’s approval standards that could impact our ability to obtain product approval and market our product candidates within the
70
Table of Contents
currently anticipated timeframes or otherwise impact the competitive market for our product candidates. Such changes may necessitate the conduct of additional development work, including preclinical and clinical trials, and manufacturing development. By example, for products intended for rare and serious diseases with unmet medical needs, the FDA is authorized to exercise regulatory flexibility when making a medical risk-benefit judgment. It is possible that whether and how the FDA exercises any regulatory flexibility, including with respect to specialized pathways, such as accelerated approval, may change, which could impact our ability to obtain product approval. Further, legal and regulatory changes may impact how we may market and sell our products in the future, if they are approved, as well as how they are reimbursed. Moreover, there have been and may continue to be changes in leadership and other staff in the federal workforce, and in agency policies, including at the U.S. Department of Health and Human Services and FDA, that may result in regulatory delays, including with respect to the FDA’s review of marketing applications and other submissions, both those reviewed under the PDUFA program and otherwise. These changes may impact the ability to communicate with and obtain guidance from the agencies, including final regulatory actions. At this time, it is too early to predict the exact nature of any changes that may take place or whether and how they may impact our business and results of operation.
Item 5. Other Information.
Director and Officer Trading Arrangements
A portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) is in the form of equity awards and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or other Company securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.
The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of Company securities
Name | Action Taken | Type of Trading | Nature of Trading | Duration of Trading | Aggregate Number |
Adoption ( | Sale | Until | Up to |
71
Table of Contents
Item 6. Exhibits.
| | |
Exhibit Number |
| Description of Exhibit |
| | |
31.1* |
| Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
31.2* |
| Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
32.1* |
| Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
32.2* |
| Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
101.INS* |
| Inline XBRL Instance Document |
101.SCH* |
| Inline XBRL Taxonomy Extension Schema Document |
101.CAL* |
| Inline XBRL Taxonomy Extension Calculation Linkbase Document |
101.LAB* |
| Inline XBRL Taxonomy Extension Label Linkbase Database |
101.PRE* |
| Inline XBRL Taxonomy Extension Presentation Linkbase Document |
101.DEF* |
| Inline XBRL Taxonomy Extension Definition Linkbase Document |
104 | | The cover page from this Quarterly Report on Form 10-Q, formatted in Inline XBRL |
* Submitted electronically herewith.
In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.
72
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | |
| PTC THERAPEUTICS, INC. | |
|
|
|
|
|
|
Date: August 7, 2025 | By: | /s/ Pierre Gravier |
| | Pierre Gravier |
| | Chief Financial Officer |
| | (Principal Financial Officer and Duly Authorized Signatory) |
73
Source:
FAQ
How did CROX revenue perform in Q2 2025?
What caused Crocs' large Q2 2025 net loss?
How profitable is the core Crocs Brand?
What is Crocs' current debt and liquidity position?
How much stock did CROX repurchase in 2025 to date?
What legal proceedings does Crocs face?
